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1. Targeted Drug Delivery 
The pharmacological response of an organism or tissue to an applied drug substance 
is, in general, directly linked to the drug concentration at the site where it is supposed to act. 
Due to this fact, many of the active ingredients in currently available medicines and drug 
therapies are not as efficient in vivo as they have already proven to be in cell cultures. 
Specifically, in many cases, the applied substances are not available in the optimum 
concentration and can therefore not exhibit the desirable effect [1]. Still, the majority of 
today’s applied drugs are delivered systematically, which leads to them being evenly 
distributed throughout the body. Their specific mode of action is mediated by localized 
receptor distributions or by certain physicochemical parameters of the target, which lead to an 
accumulation at the target site. This conventional method of drug delivery, however, results 
often in non-optimal drug efficacy and can often be associated with negative side effects, 
resulting from the use of large doses of the active ingredients that must be used. Moreover, 
there is drug resistance at the target originating from cellular drug elimination that further 
reduces the concentration of the active substances at the site of action. Finally, many current 
drugs have very poor water solubility or low bioavailability, making them very difficult to 
apply, especially if they are very rapidly cleared from the body by reticuloendothelial system 
due to their particulate character. 
Because of the difficulties associated with current drugs, targeted delivery of drug 
molecules or small particulate drug carriers to organs or certain tissue sites, an idea initiated 
by Paul Ehrlichs’s magic bullet concept, represents one of the most challenging research areas 
in pharmaceutical sciences today. For all drug therapies, the most important goal is to get the 
drugs exactly where they are needed in the body without affecting other tissues. Targeted drug 
delivery can be defined as the attempt to deliver drugs to a specific target site in the body 
where they have greatest pharmacological effects, and additionally, to not allow them to 
diffuse to other sites where they may cause damage or trigger side effects. 
In principle, successful drug targeting can be achieved by specific physical, biological 
or molecular interactions, which result in the accumulation of the pharmacologically active 
agents at the relevant sites of action. Based on the chosen mechanism of interaction two kinds 
of targeted drug delivery exist. The first kind is passively targeted drug delivery, which is 
mainly based on the physical characteristics of the diseased target tissue, such as the enhanced 
permeability and retention of tumor tissues with leaky blood vessels and imperfect lymph 
drainage (EPR-effect). Additionally, local properties, such as the pH or the presence of certain 
enzymes or the activity of bacteria can be used to achieve passive targeting to a certain site. 
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The second type of accumulation is mediated via active mechanisms of targeting, which rely 
on the expression of certain disease specific markers including certain antigens or receptors, 
which can be targeted using corresponding antibodies or ligands. The different types of drug 
targeting principles that can be found in literature are summarized in Scheme 1 [2-8]. 
 
 
Scheme 1: Schematic representation of different types of drug targeting 
 
 Successful drug targeting to specific tissues, however, is a very complicated process. It 
demands the control over various distribution and absorption processes as well as drug 
metabolism and disposition. Therefore, a number of important parameters have to be 
considered for the design of each drug targeting system. These include the nature of biological 
and cellular membranes of the target tissues, distribution and presence of specific receptors, as 
well as the activity of enzymes responsible for the subsequent drug metabolism and also the 
local blood flow, which is responsible for the transport to and from the target tissue. 
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2. Nanoparticles as Targeted Drug Delivery System 
For drug targeting approaches, particulate delivery systems of different sizes can be 
used as transport vehicles without affecting the activity of the drug ingredient by chemical 
modification. Due to limitations of tissue permeation and the necessary transport in the blood 
stream, particles for drug delivery systems must be nanometer sized and highly biocompatible 
with blood components and tissues in order to obtain long blood circulation times in the 
patient without immunological reactions. 
The nanoparticles (NPs) used for drug delivery applications are part of a rapidly 
developing field within material science. This field is nanotechnology, and it has many 
potential applications in clinical medicine and research. Due to their unique size- dependent 
optical and physicochemical properties, which include the specific absorption of 
electromagnetic waves, nanoparticles offer unique potential for the development of both 
therapeutic and diagnostic tools based on the absorption and emission of light [9]. 
 Furthermore, nanoparticles used for the purpose of drug delivery can be designed in a 
variety of different systems such as micellar solutions, liquid filled vesicles or liquid crystal 
dispersions as well as solid polymeric or metallic nanoparticle dispersions [10]. Further 
modifications of these drug carriers with ligands or other targeting molecules, specific for the 
intended site of action, allow the design of personalized medicines, which reduce the side 
effects of the drug while maximizing the therapeutic effects. Such local action is mainly 
achieved with very small nanoparticles, which sufficiently penetrate across barriers through 
small capillaries and finally into individual cells [11]. 
Based on their aforementioned properties, there are several important technological 
advantages of nanoparticles, which make them suitable for application as drug carriers: 
1) Small particle size; Nanoparticles less than 100 nm are in a similar size-range as biological 
materials like viruses, DNA and proteins. 
2) Inert surface modification; The surface of nanoparticles can be decorated with various 
molecules in order to avoid being recognized by the immune system enabling them to reach 
their target more efficiently. 
3) Targeted surface modification; The surface can be easily manipulated to achieve both 
active and passive targeting by attaching suitable targeting ligands. 
4) High carrier capacity; Drug molecules can be adsorbed, dissolved or dispersed in the 
particle matrix.  
5) Flexible loading; Based on the nanoparticle matrix material both hydrophilic and 
hydrophobic drug substances can be delivered. 
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6) Flexible route of administration; Nanoparticles can be used for various routes of 
administration including oral, pulmonary, parenteral, intraocular, for mention just a few [12-
15].     
Several types of nanoparticles have been extensively studied as vehicles to target drug 
molecules to specific sites with optimal drug release profiles. Such nanoparticulate delivery 
systems can be used to treat cancer and a wide range of other diseases [9,16,17]. Some of the 
most important therapeutic applications of nanoparticles that are currently in use are described 
below.  
 
2.1. Therapeutic Applications of Nanoparticles 
2.1.1. Cancer Therapy 
 Nanotechnological approaches promise broad applicability for therapies against 
cancer, which include molecular imaging of tumor cells, molecular diagnosis as well as 
targeted drug therapy. Moreover, continuous developments in nanotechnology hold the 
promise of more personalized oncology, in which identified genetic or protein biomarkers of 
one patient can be used to diagnose and treat cancer based on the molecular profile of the 
individual patient [18].       
For an effective anticancer treatment, applied nanoparticulate drug delivery systems 
should first be able to reach the desired tumor tissues through penetration of biological 
barriers, which are naturally present in the body as well as those barriers developed during 
tumor growth and progression. This transport should be achieved with a minimal loss of 
number and activity in the blood circulation. Second, after reaching the respective tumor 
tissues, the released drugs should have the ability to selectively kill the tumor cells without 
affecting normal cells around the tumor. Fulfillment of these two basic requisites is associated 
with significant improvement of patient survival and quality of life because local 
concentration of drugs is increased and dose-limiting toxicity of drugs is reduced. Overall, 
successful achievement of these requisites shows that targeted nanoparticles seem to have 
high potential to satisfy all the requirements for effective drug carrier systems against cancer 
[19-23]. 
In today’s cancer therapy, the occurrence of drug resistance is a major obstacle for the 
successful treatment of tumors. Poly(alkyl cyanoacrylate) nanoparticles have been found to 
provide a useful alternative at a cellular level to overcome multidrug resistance mediated by 
P-glycoprotein by increasing the intracellular concentration of the drug [24]. Similarly, 
methotrexate conjugated to gold nanoparticles is more effective in the treatment of lung 
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cancer than methotrexate alone. This finding can be attributed to the increased drug 
concentration due to the accumulation of gold nanoparticles carrying methotrexate inside the 
tumor cells [23]. More interestingly, multifunctional nanotherapeutic systems based on gold 
nanoparticles have been developed to target solid tumor carrying multiple therapeutic agents 
in order to increase the overall efficacy and also to overcome the limitations of using a single 
drug [22,25]. 
Alternative therapeutic approaches, like photodynamic cancer therapy, are based on 
the destruction of cancer cells by laser generated atomic oxygen without the use of cytotoxic 
substances. For these applications, a large amount of photosensitizer is required to generate 
enough atomic oxygen, and this is mainly achieved by targeted accumulation in cancer cells. 
This leads to only the targeted cancer cells being killed when the tumor area is exposed to the 
laser radiation. Unfortunately, remaining photosensitizer later migrates to the skin and eyes 
and renders patients sensitive to daylight exposure. To avoid these side effects, 
photosensitizers have been enclosed inside porous nanoparticles, which trap the dye and 
limited diffusion to other parts of the body. At the same time, the oxygen generating ability of 
the photosensitizers and therefore therapeutic efficiency is not affected [26].                          
 
2.1.2. Treatment of Respiratory Diseases 
Other therapeutic approaches using nanoparticles make use of the pulmonary route of 
administration, which is of increasing interest for the development of new medicines, not only 
for the treatment of lung diseases (e.g. asthma and chronic obstructive pulmonary disease), 
but also for a fast and efficient delivery of drugs into the systemic blood circulation avoiding 
parenteral application. The advantages of direct delivery to the lungs for treatment of 
respiratory diseases include the potential to reduce systemic toxicity and to achieve higher 
drug concentrations at the site of action. Additionally first-pass metabolism can be avoided, 
which mainly occurs after conventional oral administration [27,28]. Theophylline is a drug 
that reduces the inflammatory effect of allergic asthma, but it is difficult to administer it in 
appropriate dosage without causing systemic side effects. It was found that, intranasal 
inhalation of theophylline complexed with thiolated chitosan nanoparticles augmented the 
anti-inflammatory effect of the drug in relation to theophylline administered alone in a mouse 
model of allergic asthma. The beneficial effects of theophylline in treating asthma may be 
enhanced through the use of this novel drug delivery system by increasing the local 
concentration or by a slower release rate in the lung after nasal inhalation of nanoparticles 
containing theophylline [29]. It has also been reported that, the encapsulation of three 
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antitubercular drugs, isoniazid, rifampicin and pyrazinamide in alginate nanoparticles 
administered by inhalation resulted in an increase in the relative bioavailability and 
therapeutic efficacy of these drugs when compared with oral administration of the same free 
drugs, This was attributed to increased local concentration of drugs at the main site of action 
[30].              
 
2.1.3. Treatment of Cardiovascular Diseases 
One of the most recent therapeutic applications of nanoparticles is their use for the 
local delivery of active substances for the treatment of cardiovascular disorders. Targeted 
perfluorocarbon nanoparticles have been applied in animal models for the treatment of 
various cardiovascular disorders such as ruptured plaque, atherosclerotic plaque or the 
delivery of antirestenotic therapy following balloon angioplasty. Nanoscaled particles can be 
synthetically designed to potentially intervene in the lipoprotein matrix retention and 
lipoprotein uptake in cells, a process central to atherosclerosis. Nanoengineered systems 
molecules called nanolipoblockers can be used to attack the atherosclerotic plaque due to 
raised local levels of low density lipoproteins [31]. Nanotechnology here may facilitate the 
repair and replacement of blood vessels, myocardium and myocardial valves. It may also be 
used to stimulate regenerative processes, such as therapeutic angiogenesis for the treatment of 
ischemic heart disease [15].  
 
2.1.4. Treatment of Neurological Disorders  
The potential benefits of nanoparticles for the treatment of both peripheral and CNS 
disorders are tremendous and may also offer both the patient and clinician novel therapeutic 
choices. The central nervous system (CNS), including the brain, has attracted a lot of research 
attention due to the multitude of diseases linked to disorders of signal transport and 
degeneration, such as Alzheimer’s or Parkinson’s disease. Most of the therapies are limited 
due to difficulties in overcoming the blood-brain barrier (BBB). The use of nanoparticles to 
deliver drugs to the brain across the BBB may provide significant advantages over current 
strategies, since particles can be used to mask the transport limiting properties of the drug 
substances to protect drugs from chemical or enzymatic degradation in the blood stream and 
also to provide the opportunity for a sustained release, which can additionally reduce the 
peripheral toxicity of the free drug substances. It has been reported that nanoparticles coated 
with polysorbate 80 have the ability to penetrate the BBB and deliver drugs of various 
chemical structures (including peptides, hydrophilic and lipophilic compounds) to the brain 
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[32,33]. When a suspension of polysorbate-coated nanoparticles is introduced into blood, 
apolipoproteins of the plasma adsorb on the particle surfaces, which then interact with 
receptors of low-density lipoproteins in the endothelial cells of cerebral blood vessels and 
subsequently stimulate the endocytosis of the particles [34,35]. Drugs that have been 
successfully transported to the brain using this delivery system include loperamide [36], 
dalagrin (a short peptide, Leu enkephalin analogue), kyotorphin [37], nerve growth factor 
[38], tubocurarine [39] and doxorubicin [40].  
Other therapeutic approaches with nanoparticles utilize free radical mediated damages, 
which is known to play a major role in ischemic and degenerative disorders of the CNS. For 
example, water soluble derivatives of buckminsterfullerene C60 are used as a unique class of 
nanoparticles with potent antioxidant properties. Furthermore, it has been reported that 
nanoparticles composed of cerium oxide or yttrium oxide protect nerve cells from oxidative 
stress and their observed neuroprotection is also independent of particle size. The ceria and 
yttria nanoparticles act as direct antioxidants, which limit the amount of reactive oxygen, 
which is known to kill cells. Consequently, it can be surmised that this group of nanoparticles 
can modulate many kinds of oxidative stress in biological systems in addition to in the central 
nervous system [41]. 
 
2.1.5. Ocular Drug Delivery  
For more accessible organs, like the eye, nanoparticles offer advantages over presently 
known therapies. Conventional eye drops represent about 90% of all ophthalmic drug 
formulations, and it is well known that up to 95% of the applied drug is lost through 
immediate tear drainage. This mechanism is useful for protecting our eyes against the 
exposure of noxious substances. For these applications, nanocarriers such as nanoparticles, 
liposomes or high molecular weight dendrimers, can be easily administered as eye droplets. 
These nanocarriers may provide prolonged residence time due to interactions with the ocular 
surface after instillation, which enable them to avoid the natural clearance mechanism of the 
eye. In combination with controlled drug release from these particles, it should be possible to 
develop ocular formulations that provide local therapeutic concentrations for long periods of 
time, thereby reducing the dose administered as well as the necessary instillation frequency. 
For intraocular drug delivery, the same mechanisms can be used to release the drug in a 
controlled way, reducing the number of intraocular injections required to maintain 
therapeutically active concentrations [15]. Another potential advantage of these systems is the 
targeting to specific sites of action, which can lead to a necessary dose decrease and 
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consequently a decrease of side effects [15]. For all of these applications, the formulation of 
biodegradable polymers as colloidal systems allows enhanced ocular drug delivery by 
immobilization of the particles inside and on the eye for long periods of time, while 
additionally avoiding the need to remove the empty delivery systems from the patient due to 
the degradation of the polymer carrier. 
In recent investigations, chitosan based nanoparticles have been investigated for the 
delivery of drugs to the ocular mucosa using the immunosuppressive peptide cyclosporine A 
as a model drug. The expected advantage of these systems in ocular drug delivery is their 
ability to contact intimately with the corneal and conjunctival surfaces, thereby prolonging 
and increasing the delivery of the drug substance to external ocular tissues without 
compromising the inner ocular structures and avoiding systemic drug exposure [42]. 
Consequently, these nanoparticulate systems show great promise with regard to the 
circumvention of the present limitations for the treatment of external inflammatory or 
autoimmune ocular diseases such as keratoconjuctivitis sicca, or dry eye disease. The 
described local application and immobilization of nanoparticles inside the eye is completely 
different from the systemic administration of nanoparticles, where the particles are designed 
to circulate inside the body until reaching the site of action. This extended range of 
application reflects and confirms the usefulness of nanoparticles as a versatile drug delivery 
system. 
 
2.1.6. Treatment of Infections 
A final example for the application of nanoparticulate delivery systems are colloidal 
drug carriers, such as liposomes and nanoparticles, which are easily taken up by phagocytic 
cells and accumulate in the organs of the reticuloendothelial system, which make them useful 
for the treatment of intracellular infections with antibiotics that would normally not 
sufficiently access the intracellular sites. Consequently, in vitro and in vivo experiments with 
drug substances incorporated in liposomes and nanoparticles did demonstrate the increased 
therapeutic efficacy of substances, such as amphotericin B, dihydrostreptomycin, amikacin 
and ampicillin, against a number of microorganisms, including Leishmania donovani, 
Candida albicans, Staphylococcus aureus, Mycobacterium avium, Listeria monocytogenes, 
and Salmonella typhimurium [43,44]. Furthermore, polymeric nanoparticles have also been 
applied to develop an oral delivery system of the otherwise only injectable streptomycin. The 
results of the biodistribution  and activity studies of particle-loaded antibiotic suggested that 
nano-encapsulation of streptomycin might be useful in the development of an oral dosage 
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form of streptomycin and perhaps other injectable antibiotics, since encapsulated drugs 
showed a significant increased bioavailability after oral administration. The enhanced 
bioavailability is attributed to the intestinal absorption of antibiotic-loaded nanoparticles by 
the intestinal epithelium and sustained drug release after reaching the systemic circulation 
[45].  
 The continuing increase in microbial drug resistance has led to widespread problems 
in the treatment of conventional bacterial infections. Of particular concern are those illnesses 
caused by methicillin or multiple resistances staphylococcus aureus (MRSA), which are 
responsible for the majority of all hospital-acquired infections. Clinical complications and 
nearly 100,000 deaths each year are attributed to these infections in the United States alone. 
Since penicillin and other β-lactam antibiotics have been the basis in the clinical treatment of 
bacterial infections, their effectiveness is now significantly compromised in bacteria that 
produce β-lactamase enzymes, which efficiently hydrolyzes the β-lactam ring to an inactive 
ring-opened product. An additional incorporation of these antibiotics into nanoparticle 
matrices may successfully shield them from bacterial penicillinase degradation and render 
them effective against penicillinase producing bacteria [46,47]. 
 
2.2. Imaging and Diagnosis 
Nanoparticles targeted to certain structures give us the ability to identify individual 
cells within organs or find molecular changes within tissues that we otherwise cannot detect 
through conventional imaging because of these nanoparticles have high sensitivity and 
photostability, which allow imaging for prolonged periods [48]. Several types of nanoparticles 
have been specifically designed for diagnostic and imaging purposes: the most frequently 
used are gold nanoparticles (GNPs), quantum dots (QDs) and magnetic nanoparticles. GNPs 
are known for their high electron contrast, this is why they are used as markers for all kinds of 
electron microscopy.  
QDs are nanometer sized inorganic fluorophores that are based on different types of 
semiconductors. They offer significant advantages over conventionally used organic 
fluorescent markers. They are much brighter than conventional fluorescent dyes and can be 
tuned by alteration of their size to shine at different emission wavelengths. Due to their high 
photostability they can be used for much longer observation times in comparison to organic 
dyes, which are often very sensitive to photobleaching. This increased length of observation 
time is crucial to study slower cellular process. Fluorescent particles can moreover help to 
identify new cellular receptors as targets for new drug candidates and a more detailed 
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understanding of the behavior of these receptors, including their activation or internalization. 
This understanding can open up new treatment options for nanoparticulate delivery systems 
[13,49]. 
Superparamagntic iron oxide nanoparticles (SPIONs), measuring 2-3 nm, have been 
used in conjunction with magnetic resonance imaging (MRI) to reveal small and otherwise 
undetectable lymph-node metastases. Ultrasmall SPIONs also enhance MRI contrast for 
successful imaging of cerebral ischemic lesions. Surface modified dextran-coated iron oxide 
nanoparticles also enhanced MRI visibility of intracranial tumors for longer time [50].  
Early diagnosis of Type I diabetes (insulin-dependent diabetes mellitus, IDDM) is 
very important for the treatment of this disease. The early and sensitive diagnosis depends on 
the detection of autoantibodies, which are present before clinical onset. Supramolecular 
protein nanoparticles have been applied by Lee et al. [51] for ultrasensitive early detection of 
antibodies of IDDM. The principles of detection depend on the formation of supramolecular 
protein nanoparticles by the self-assembly of the antigenic protein expressed in bacteria. Each 
nanoparticle has many binding sites for the specific antibody (the early marker of type I 
diabetes). After complexation with further nanoparticles that carry polylysine residues 
suitable for the binding of DNA, the nanoparticles-antibodies complexes are detected by using 
highly sensitive PCR. Similar supramolecular protein nanoparticles would also be useful in 
the diagnosis of infectious diseases, such as such as AIDS and hepatitis C during the early 
phase of infection, when the concentration of antibodies is very low. 
Nanoparticles are also attracting considerable interest as contrast agents for other types 
of medical imaging. Hainfeld et al. [52] showed that, gold nanoparticles are useful X-ray 
contrast agents that offer novel physical and pharmacokinetic advantages over the currently 
used agents. They, for example, enable higher contrast and also longer imaging times than the 
currently standard iodine-based agents. 
 The overproduction of hydrogen peroxide is linked to many different diseases and 
there is consequently a great interest in the development of contrast agents that can image 
hydrogen peroxide production in vivo. It has been demonstrated that nanoparticles formulated 
from peroxalate ester and fluorescent dye image hydrogen peroxide with specificity and 
sensitivity. The peroxalate nanoparticles image hydrogen peroxide by undergoing a three-
component chemiluminescent reaction between hydrogen peroxide, peroxalate esters and a 
fluorescent dye. First hydrogen peroxide diffuses into the nanoparticles and reacts with 
peroxalate ester groups, generating a high energy-dioxetanedione that chemically excites 
encapsulated fluorescent dyes through the chemically initiated electron-exchange 
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luminescence mechanism and leads to the chemiluminescence. Peroxalate nanoparticles have 
great potential for imaging of hydrogen peroxide-associated diseases, given their high 
specificity and sensitivity and their capability for deep-tissue-imaging [53]. 
 
3. Gold Nanoparticles 
Among the colloids of metallic and semiconductor origin, gold nanoparticles stand out 
as one of the most extensively investigated systems. This is mainly due to the fact that 
colloidal gold has well defined chemical, physical electronic and optical properties with 
respect to shape and size [54]. Also, gold nanoparticles are of special interest for research due 
to their potential applications in biomedical, electronic and optical materials [55]. In 
biomedical applications, gold nanoparticles are used for rapid and sensitive diagnostic assays 
[56], for radiotherapy and imaging [57,58] and as the basis for drug and gene delivery systems 
[59-61]. 
 
3.1. Advantages of gold nanoparticles 
 Gold nanoparticles (GNPs) play a special role in nanoscience and nanotechnology due 
to the following facts;  
1. Gold is most stable at the nanoscale [62].  
2. GNPs have unique optical properties. GNPs exhibit strong absorption of 
electromagnetic waves in the visible range due to surface plasmon resonance (SPR). 
SPR is caused by the oscillation of the conductive electrons on the metal surfaces 
upon irradiation by electromagnetic waves. The wavelength of the peak absorption 
here depends on many factors like particle size, dielectric constant of the surrounding 
media, and the inter-particle distance. Spherical nanoparticles have a single plasmon 
resonance extinction peak at around 520 nm, which does not shift extensively by 
change in the size and refractive index of the surrounding medium [63-65].  
3. GNPs can be synthesized in different sizes and in different media according to the 
desired application. 
4. GNPs provide a versatile nanoscale platforms that can easily be functionalized with 
small drug molecules, polymers and biomaterials for many potential applications [66]. 
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3.2. Synthesis of gold nanoparticles 
Different methods have been developed and optimized to prepare and subsequently 
characterize gold nanoparticles. For the preparation of nanoparticles, special precautions must 
be taken to avoid uncontrolled growth and aggregation, because single particles tend to be 
unstable in solution. The most frequent synthesis method for gold nanoparticles in aqueous 
medium is the chemical reduction of gold salts such as (HAuCl4) by tri-sodium citrate. In this 
method, the citrate salt acts initially as the reducing agent to reduce Au (III)3+ ions to Au(0) 
and later also functions as stabilizing agent by forming a layer of citrate anions on top of the 
nanoparticle surface. The adsorption of citrate anions on the particle surface charges the 
particles negatively and induces enough electrostatic repulsion forces between individual 
particles to keep them separately dispersed in the synthesis medium [67-72]. Particles 
synthesized by citrate reduction can be obtained as almost monodisperse spheres, the sizes of 
which are controlled by the initial reagent concentrations and the chosen reaction conditions. 
The particles in aqueous dispersion are characterized by a deep red color with surface 
plasmon resonance peak at about 524 nm as shown in Figure 1 [73]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: UV-Vis absorption spectra of different gold nanoparticles preparations 
Insert: Flask with freshly prepared gold nanoparticles  
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3.3. Stabilization and functionalization of gold nanoparticles 
 For successful application of GNPs, they must be stabilized in order to maintain their 
individuality upon the changing of the dispersion medium. For this task, self assembled 
monolayers (SAMs) of polymers are frequently used as sterically stabilizing agents. SAMs 
are ordered molecular arrangements that are formed by spontaneous adsorption to a surface 
with specific affinity of its head group to the underlying substrate [74]. In other words, SAMs 
are thin monolayers of organic molecules that have end groups that spontaneously and 
selectively interact with metal or semiconductor substrates [75]. Recently, the synthesis, 
functionalization and assembly of monolayer-protected gold nanoparticles have been 
extensively studied, and particles have been designed that are suitable for application in many 
fields such as discovery of biomarkers [50], molecular imaging and radiotherapy [57,58], and 
DNA delivery [60]. For all of these particles, thiol groups and disulfides have a very strong 
tendency to spontaneously react with the gold surfaces, explaining the high popularity of 
modifying gold surfaces. Such adsorption in general results in the formation of well-organized 
SAMs due to the strong chemical bond formed between gold and sulfur [76]. 
For all biomedical applications, the surface functionalization of gold nanoparticles is 
the essential prerequisite for applying them to cell cultures or allowing selective interactions 
with organs, tissues, cells or even biomolecules. For many different applications, it has been 
reported that poly(ethylene glycol) (PEG) surface modification of gold nanoparticles 
significantly improves their dispersion stability, especially, in the presence of high electrolyte 
concentrations, which would furthermore lead to the breakdown of the electrostatic repulsion 
of the citrate coating. Additionally, PEG layers inhibit unspecific protein adsorption to the 
particle surfaces due to steric repulsion effects of the tethered PEG strands. PEG-modification 
(PEGylation) of nanoparticles imparts a stealth-shielding of these particles and prevents 
unspecific opsonins from recognizing the particles, thereby limiting the phagocytosis by the 
RES cells and increasing the systemic circulation time from minutes to hours or even days 
[77]. The protective action of PEG is mainly grounded in the formation of a dense, 
hydrophilic cloud of long flexible polymer chains on the surface of the colloidal particle that 
reduces the adsorption of opsonins and thus also reduces the hydrophobic interaction with the 
RES. The tethered or chemically anchored PEG chains protect the surface in different spatial 
conformations depending on their molecular weights, thus preventing the opsonization of the 
gold particles, which usually leads to the uptake by macrophages of the RES and causes 
preferential accumulation in the liver and spleen. Attached PEG is non-toxic, non-
immunogenic and approved by the FDA for internal use in humans. Furthermore, it is 
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included in the list of inactive ingredients for oral and parenteral administration [78-81]. The 
mechanism of steric hindrance of PEG modified surface coated nanoparticles was proposed 
by Gref et al. [82]. The water molecules included in the PEG layers form a structured shell 
through hydrogen bonding with the ether oxygen’s of PEG. The tightly bound water then 
forms a hydrated film around the particles and consequently repels all interactions with 
proteins and other nanoparticles.     
Besides surface bound or conjugated PEG, amphiphilic block co-polymers such as 
poloxamers and poloxamine, consisting of blocks of hydrophilic PEG and hydrophobic 
poly(propylene oxide) (PPO) have been applied to impart nanoparticles with stealth-shielding 
properties. The hydrophobic section of the polymers, which contains the PPO units, can be 
used to adsorb and anchor the polymer molecules onto the particle surface, while the 
hydrophilic PEG section can extend into the solution and shield the particle surfaces. This 
method is simple to achieve and can also impart increased RES avoidance of the particles. 
Conversely, it has the drawback that surface adsorbed polymers can desorb again, leaving 
spaces in the surface coating where proteins can subsequently bind. Beyond this, proteins may 
also be adsorbed to the hydrophobic part of the polymers, and this has detrimental effects on 
colloid stability [83]. Accordingly, several trials have been done to increase the strength of the 
polymer attachment to the gold surfaces. Many publications report the utilization of thiol-
terminated poly(ethylene glycol) for the preparation of water soluble and stable gold 
nanoparticles, which is very important for the biologically applied particles [84-89]. Other 
organosulphur compounds, such as aliphatic or aromatic thiols and disulfides, also form self-
assembled monolayers (SAMs) on gold surfaces due to the chemisorptive Au-S bond, which 
forms very strong links due to the high affinity of thiols for the gold surface [90]. In addition 
to the stabilization of nanoparticles, functionalization of the second terminal end of 
thioalkylated poly(ethylene glycol)s with certain functional groups, such as amine groups, 
provides valuable versatile polymers for the preparation of surface functionalized gold 
nanoparticles. Therefore, a coating of nanoparticles with such bifunctional polymers produces 
fairly stable nanoparticles and at the same time provides terminal functionality for the 
installation of targeting ligands, which can later interact with the specific receptor or target 
tissue [54].              
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4. The Need for Bone Tissue Targeting 
Many chronic bone diseases, such as osteoporosis and osteoarthritis, are closely 
associated with the natural aging process and consequently gain more importance in aging 
societies. Osteoporosis, for example, is a bone debilitating disease that causes nearly 1.3 
million bone fractures each year. In addition to the chronic and destructive diseases, bone is 
also affected by various types of cancers, originating from bone tissue or as metastases from 
other tissues (90% of patients that died of breast cancer or prostate cancer also have skeletal 
metastases). Bone cancer and cancer metastases are often associated with significant pain, and 
their therapy is generally very difficult since the tissue is very difficult to reach with 
irradiation.  
A number of currently known therapeutic agents are beneficial for the treatment of 
different bone diseases. However, because bone tissue is distributed throughout the body, the 
systemic drug concentration needs to be maintained at a level such that the drugs exhibit 
pharmacological activity sufficiently also at the peripheral site. This often causes unfavorable 
systemic effects, leaving a very narrow therapeutic window for the treatment of bone diseases. 
The incorporation of osteotropicity to a bone therapeutic agent may, therefore, dramatically 
alter the pharmacokinetic profile to favor skeletal deposition [91-95]. 
Apart from the treatment of osteoporosis or cancer, delivery systems for bone 
targeting could significantly improve other treatment opportunities. Bone targeting could 
increase the efficacy and reduce toxicity or the side effects of new and already applied drugs 
by altering their pharmacokinetics and biodistribution by restricting their biological action to 
the skeletal system [95]. 
To develop successful drug delivery systems for treatment of bone diseases, a sound 
rationale based on the bone biology is needed. To this end, an overview on the structure and 
biological functions of the bone tissue will be presented [95]. 
 
5. Structure of Bone Tissue 
Bone tissue is a specialized form of connective tissue and is the main element of the 
skeletal tissues. It is composed of cells and a calcified extracellular matrix, in which 
stabilizing fibers are embedded. Bone is a rather unique tissue that performs several functions 
in addition to contributing to body shape and form. It is the major attachment site for tendons 
and muscles, essential for locomotion and other movements of the body. In some parts of the 
body, bones also provide the protective structures for vital tissues, such as brain, heart, lung, 
bladder and pelvis viscera. Bone also serves as the main source and depot for minerals and 
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corresponding anions, mainly calcium and phosphate, and as such is intimately involved in 
the mineral homeostasis of the body. In addition, the bone marrow is the place where most of 
the blood components, such as blood or immune cells, are formed. Finally, there are also 
mineralized tissues that have very specialized functions, such as for example the bones of the 
inner ear, which are responsible for the transmission of sound. The actual composition of 
bone varies strongly with age, anatomical location, and the general health and nutritional 
state. In general, the bone mineral accounts for about 50-70% of adult bone mass, the organic 
matrix for about 20-40%, water for about 5-10% and embedded lipids for about 1-5% [95-97].  
Bone in human and other mammalian bodies is generally classified into two types. The 
dense outer shell is termed “cortical bone”, and is also known as compact bone. The inside 
contains a much finer network of bone, which more resembles a sponge, and is termed spongy 
or cancellous bone. Cortical bone is much denser with a porosity ranging between 5% and 
10% and is found primarily in the shaft of long bones, but it also forms the outer shell around 
cancellous bone at the end of joints and in the vertebrae as shown in Figure 2 [97,98]. 
Bone has the ability to repair itself without leaving behind scar tissue. It also rapidly 
removes and replaces mineral storage based on metabolic demand, and it structurally reshapes 
in response to alterations in the mechanical stimului (e.g. following fractures or degenerative 
diseases). Four distinct cell types are responsible for carrying out the local formation, 
resorption, and maintenance of bone. These are osteoblasts, osteoclasts, osteocytes and the 
bone lining cells. Osteoblasts are the cells that synthesize the bone matrix and participate in 
bone mineralization. The functions of osteoblasts are influenced by a number of endocrine 
and cytokine mediators such as parathyroid hormone, prostaglandins, estrogens, vitamin D 
and some cytokines. Osteoclasts on the other hand, are multinucleated giant cells mainly 
responsible for resorption of bone, which also takes place during regular remodelling of the 
bone tissue. There are numerous factors that play a role in the regulation of osteoclast 
functions and bone resorption, which include parathyroid hormone (PTH), PTH related 
peptide, calcitonin, glucocorticoids, vitamin D, prolactin, interleukine-1 (IL-1), interleukine-6 
(IL-6), tumor necrosis factor (TNF), prostaglandins, interferon-gamma, and members of the 
transforming growth factors beta superfamily, including bone morphogenetic proteins and 
others. Osteocytes are cells, which are buried within mature bone and are formed from 
osteoblasts that have been entrapped during bone formation. Several important roles are 
attributed to these cells, one of the most important being the maintenance of mineral 
homeostasis by permitting the diffusion of fluids and minerals through the cannicular system. 
Osteocytes may also serve as a mechanical damage sensor responsible for initiating bone 
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remodelling or repair. Finally, the bone lining cells are formed by inactivation of osteoblasts 
or perhaps other mesenchymal type cells and they are mainly present on the surfaces of adult 
bone. The role of bone lining cells includes the partitioning of bone fluid compartment from 
interstitial fluids, the nutritional and metabolic support of osteocytes, and the initiation of 
osteoclast mediated resorption of bone [96,97,99-102].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Diagram represents the structure of different types of bone. 
 
 Besides the metabolically active cellular portion of bone, it also contains the non-
living but very important bone matrix. It is the major constituent of bone and it is a well 
organized composite material consisting of an organic and an inorganic component [103]. 
About 90% of the organic matrix of bone is composed of type I collagen, which is synthesized 
by the osteoblasts and deposited in distinct layers known as lamellae in mature bones. The 
organic component of the matrix gives the bone its outer shape and contributes to its ability to 
resist tensional load. Bone also contains a variety of noncollagenous proteins that may be 
important in the organization of the matrix, the mineralization of the bone, and the behavior of 
the bone cells. These proteins include osteocalcin, osteonectin, bone sialoprotein, bone 
phosphoproteins and small proteoglycans. Living bone matrix obviously also contains many 
Chapter 1                                                                            Introduction and Goals of the Thesis 
 
25 
different growth factors that can influence the function of bone cells and thereby regulation 
the function of this tissue [97,98].    
The inorganic matrix, or mineral phase of bone, constitutes about 75% of the bone 
tissue mass and it is composed principally of calcium ions and phosphate, which are 
combined to form specific hydroxyapatite crystals of the composition [Ca10(PO4)6(OH)2]. 
The hydroxyapatite in bone consists of very small crystals and contains many minute 
impurities, including carbonate or magnesium. Bone apatite is usually referred to as a “poorly 
crystalline, carbonate-substituted apatite” because of the impurities in the crystals, which are 
important in rendering bone apatite more soluble, thus permitting the apatite to release ions 
when needed for homeostasis or for the remodeling of bone [104]. The inorganic matrix of 
bone performs two essential functions: it serves as ion reservoir, and it gives bone most of its 
stiffness and strength. Approximately 99% of the body calcium, approximately 85% of the 
phosphorous and between 40% and 60% of the total body sodium and magnesium are 
associated with the bone mineral crystals [97].  
 
6. Ligands for Bone Targeting 
 The bone’s most distinguishing property from the rest of the human body is the 
presence of bone mineral, hydroxyapatite, which is not present in any other tissue under 
normal circumstances. A very practical approach for the design of bone targeting systems is to 
synthesize drugs or drug conjugates that have a very high affinity for hydroxyapatite, which 
consequently leads to an accumulation in bone after systemic administration. Although, a 
number of drug targeting systems showed promising improvements of the therapeutic index 
by increasing efficacy and minimizing adverse side effects, a true bone-specific delivery 
system still remains to be developed. To attain this goal, there are several molecules and 
moieties that can be used as selective-bone targeting ligands. Ideally, a bone-targeting moiety 
should have the following properties: it must possess a strong affinity for hydroxyapatite, the 
targeting moiety must be chemically modifiable to allow conjugation to the biomaterials used 
to construct the delivery system, the introduction of bone-targeting ligands must not render 
the delivery system toxic, and the biological effects of the targeting moiety itself should be 
minimal, or at least it should not interfere with the biological activity of the payload [95]. 
Several bone targeting moieties that possess these characteristics are known, and these are 
now described briefly. 
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6.1. Bisphosphonates 
Bisphosphonates (BPs) are synthetic analogues of the inorganic pyrophosphate (PPi), 
a naturally occurring polyphosphate present in serum and urine, which can prevent 
calcification of bone by binding to newly forming crystals of hydroxyapatite [105]. 
Bisphosphonates consist of two phosphonate groups linked by phosphoether bonds to a 
central (geminal) carbon atom (Figure 3; P−C−P structure). Unlike the unstable nature of 
P−O−P bonds, the P−C−P structure is highly resistant to hydrolysis under acidic conditions as 
well as to cleavage by pyrophosphatases. Two additional covalent bonds to the geminal 
carbon atom of bisphosphonate can be formed with carbon, oxygen, halogen, sulphur, or 
nitrogen atoms giving rise to a wide range of possible chemical structures of bisphosphonates 
[105-108].  
The P−C−P structure of bisphosphonates imparts the ability to bind divalent metal 
ions, such as Ca2+. For this reason, after being administered, bisphosphonates are rapidly 
cleared from the circulation and localize to the bone surface at sites of active bone 
remodeling, particularly areas undergoing osteoclastic resorption [109].     
   
 
P
O
P
OH
OH
O
OH OH
O
 
 
P
P
OH
OH
O
OH OH
O
R1
R2
 
Pyrophosphoric acid Bisphosphonic acid 
Figure 3: The structure of pyrophosphate and bisphosphonate 
   
The ability of bisphosphonates to bind to bone mineral, preventing both crystal growth 
and dissolution, was enhanced when the R1 side chain was a hydroxyl group rather than a 
halogen atom. The presence of a hydroxyl group at the R1 position increases the affinity for 
calcium owing to the ability of the bisphosphonates to chelate calcium ions by tridentate 
instead of bidentate binding. In addition to antimineralization properties, bisphosphonates are 
also capable of inhibiting bone resorption in vitro and in vivo. This property requires the 
P−C−P structure and could not be achieved by the monophosphonate or with P−C−C−P or 
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P−N−P compounds. Furthermore, the antiresorptive effect seems not to depend on the 
adsorption of bisphosphonate to bone mineral and the subsequent prevention of 
hydroxyapatite dissolution, because some bisphosphonate derivatives with less affinity for 
hydroxyapatite are even more potent antiresorptive agents, despite not being bound to the 
hydroxyapatite. Bisphosphonates inhibit bone resorption by their cellular effect on 
osteoclasts, rather than by a purely physicochemical mechanism [105,110-112]. 
 Bisphosphonates are nowadays used for the treatment of patients with various 
disorders affecting the skeleton including osteoporosis [113], metastatic bone diseases [114-
116] and Paget’s disease [117]. The pharmacological action of bisphosphonates is mediated 
through their action on osteoclasts with four different postulated mechanisms: inhibition of 
osteoclast recruitment, inhibition of osteoclast adhesion, shortening of osteoclast life span 
(apoptosis) and inhibition of osteoclast activity. However, it also has been shown that 
bisphosphonates have an inhibitory action also on osteoblasts, macrophages and certain tumor 
cells [105,118]. Therefore, the major concern for using bisphosphonates as bone-targeting 
moieties is their possible pharmacological effect on the bone cells. Particle conjugated 
bisphosphonates may thus still be capable to induce apoptosis in osteoclasts, and if a 
controlled release mechanism is used, caution must be taken that free bisphosphonate may 
counteract the activity of intended payload drug. In addition, one should avoid using 
bisphosphonates as a bone targeting ligand, if an osteoclast-mediated release mechanism of 
the active material is applied [95].     
In order to attempt bone targeting of other molecules than bisphosphonates, suitable 
conjugates must be developed. The main limitation of this approach is the fact that osseous 
tissues in contrast to other tissues, have a very low blood flow rate, because they mainly 
consist of inorganic hydroxyapatite mineral. Since this hydroxyapatite and the calcified 
tissues are the main targets for accumulation of bisphosphonates and their conjugates, long 
blood circulation times before the drugs reach their targets must be expected. Successful 
osteotropic drug-delivery systems based on this bisphosphonic prodrug concept as a novel 
method for site-specific delivery of other drugs to the osseous tissues have been developed 
making use of the adsorption of the prodrug to the mineral component of the bone [119]. To 
prove this concept, Erez et al. [120] demonstrated two chemical options to construct 
hydrolytically activated chemotherapeutic prodrugs containing the bisphosphonate bone-
targeting ligand. The first option is applicable for any drug molecules that possess a hydroxyl 
group. Here, the drug is attached to the bisphosphonate component through a labile ester 
linkage. The second option is suitable for drug molecules with amine functional groups. In 
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this case, a degradable linker is used to attach the drug to bisphosphonate component through 
a carbonate-labile linkage. This concept was demonstrated using camptothecin (containing 
hydroxyl group) and tryptophan (a model molecule for drug with amine functionalities). Both 
prodrugs bound successfully to pure hydroxyapatite, a model substance resembling bone, and 
were hydrolytically activated under physiological conditions. 
Bisphosphonate-coupled radiopharmaceuticals are already widely used in clinics for 
imaging and pain palliation of the skeleton. Ogawa et al. [121] developed a novel 99mTc-
chelate-conjugated bisphosphonate as a bone scintigraphic agent. The obtained results showed 
that the radiopharmaceutical conjugated-bisphosphonate was selectively distributed to the 
skeleton, specifically favoring sites of high bone turnover. In this case, bone-specificity was 
mediated by the bisphosphonate affinity for the apatite surface. 
For this thesis, bisphosphonate moieties were selected as the bone targeting ligand, 
because they are chemically very stable synthetic compounds that resist chemical and 
enzymatic hydrolysis induced by osteoclasts and therefore seem to possess the capability for 
modifying  a previously-developed delivery system without affecting the chemical integrity of 
the targeting ligand [122]. 
 
6.2. Acidic oligopeptides. 
Recently, another drug delivery system using acidic compounds, namely 
oligopeptides, was developed to target bone. This unique approach is based on the well 
known structures of several non-collagenous bone proteins that have a repetitive sequence of 
several acidic amino acids (L-aspartic acid or L-glutamic acid) that makes them adhesive to 
hydroxyapatite. Osteopontin and bone sialoproteins, two major non-collagenous proteins of 
bone, have L-Asp and L-Glu repetitive sequences and rapidly bind to hydroxyapatite after 
addition to osteoblastic cell culture [123,124]. Studies indicated that the minimum number of 
amino acids in the sequence should not be less than six in order to obtain high binding to 
hydroxyapatite. There is no effect of either the chemical nature of the acidic amino acid 
(aspartic or glutamic) or the optical isomer form (L or D) on the in-vitro binding to bone 
mineral [125-127]. The affinity of acidic oligopeptides to hydroxyapatite is due to ionic 
interactions between the negatively charged acid groups of these peptides and the positively 
charged calcium ions within the mineral component of bone at physiological pH [128]. The 
structure of commonly used acidic oligopeptides is indicated in Figure 4. 
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Figure 4: The structure of commonly used acidic oligopeptides  
                                   
 Because of the unique features of these compounds, much effort has been directed to 
conjugate non-specific bone agents with small acidic peptides in order to obtain 
osteotropicity. A prodrug conjugate consisting of β-estradiol (E2) and L-Asp-hexapeptide has 
been prepared and was used to target bone tissue for the treatment of postmenopausal 
osteoporosis. The clinical use of E2 alone is limited by adverse effects, due to the fact that E2 
easily penetrates biological membranes. By conjugating estradiol with the hydrophilic 
peptide, the prodrug was designed to improve patient compliance. In the in-vivo study, the 
prodrug conjugate was selectively delivered to the bone and it was eliminated very slowly 
after injection into mice. This finding also confirmed the usefulness of acidic polypeptides as 
selective bone targeting ligands [129].   
   
6.3- Tetracyclines. 
  Other acidic components with known bone-targeting ability include the tetracyclines, 
yellow crystalline substances from the metabolites of the actinomycete Streptomyses rimosus 
with a wide range of antibiotic activities. While tetracyclines possess a wide range of 
biological activity, they all have a similar basic molecular structure as shown in Figure 5. 
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Figure 5: The basic structure of tetracycline 
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 Tetracyclines are mainly deposited in the newly-formed bone after injection into the 
living organism. This is due to the direct reaction between tetracycline and one or more of 
inorganic components of the mineralized tissue, the most likely species being hydoxyapatite. 
The affinity of tetracycline for hydroxyapatite is due to its chelation capacity for calcium ions 
present at the surface of the mineral bone matrix [95,130]. 
 Due to their high affinity for bone, tetracyclines have been conjugated with some 
therapeutic agents for improved diagnosis and treatment of skeletal diseases. They have been 
conjugated with synthetic polymers to develop water soluble polymeric bone-targeting drug 
delivery system based on PEG and HPMA copolymer. These systems may be used as 
universal vehicles for the targeted delivery of bone therapeutics [131]. Because of the uptake 
of tetracycline in vivo by the centers of active bone formation, Frost et al. [132] applied it as a 
marker to measure the rate of bone formation at the level of osteoblast. However, the 
complicated structure of tetracyclines and their poor chemical stability seems to hinder further 
utilization of tetracyclines as bone targeting moieties. 
 
6.4. Miscellaneous. 
 In addition to all of the above mentioned compounds, a few other molecules have been 
applied as bone-targeting moieties. These chemical groups include polymalonic acid, sialic 
acid, N-methacrylamido salicylic acid, N-acryloyl aspartic acid, phosphonylated 
polyphenylene oxide, and non-ionic polymers such as glucan. The structures of some of these 
compounds are presented below in Figure 6 [95].    
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Figure 6: The structure of miscellaneous bone-targeting ligands 
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7. Goals of the Thesis 
The main objective of this work was the preparation, optimization and investigation of 
nanoparticulate bone targeted drug delivery systems using the well known gold nanoparticles 
as model system for the investigation and basis for the versatile production of the particles.  
The chosen gold nanoparticles represent an excellent model candidate in the field of 
nanoparticle-based targeted drug delivery because they can be easily obtained in the desired 
size, they are easy to manufacture, and they can be easily modified to impart various 
functionalities by conjugation with various biomaterials and other molecules without altering 
the biological activity of the conjugated compounds. Additionally, gold nanoparticles can be 
easily detected by UV-Vis spectroscopy due to their unique optical properties such as 
distinctive extension band in the visible region (SPR) due to the surface plasmon oscillation 
of the free electrons [133-135]. 
 
One of the essential requirements for this design of nanoparticles is long blood 
circulation time to allow them to reach the specific target sites. In order to achieve this, the 
nanoparticle surfaces must be coated with a layer of hydrophilic polymers such as 
poly(ethylene glycol) to avoid rapid uptake by the reticuloendothelial system (RES). At the 
same time, the polymer could act as platform for further functionalization of the nanoparticles 
with targeting ligands [136]. 
 
Along these lines chapter 2 describes the synthesis of poly(ethylene glycol)-undecyl 
mercaptane, either methoxy or amine terminated used for the functionalization of the gold. 
The synthesized polymers are characterized by their high affinity for gold surfaces and the 
formation of a well ordered self assembled monolayer due to the presence of the alkanethiol 
parts. Amine terminated poly(ethylene glycol)-undecyl mercaptane was also functionalized 
with bisphosphonate as a bone targeting ligand and successfully proved its affinity for 
hydroxyapatite. 
 
The necessary optimization of polymer synthesis using retrosynthesis approaches was 
used to establish suitable methods to obtain highly pure derivatives of poly(ethylene glycol)-
undecyl mercaptane. Various experiments using other synthesis schemes were used to 
determine the optimal reaction conditions for the synthesis of the required polymers (Chapter 
3). 
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Chapter 4 outlines the preparation and optimization of the gold nanoparticles suitable 
for intravenous administration by citrate reduction. The obtained nanoparticles were coated 
with methoxy poly(ethylene glycol)-undecyl mercaptane and amino poly(ethylene glycol)-
undecyl mercaptane. The prepared nanoparticles were characterized by size determination 
(using photon correlation spectroscopy and TEM), zeta potential measurements and UV-Vis 
spectroscopy. Furthermore, the stability of polymer modified nanoparticles was tested in the 
presence of sodium chloride, BSA and serum to simulate the later in vivo conditions.  
 
The objective of the further work was the evaluation of the in vitro binding of 
bisphosphonate-functionalized gold nanoparticles to hydroxyapatite (HA). The effect of 
coating with different concentrations of bisphosphonate on the in vitro affinities of 
nanoparticles for hydroxyapatite at room temperature was investigated. In order to simulate 
the in vivo conditions, in vitro binding of bisphosphonate-functionalized gold nanoparticles to 
endobone was also studied in the presence of calcium chloride, BSA and serum (Chapter 5). 
 
The final goal of the thesis was to test bisphosphonate functionalized gold 
nanoparticles in vivo. Nanoparticles were labeled with radioactive indium in order to track 
them after intravenous injection. The biodistribution in different organs and the 
pharmacokinetics of functionalized and control gold nanoparticles in mice were investigated 
(Chapter 6). 
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Abstract 
 Heterobifunctional poly(ethylene glycol) derivatives have a wide range for biomedical 
applications ranging from the modulation of the solubility of badly soluble compounds to the 
surface modification of implants. For the modification of variously shaped gold surfaces 
thioalkylated poly(ethylene glycol)s are well established, since they form very stable self 
assembled monolayers (SAMs). For a more sophisticated functionalization, the polymers 
should furthermore provide functional groups, which can be used for the attachment of other 
molecules. For this study two different polymers (methoxy poly(ethylene glycol)-undecyl 
mercaptane and amino poly(ethylene glycol)-undecyl mercaptane) were synthesized applying 
a new synthetic strategy. Subsequently, a suitable bone targeting ligand, bisphosphonate, well 
soluble in non aqueous media was synthesized and reacted with the amine terminus of the 
polymer using standard DCC/NHS chemistry. The obtained polymers were characterized by 
1H-NMR, HPLC and mass spectroscopy and demonstrated a high degree of purity. 
Furthermore, it was demonstrated that the bisphosphonate-modified polymers bind to gold 
surfaces and to hydroxyapatite, which indicated the successful linkage of the two 
functionalities. Consequently, the synthesized polymers seem to be promising for the 
preparation of functionalized gold nanoparticles, which additionally exhibit a high affinity for 
the bone mineral hydroxyapatite. 
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1. Introduction 
In order to modify biomaterial surfaces, like polymers or metals, bifunctional 
derivatives of poly(ethylene glycol) play an important role due to their unique properties, like  
high water solubility, good biocompatibility, low cytotoxicity, low immunogenicity, low 
protein binding and subsequent poor cell adhesion [1-4]. An additionally introduced 
bifunctionality furthermore allows for the selective attachment to surfaces and the 
presentation of specific groups suitable to introduce further functions into the polymers, like 
for example controlled cellular adhesion, immobilization of bioactive compounds or also the 
targeting to a certain cell type or tissue. The so far most prominent applications of 
functionalized PEG molecules include: PEGylation of peptide and protein drugs [5-9], 
preparation of hydrogels for drug delivery applications [10,11], as well as the surface 
modification of materials in order to control cellular adhesion [12] or the surface stabilization 
and functionalization of different nanoparticles [13-15]. 
For all of these applications, thiol functionalized or thioalkylated poly(ethylene 
glycol)s are known to binds strongly to gold surfaces due to their spontaneous and very 
specific adsorption of the thiol or disulfide derivatives to the gold surfaces, leading to the 
formation of very stable self assembled monolayers (SAMs). For these applications, the 
alkanethiol part of the polymers is essential to form a highly stable, highly ordered and well 
oriented monolayer film due to the present Van der Waals interactions between neighboring 
alkyl chains, which almost form crystal structures during their assembly [16]. Also, the 
binding of the sulfur head group to the gold substrate occurs in the form of the metal thiolate, 
which is an extremely strong bond and subsequently the resulting monolayer are quite stable 
[17-19]. It is reported in literature that the minimum length of used alkyl chain should be 11 
carbon atoms in order to obtain a densely packed almost crystalline like assembly of the 
chains. Shorter aliphatic parts (less than 11) consequently produce less ordered structures with 
a lower packing density and also weaker coverage of the underlying gold surfaces [20-22]. 
The application of poly(ethylene glycol) as surface coating is well known to prevent 
non specific adsorption of proteins to the modified surfaces. The PEG mediated protein 
resistance also of SAMs is due to the formation of stable interfacial aqueous layer, which 
prevents a direct contact between the underlying biomaterial surface and the proteins, and 
furthermore exhibits also no interactions between the uncharged PEG and the protein 
molecules [23]. It is described in literature that the inhibition of the unspecific protein 
adsorption to PEG modified surfaces is almost independent on the chain length of the PEG 
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coating, but a minimum chain length of PEG is required to diminish cellular adhesion, which 
is found to be about 2000 Da [24,25]. 
The functionalization of PEG for surface coatings is already described in literature to 
achieve specific interactions with cells. Knerr and et al. [12] reported the modification of gold 
coated quartz surfaces with alkanethiol PEG modified with RGD containing adhesion 
sequences in order to measure the cellular adhesion using the quartz crystal microbalance. 
Functionalized gold nanoparticles have been also used to target specific organs in the body 
via the surface receptors of certain cells. Here, folic acid modified poly(ethylene glycol) 
coated nanoparticles were used to target folate receptor on cancer cells [26] or PEG-thiol 
coated gold nanoparticles were used as a platform to optimize hepatocyte-targeted delivery in 
vivo using galactose targeting moieties [27] 
In order to achieve bone targeting of nanoparticles, we chose bisphosphonates, organic 
analogues of pyrophosphate, due to their exceptional high affinity to bone mineral, which 
already led to their exploration for targeting different pharmacological agents to bone tissues 
[28]. Currently, bisphosphonates are the most important class of antiresorptive drugs used in 
the treatment of metabolic bone diseases, including osteoporosis, tumor-associated osteolysis 
and also subsequent hypercalcemia. All these compounds have a very high affinity for 
calcium ions and therefore mainly target the bone mineral, where they are as primarily 
adsorbed drugs internalized by the bone resorbing osteoclasts and subsequently inhibit their 
physiological function [29]. Bisphosphonates have also been studied as tool to achieve a high 
bone mineral affinity for various other materials. Functional nanoparticles for the treatment of 
bone disease were designed by surface modification of PLGA particles using alendronate as 
targeting moiety. The observed HA affinity assay suggested that the alendronate-modified 
PLGA nanoparticles have the potential to the targeted these drug delivery systems to bone 
[30]. 
Additionally, protein-based therapeutic agents intended for treatment of bone diseases 
have been prepared by direct chemical conjugation with bisphosphonate. It was demonstrated 
by several experiments that conjugation of bone-seeking bisphosphonate with various bigger 
proteins improved their localized delivery to mineralized tissues [31-36]. Also the delivery of 
an antineoplastic agent, methotrexate, to bone through chemical ligation with bisphosphonate 
has been achieved and demonstrated an over five times greater antineoplastic activity against 
osteosarcoma compared to methotrexate alone [37]. Hirabayashi et al. [38] described the 
development of diclofenac prodrugs linked to bisphosphonate (DIC-BP) creating an 
osteotropic drug delivery system (ODDS). Their results demonstrated that the synthesized 
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prodrug provides a localized and prolonged release of diclofenac, while at the same time 
preventing adverse side effects in the stomach. In an attempt to achieve higher drug loading 
per molecule alendronate and an also bone targeting aspartic acid peptide were conjugated to 
water-soluble polymers as polymer based bone targeting system. Alendronate and aspartic 
acid were introduced in the polymers either by direct conjugation or by copolymerization with 
the corresponding monomers. The obtained results for their bone targeting affinities also 
showed that these novel delivery systems were accumulated in the bone tissue [39].  
The main drawbacks for conjugating bisphosphonates to polymers or other compounds 
are the limited abilities to detect their binding due to the lack of a sufficient chromophore and 
the limited solubility in non aqueous media due to their high polarity. 
The goal of this study was the establishment of a synthesis providing a bisphosphonate 
labeled poly(ethylene glycol) suitable for the surface functionalization of differently sized 
gold particles in order to provide systems for the investigation of bone targeting of 
nanoparticles. In order to achieve this, an organic soluble bisphosphonate with an aromatic 
ring as chromophore was chosen to conjugate to thiol alkane modified poly(ethylene glycol). 
The polymers should, furthermore, be provided with a high purity in order to estimate the 
surface composition on the later used gold particles based on the polymer amounts used for 
their assembly. 
 
2. Materials and Methods 
Tetraethyl methylenebisphosphonate, diethylamine, 11-bromo-1-undecene, sodium 
hydride, N-hydroxysuccinimide (NHS), N,N\-dicyclohexylcardodiimide (DCC), ethylene 
oxide, and ammonium persulfate, were obtained from Fluka (Buchs, Switzerland). P-toluene 
sulfonic acid monohydrate, 3,5-diaminobenzoic acid, poly(ethylene glycol) monomethyl ether 
(mPEG, Mw 2000 Da), α,α´ azoisobutyronitrile (AIBN), thioacetic acid, potassium 
bis(trimethylsilyl) amide, di-t-butyl dicarbonate (BOC), tetramethylsilane (TMS), 
bromotrimethylsilane, amylamine, DEAE-sephadex A25 and dialysis tubing with a molecular 
weight cut-off (MWCO) of 1000 Da were acquired from Sigma-Aldrich Chemical Company 
(Steinheim, Germany). Paraformaldeyde, calcium hydride, methanol, toluene, 
dichloromethane, chloroform, acetonitrile, tetrahydrofuran (THF), acetone, 1,4-dioxane, 
sodium sulphate, hydrochloric acid, sulfuric acid, acetic acid, sodium acetate, ammonium 
carbonate, zinc powder, ammonium heptamolybdate tetrahydrate, diethyl ether, ascorbic acid 
and hydroxyapatite (HA) were purchased from Merck (Darmstadt, Germany). Deuterated 
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chloroform was from Deutero GmbH (Kastellaun, Germany). Ibandronate as standard 
substance was a generous gift from Boehringer (Mannheim, Germany). 
 
2.1. Synthesis of 3,5-Di(ethylamino-2,2-bisphosphono)benzoic Acid: 
3,5-Di(ethylamino-2,2-bisphosphono)benzoic acid as bisphosphonate carrying label 
for the polymers was synthesized according to a procedure described by Bansal et al. [40] 
(Scheme 1). Briefly, dietylamine (0.580 g, 8 mmol) and paraformaldeyde (1.212 g, 40 mmol) 
were added to 25 ml of methanol and the mixture was slightly warmed until a clear solution 
was obtained. Tetramethyl methylenebisphosphonate (1) (2.326 g, 8 mmol) was added and the 
mixture was refluxed for 24 h, and methanol was removed under vacuum and subsequent 
addition and evaporation of toluene. This last step was repeated to ensure complete removal 
of methanol from the solution of the product. This reaction leads to the formation of tetraethyl 
2-methoxyethylene-bisphosphonate (2), which was finally dissolved in 100 ml of toluene. 
Catalytic amounts of p-toluenesulfonic acid monohydrate (5 mg) were added and the solution 
was refluxed for 14 h using a Soxhlet apparatus containing calcium hydride for the complete 
removal of methanol and water. After the reaction toluene was evaporated and the obtained 
product was dissolved in chloroform (50 ml) and washed three times with 30 ml of water. The 
organic layer was subsequently dried with anhydrous sodium sulphate and concentrated to 
yield an oily residue. The crude product was purified by fractional distillation to a produce a 
clear liquid of the boiling point 115-116 °C, which is characteristic for the tetraethyl 
ethenylidenebis(phosphonate) intermediate (3) [41]. The intermediate (3) (0.96 g, 3.2 mmol) 
and 3,5-diaminobenzoic acid (4, 0.24 g, 1.6 mmol) were subsequently heated in 30 ml of 
tetrahydrofuran at 60 °C for 5 h to produce 3,5-di(tetraethyl ethylamino-2,2-bisphosphonate) 
benzoic acid (5). Tetrahydrofuran was removed under vacuum and the product (5) (0.9 g, 1.18 
mmol) was dissolved in dry dichloromethane (10 ml) and bromotrimethylsilane (4.02 g, 26.2 
mmol) was added drop wise at 0 °C. The obtained mixture was then stirred at room 
temperature for two days. Finally, dichloromethane was evaporated and 3,5-di(ethylamino-
2,2-bisphosphono)benzoic acid (6) was obtained and purified by anion exchange 
chromatography using DEAE-sephadex A25. 
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Scheme 1: Synthesis of targeting ligand for hydroxyapatite binding 
 
2.2. Purification of bisphosphonate by DEAE-sephadex A25 
A weak anion exchange material, DEAE-sephadex A25, was used for the purification 
of the hydrolyzed bisphosphonate. The sephadex was swollen in acetate buffer (pH=4) for 
two days; the dissolved bisphosphonate was than loaded in the same buffer onto the swollen 
column material. Resin loaded with bisphosphonate was washed two times with the loading 
buffer using Buchner funnel to remove the impurities. Bisphosphonate was eluted from the 
resin by using 0.2 M ammonium carbonate. The ammonium carbonate solution was then 
freeze dried giving dry product. The pure final product was characterized by 1H, 13C, 31P-
NMR, ion pair chromatography, and mass spectroscopy 
 
2.3. Bisphosphonate characterization 
2.3.1. NMR analysis 
1H-NMR (nuclear magnetic resonance spectroscopy) spectra were recorded on a 
Bruker Avance 600 spectrometer (Bruker Biospin, Rheinstetten, Germany).  
2.3.2. Ion-pair chromatography 
Samples with hydrolyzed bisphosphonate group were investigated by high pressure 
liquid chromatography (HPLC) using a setup consisting of a DGU-14A degasser, LC-10-AT 
pump, SIL-10 AD autosampler, RF-10A XL fluorescence detector, SPD-10A VP UV-Vis 
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detector and SCL-10A VP controller (Shimadzu, Duisburg, Germany). The samples were 
separated on C18 column (25 cm × 4.6 mm I.D., 5 µm) purchased from Supleco (Deisenhofen, 
Germany). The mobile phase used was a mixture of 18 mM n-amylamine aqueous solution 
(adjusted to pH 7.0 with acetic acid) and acetonitrile (95%:5% (V/V)). The flow rate was kept 
constant at 1 ml/min and the experiments were conducted at room temperature [42,43]. 
2.3.3. ESI-Mass 
Mass spectra of the synthesized compounds were obtained using the TSQ7000 
electrospray- mass spectrometer (ThermoQuest, San Jose, CA, USA) with the detection range 
of 1-1000 Da. 
 
2.4. Synthesis of poly(ethylene glycol)-undecyl mercaptane derivatives: 
2.4.1. Methoxy poly(ethylene glycol)-undecyl mercaptane (mPEG2000C11H22SH) 
To synthesize thioalkylated poly(ethylene glycol) monomethyl ether, the synthetic 
Scheme 2 was applied. 5 g (2.5 mmol) of methoxy poly(ethylene glycol) (7) were melted in 
an oil bath under argon atmosphere. 600 mg (25 mmol) of sodium hydride were added to the 
molten mPEG and stirred at 110-120 oC until the evolution of hydrogen abated (about 20 
minutes). 11-bromo-1-undecene (8) (2.33 ml, 10 mmol) was added to the reaction flask and 
the mixture was stirred at the same temperature overnight to form the ether product. At the 
end of the reaction, the remaining hydride was quenched by the addition of 30 ml of 
methanol. After evaporation of methanol, the residue was dissolved in toluene, filtered to 
remove inorganic salts precipitated in toluene. Finally, toluene was evaporated and the 
obtained residue was dissolved in acetone and precipitated in cold diethyl ether to yield the 
product methoxy poly(ethylene glycol)-undecene (9). For the addition of thioacetic acid to the 
terminal double bond, 4.4 g (2 mmol) of the intermediate 9 and 0.480 g (3 mmol) of α,α’-azo-
isobutyronitril (AIBN) were dissolved in 30 ml of dry methanol (dried by using a molecular 
sieve of 4Å). 2 ml of thioacetic acid were added and the reaction mixture was stirred under 
reflux for 72 h. Finally, remaining methanol was evaporated using the rotary evaporator, and 
the obtained polymer residue was dissolved in acetone and subsequently precipitated in cold 
diethyl ether yielding compound 10 [17]. The following  hydrolysis of the thioacetate ester 10 
to the free thiol group was carried out in methanolic HCl as described by Bain et al. [22] to 
give the methoxy poly(ethylene glycol)-undecyl mercaptane (11 a), which was purified by 
repeated precipitation in cold diethyl ether. The synthesized polymer was characterized by 
1H-NMR and HPLC to determine the conversion and the purity of the synthesized compound. 
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Scheme 2:  Synthesis of the bifunctional PEG-undecyl mercaptane  
 
2.4.2. Amino poly(ethylene glycol)-undecyl mercaptane (H2N-PEG2000C11H22SH). 
A similar reaction scheme (Scheme 2) was applied for the synthesis of the 
corresponding amine derivative of the polymer with some slight modifications due to the 
present amine group. Amine group protected t-butoxycarbonyl amino (polyethylene glycol) 
(BOC-NH-PEG) was used instead of methoxy poly(ethylene glycol) in order to prevent the 
alkylation of the amine group during the Williamson ether synthesis. The corresponding 
poly(ethylene glycol)-monoamine was synthesized by polymerization of ethylene oxide with 
potassium bis(trimethylsilyl) amide as anionic initiator according to methods described in 
literature [44,45]. The terminal amine group was then protected by di-t-butyl dicarbonate 
(BOC) by stirring it overnight in a mixture of dioxane and water in the presence of potassium 
hydroxide [46]. The efficiency of obtained amine protection was examined by measurement 
with the amine reactive fluorescamine [47,48]. After amine group protection, the reaction 
with 11-bromundecene was completed as described above for the methyl terminated 
poly(ethylene glycol). In the final step, the used methanolic HCl hydrolyzed not only the 
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thioacetate ester to free thiol, but also deprotected BOC protected amine to yield the free 
amino poly(ethylene glycol)-undecyl mercaptane (11 b). 
 
2.4.3. Conjugation of amino poly(ethylene glycol)-undecyl mercaptane with 3,5-
di(tetraethyl ethylamino-2,2-bisphosphonate)benzoic acid. 
The polymer was conjugated to the bisphosphonate carrying benzoic acid using 
standard carbodiimide chemistry as depicted in reaction Scheme 3. Briefly, 1.5 g (2 mmol) of 
the still ethyl protected bisphosphonate compound 5 were dissolved in 50 ml of dry dioxane 
(dried by 4Å molecular sieve). To this solution, 0.46 g of N-hydroxysuccinimide (4 mmol) 
and 0.824 g (4 mmol) of N,N’-dicyclohexylcardodiimid were added and the obtained solution 
was stirred for two hours at room temperature in order to activate the carboxyl group of the 
bisphosphonate for the reaction. After that, 2.2 g (1 mmol) of the amine terminated 
poly(ethylene glycol)-undecyl mercaptane (11b) were added and the flask was further stirred 
for two days. Afterwards the precipitated dicycloexylurea was filtered off, and the solvent 
dioxane was evaporated under vacuum, the obtained product was again dissolved in acetone 
and precipitated twice in cold diethyl ether, and finally collected by suction filtration and 
subsequently dried under vacuum. To obtain the final product bearing the free bisphosphonate 
group, the ethyl groups of the esters were removed by subsequent mild hydrolysis using 
bromotrimethylsilane as reagent. 3 g of the compound 13 were dissolved in 10 ml of 
dichloromethane and cooled to 0 °C. 5 ml of bromotrimethylsilane were added drop-wise to 
this solution and the mixture was further stirred at room temperature for two days. After 
evaporation of dichloromethane, 20 ml of methanol were added and the mixture was stirred 
overnight and subsequently methanol was removed by heat treatment. The dried final product 
was dissolved again in buffer and subsequently purified by DEAE-sephadex A25 similarly as 
described for the bisphosphonate and finally dried using freeze drying of the eluted buffer 
solution. Only, a further purification step was added, which is the dialysis of the freeze dried 
product for two days against de-ionized water using dialysis tubing of molecular weight cutoff 
(MWCO) 1000 Da in order to remove non-evaporated buffer salts and eventually free 
bisphosphonate also retained by the ion exchange column. 
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Scheme 3:  Synthesis of bisphosphonate conjugated polymer 
 
2.5. Polymer characterization 
2.5.1. 1H-NMR 
For NMR spectra of the polymers, they were dissolved in CDCl3 with tetramethyl-
silane as internal standard, if applicable due to the solubility of the bisphosphonate, and 
subsequently measured using Bruker Avance 600 spectrometer (Bruker Biospin, Rheinstetten, 
Germany). 
2.5.2. MADI-ToF mass Spectrometry 
Matrix assisted laser desorption/ionization mass spectrometry (MALDI-ToF MS) data 
were acquired on a HP G2030A spectrometer using a positive ion mode. The polymers were 
analyzed using the molecular weight range of 0-6000 m/z, data were recorded for about 150 
laser shot per spectrum using indoleacrylic acid dissolved in THF (0.15 mg/ml) as matrix 
component. The samples were prepared on the MALDI target by depositing 1 µl of a mixture 
of matrix solution and polymer solution (1 mg/ml) (3:1), which were subsequently dried 
under vacuum at room temperature. 
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2.5.3. RP-HPLC 
HPLC analysis of the synthesized polymers was performed on the same HPLC system 
as used for analysis of the bisphosphonate. A linear gradient of 20% to 100% solvent B (90% 
acetonitrile in water) in solvent A (10% acetonitrile in water) over 30 min. was applied as 
mobile phase at a flow rate of 1 ml/min. 50 µl samples (5 mg/ml) were separated at 40 °C 
using a combination of two macroporous reversed phase columns, namely a PLRP-S guard 
column and an analytical column (PLRP-S 300 Å, 5 µm, Polymer Laboratories, Amherst/MA, 
USA). The samples were detected by a low temperature evaporative light scattering detector 
(ELSD–LT Shimadzu GmbH, Duisburg, Germany). 
2.5.4. Phosphate assay 
The phosphate content of the polymers modified with bisphosphonate was determined 
according to a reported test method [49]. For the phosphate detection organic bound 
bisphosphonates are oxidized to orthophosphate by ammonium persulfate followed by a 
reaction with molybdenum-ascorbate to yield the phosphomolybdate chromophore, which is 
detected at 820 nm using UV-Vis spectroscopy. A standard substance for bisphosphonate 
(ibandronate) was used for the preparation of a calibration curve. Briefly, 0.1 ml of a solution 
containing 1-10 µM of ibandronate were mixed with 0.1 ml of 50 µM ammonium persulfate 
and the samples were heated in a boiling water bath for 5 minutes. Then 1 ml of the 
molybdate-ascorbate reagent [50] was then added and the samples were heated for another 
10 minutes in the boiling water bath. After cooling down to room temperature, the absorbance 
was measured at 820 nm using a plate reader (Shimadzu CS-9301 PC, Shimadzu, Duisburg, 
Germany). An amount of the final product equivalent to 2.5 µM phosphate was then taken 
and treated similar to ibandronate for the quantification of the incorporated bisphosphonate 
molecules. 
 
2.6. Testing the polymer’s binding functionalities (binding to hydroxyapatite or gold) 
The dual functionalities of the polymer were explored by testing its affinity to 
hydroxyapatite (HA) powder (due to the presence of bisphosphonate groups) and gold 
surfaces (due to the presence of the alkanethiol part). For HA binding, 2 ml of the polymer 
modified with free bisphosphonate (1 mg/ml) were added to an Eppendorf centrifuge tube 
containing 10 mg of accurately weighed hydroxyapatite powder. The tube was agitated in a 
horizontal shaker adjusted to 200 rpm at room temperature overnight. After that, the tube was 
centrifuged at 3000 rpm and the liquid supernatant was subsequently analyzed by the above 
described ion pair HPLC [51]. 
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Binding to gold surfaces was tested according to the following procedure: 1 ml of free 
bisphosphonate modified polymer solution (1mg/ml) was added to four glass cover slips 
coated by a thin layer of gold (18*18 mm) at room temperature. After one day of shaking, the 
solution was analyzed for the presence of the polymer by HPLC [12]. 
 
3. Results and Discussion 
3.1. Synthesis of 3,5-Di(ethylamino-2,2-bisphosphono)benzoic Acid: 
The two bisphosphonate compounds 5 and 6 were synthesized as targeting ligands, 
since they are suited to overcome problems associated with the commercially available 
bisphosphonates, like solubility in organic solvents or lack of possible conjugation schemes to 
the PEG derivatives. The used bisphosphonates have the following advantages: firstly, two 
bisphosphonate groups are contained in one attached molecule, which then consequently has a 
higher hydroxyapatite binding affinity compared to compounds containing only one 
bisphosphonate group. Secondly, the ease of detection due to the presence of an aromatic 
benzene ring, which can be either detected using its fluorescence or alternatively by UV 
absorption, which is sufficient to distinguish it from the unmodified PEG polymer. 
Furthermore, the compounds both provide a free carboxylic group for subsequent easy 
conjugation with primary amines using DCC chemistry. The synthesis of the ester 3,5-
di(tetraethyl ethylamino-2,2-bisphosphonate)benzoic acid 5 and the free acid 3,5-
di(ethylamino-2,2-bisphosphono)benzoic acid 6 are depicted in Scheme 1. The synthesis 
started with bisphosphonate compound 1, which underwent methoxy methylation with 
methanol and paraformaldehyde in the presence of diethyl amine to yield the intermediate 2 
(first step). [1H-NMR spectrum for 2, δH (CDCl3): 4.19 (m, 8H, OCH2CH3), 3.63 (m, 2H, 
CH3OCH2), 3.2 (s, 3H, CH3O), 2,52 (tt, 1H, PCHP) and 1,18 (t, 12H, CH2CH3)]. 
The unstable Intermediate 2 was then converted to the unsaturated compound 3 by 
elimination of methanol, catalyzed by refluxing it with trace amounts of p-toluenesulfonic 
acid in toluene. Methanol is thereby removed from the reaction mixture by calcium hydride 
using a Soxhlet apparatus (step 2). [1H-NMR spectrum for 3, δH (CDCl3): 6.98 (dd, 2H, 
CH2=), 4.15 (m, 8H, OCH2CH2), and 1.3 (m, 12H, CH3CH2)]. The chemical shifts of both 
compounds 2 and 3 are in a good agreement with that described in the literature [40,41]. 
Compound 5 was obtained by anti-Markovnikov addition of the amine groups of 3,5-
diaminobenzoic acid, compound 4, to the double bond of intermediate 3 (step 3). [1H-NMR 
spectrum for 5, δH (CDCl3): 6.91 (s, 2H, ortho protons of benzene ring), 6.15 (s 1H, para 
proton of benzene ring), 4.15 (m, 16H, -O-CH2-CH3), 3.78 (m, 4H, -NH-CH2-CH), 2.75 (tt, 
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2H, P-CH-P) and 1,37 (t, 24H, -O-CH2-CH3). ESI-Mass spectrum for 5 is presented in Figure 
1; MS: m/z 753.2 (M+H+), 775.2 (M+Na+) and 791.2 (M+K+)]. 
Hydrolysis of the phosphonate esters of compound 5 was achieved by using the mild 
dealkylating agent also used for peptide synthesis, bromotrimethylsilane (step 4). 
Bromotrimethylsilane here firstly forms a silyl ester intermediate with replacing of the ethyl 
groups. This silyl ester is unstable and can subsequently be easily hydrolyzed by water or 
methanol yielding the free acid form (compound 6). The 1H-NMR spectrum for 6 
demonstrated disappearance of the phosphonate esters due to the lack of any signals from the 
ethyl groups. [MS m/z 527.2 (M-), 263.1 (M2-) and 174.8 (M3-)]. 
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Figure 1: ESI-Mass spectra of 3,5-di(tetraethyl ethylamino-2,2-bisphosphonate)benzoic 
acid( compound 5) 
 
3.2. Synthesis of poly(ethylene glycol)-undecyl mercaptanes: 
3.2.1. Methoxy poly(ethylene glycol)-undecyl mercaptane (mPEG2000C11H22SH). 
Alkanethiol terminated poly(ethylene glycol) monomethyl ether was obtained through 
a three-step synthesis as described in reaction Scheme 2. For the reaction the poly(ethylene 
glycol) monomethyl ether (7) was deprotonated by 10 equivalents of sodium hydride and 
subsequently reacted with an excess of the 11-bromo-1-undecene (8) in order to obtain a 
complete modification of the added PEG polymers to methoxy poly(ethylene glycol)-
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undecene (9). Subsequently the polymers were precipitated in cold ether, which is a good 
solvent for eventually residual alkene. The terminal double bond of the alkene part is not 
reactive under these conditions and therefore did not need any protection. [1H-NMR spectrum 
for intermediate (9), δH (CDCl3): 5.8 (m, 1H, -CH=), 4.95 (t, 2H, CH2=), 3.5-3.9 (m, ~180 H, 
-OCH2CH2-), 3.45 (m, 2 H, -OCH2-C-C-C), 3,3 (s, 3 H, CH3O-), 2.0 (m, 2 H, -CH2CH=) and 
1.7-1.2 (m, 14 H, the remaining protons of the alkene part)]. 
Radical addition of thioacetic acid to the double bond of compound 9 was performed 
by applying heat in the presence of AIBN as radical initiator. This reaction follows anti-
Markovnikov rule and yields acetate protected thiol derivatives (10) with a high conversion 
(above 95%). The 1H-NMR spectrum of compound 10 is characterized by the disappearance 
of the signals attributed to the double bond of the alkene located at 5.8, 4.95 and 2,0 ppm and 
the appearance of new signals at δH (CDCl3): 2,85 ppm (t, 2 H, -CH2S) and 2.3 ppm (s, 3H, -
SCOCH3) for the thioacetic acid part. There were no obvious changes observed for other 
proton signals, which are related to mPEG chain and the aliphatic part of the molecule. The 
final deprotection of the of the thioacetate group of compound 10 to free thiol was carried out 
under acidic condition using anhydrous solution HCl in MeOH [52,53]. [1H-NMR spectrum 
of the final product mPEG2000C11H22SH (11a), (Figure 2, above spectrum), δH (CDCl3) 3.5-
3.9 (m, 180 H, -OCH2CH2), 3.45 (m, 2 H, -OCH2-), 3.3 (s, 3 H, CH3O-), 2.55 (tt, 2 H, -
CH2SH) and 1.7-1.2 (m, 18 H, the remaining protons of the alkane part)]. 
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Figure 2: 1H-NMR spectrum of methoxy poly(ethylene glycol)-undecyl mercaptane (above 
spectrum) and amino poly(ethylene glycol)-undecyl mercaptane (low spectrum)  
 
3.2.2. Synthesis of amino poly(ethylene glycol)-undecyl mercaptane (NH2PEG2000-
C11H22SH). 
Poly(ethylene glycol) monoamine with a molecular weight of 2.000 Da was 
synthesized as reported earlier [45]. The actual molecular weight of the polymer was 
confirmed by MALDI-ToF and 1H-NMR. The results indicated that the obtained average 
molecular weight of NH2-PEG-OH was about 1960 Da. For the further reaction the primary 
amine of NH2-PEG-OH was protected with an excess of BOC-anhydride in presence of 
potassium hydroxide solution. Under these alkaline conditions, BOC protection is only 
achieved for the amine group, since the diester formed with the hydroxyl group is again 
cleaved under these reaction conditions. Based on a standard fluorescamine assay, it was 
found that the protected polymer contains less than 1% free amine indicating a sufficient 
protection of the terminal amine with BOC. [1H-NMR spectrum of BOC-NH-PEG-OH is 
characterized by the following signals; δH (CDCl3): 3.5-3.9 ppm (m, 180 H, -OCH2CH2-) and 
1.45 ppm (s, 9 H, -C(CH3)3)]. 
The BOC protected poly(ethylene glycol)-monoamine was then reacted with 11-
bromo-1-undecene in the presence of sodium hydride as described for the methoxy derivative 
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to yield the protected poly(ethylene glycol) monoamine-undecene as described in Scheme 2. 
The use of the BOC-protected polymer prevented the possible alkylation of the amine group 
to take place. The reaction was then completed with the thiol addition and the hydrolysis of 
the protective groups as described for the synthesis of methoxy poly(ethylene glycol)-undecyl 
mercaptane. [1H-NMR spectrum of pure amino poly(ethylene glycol)-undecyl mercaptane (11 
b) is presented in Figure 1 (low spectrum). The spectrum is characterized by the following 
signals δH (CDCl3) 3.5-3.9 (m, 180 H, OCH2CH2), 3.45 (m, 2 H, -OCH2-), 2.8 (t,t, 2 H, -
CH2NH2), 2.55 (tt, 2 H, -CH2SH) and 1.7-1.2 (m, 18 H, the remaining protons of the alkane 
part)].  
 
3.2.3. RP-HPLC: 
HPLC chromatograms of the different synthesized and used polymers are presented in 
Figure 3, the chromatogram of the methoxy poly(ethylene glycol)-undecyl mercaptane 
(mPEG-AlkSH) is characterized by two neighboring peaks. The first peak eluted at about 20 
minutes is related to the reduced (singly present) portion of the synthesized polymer and the 
second peak eluted at about 22 minutes is related to the oxidized, dimeric portion of the 
polymer. Both alkylated polymer species are retained longer on the solvent material, which is 
related to their increase hydrophobicity compared to methoxy poly(ethylene glycol) (mPEG), 
which is eluted at 16 minutes. The oxidized polymers are eluted at the later time point, 
because the oxidized form has a high molecular weight and at the same time it is less 
hydrophilic due to the presence of the disulfide bond.  
The chromatogram of the corresponding poly(ethylene glycol) monoamine is also 
characterized by a single peak eluted at about 15 minutes, which is significantly broader than 
the methoxy derivative since it is obtained by custom synthesis. In case of the modified amino 
poly(ethylene glycol)-undecyl mercaptane (NH2-PEG-AlkSH), also two peaks can be detected 
in the chromatogram. One peak eluting at 19 minutes due to the reduced portion and the other 
peak eluted at about 22 minutes, which is due to the oxidized portion of the polymer. The 
broad peaks obtained for these polymers are due to the wider molecular weight distribution of 
the poly(ethylene glycol) monoamine used for the synthesis of the thioalkylated polymer [54]. 
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Figure 3: HPLC chromatograms of methoxy poly(ethylene glycol)-undecyl mercaptane 
(mPEG-AlkSH), methoxy poly(ethylene glycol) (mPEG),  poly(ethylene glycol) monoamine 
(PEG-NH2) and amino poly(ethylene glycol)-undecyl mercaptane(NH2PEG-AlkSH)   
 
3.2.4. MALDI-ToF mass spectrometry 
For further characterization and elucidation of the obtained polymer structures, matrix-
assisted laser desorption/ionization time-of-flight mass spectroscopy (MALDI-ToF-MS) was 
used. The peak molecular weight (Mp) of the synthesized poly(ethylene glycol) monoamine 
was found to be 1947 Da, which approximates the molecular weight calculated by 1H-NMR. 
Adjacent peaks differing from each other by a mass difference of 44 Da represent the typical 
mass of one ethylene oxide unit, which is the repeating unit of the PEG chain. MALDI-ToF 
mass spectra of methoxy poly(ethylene glycol)-undecyl mercaptane and amino poly(ethylene 
glycol)-undecyl mercaptane proved that the polymers are obtained as mixtures of the reduced 
and oxidized form as demonstrated by the observed double molecular weights. The peak 
molecular weight of the reduced form of amino poly(ethylene glycol)-undecyl mercaptane 
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was 2148 Da, which agrees with the calculated value. The peak molecular weight of the 
oxidized form is about 4232 Da, which can be explained with the formation of disulfide form 
of two polymer chains. Similar values were measured for the molecular weights of the 
methoxy poly(ethylene glycol)-undecyl mercaptane, 2158 Da were observed for the monomer 
and 4431 Da for the dimer. 
 
3.2.5. Polymer modified with bisphosphonate: 
For the final modification of the amino poly(ethylene glycol)-undecyl mercaptane the 
unhydrolyzed bisphosphonate was linked to the polymer via an amide bond between the 
carboxylic group of the bisphosphonate and the primary amine terminus of the polymer. The 
reaction was carried out applying standard DCC and NHS chemistry in non aqueous media as 
depicted in Scheme 3. The molar ratio between the bisphosphonate and the polymer was kept 
at 2:1, which is low compared to the ratios used in literature, to avoid a modification of both 
ends of the polymers with bisphosphonate (thiol should be kept free for the binding to gold) 
[55]. The measured 1H-NMR spectrum of the product showed the characteristic peaks of both 
parts of the polymer and of the bisphosphonate. Bromotrimethylsilane supported hydrolysis of 
the ester group of the bisphosphonate resulted in the free bisphosphonate modified polymer 
(compound 14). 
Bisphosphonates and also the polymers conjugated to these molecules are highly 
hydrophilic compounds and it is consequently very difficult to retain them sufficiently on a 
reversed phase column. For this reason, ion-pair HPLC has been used for separation of these 
compounds. To form the ion pair, the polymers are combined with a lipophilic positively 
charged amyl amine contained in the mobile phase, which can then be retained on the non 
polar stationary phase and still allow detection with ELSD detector, which is necessary to 
identify the non UV adsorbing polymers [56]. The HPLC chromatogram of the final product 
is compared to that of the free bisphosphonate (compound 6) and also amino poly(ethylene 
glycol)-undecyl mercaptane in Figure 4. The hydrolyzed bisphosphonate (compound 6) (BP), 
which contains two free bisphosphonate groups, is eluted at about 16 minutes (detected by 
fluorescence detector). The polymer alone (NH2-PEG-AlkSH), which doesn’t contain any 
acidic functionality to pair with the amyl amine, is not retained on the C18 RP column and is 
consequently eluted very early with the injection peak at about 5 minutes (detected by ELSD). 
The synthesized polymer, which is modified with the bisphosphonate (BP-PEG-AlkSH) is 
eluted at about 10 minutes in between the two other compounds, and can be detected with 
both the fluorescence detector and the ELSD, which also indicated the incorporation of 
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polymer and bisphosphonate. The increase of the polymer’s retention time modified with 
bisphosphonate in comparison to the polymer alone indicates that it contains the free 
bisphosphonate group and consequently it is retained inside the column for a longer time. The 
decrease in the retention time compared to the bisphosphonate alone indicates that the 
modified polymer is more hydrophilic than bisphosphonate, due to the presence of PEG chain 
and the disappearance of the carboxylic group. The small peak eluted later at 12 minutes is 
most likely again due to the oxidized form of the polymer. 
 
Figure 4: Ion-pair HPLC chromatograms of 3,5-Di(ethylamino-2,2-bisphosphono)benzoic 
acid using fluorescence detector, free bisphosphonate modified amino poly(ethylene glycol)-
undecyl mercaptane using fluorescence detector and ELSD,  and amino poly(ethylene 
glycol)-undecyl mercaptane using ELSD 
 
The estimated bisphosphonate content of the polymer as determined from the 
phosphate assay is 97 ± 2,32 % of the theoretical value, which was quantified as inorganic 
phosphorus (using ibandronate for the standard curve) after oxidation and complexation with 
molybdate reagent. This also indicates a successful binding of the phosphate to the polymer 
and a successful removal of the excess of bisphosphonate by the dialysis. 
 
3.3.6. Binding to hydroxyapatite and gold surface 
The final bisphosphonate modified polymer exhibited a high affinity to gold and 
hydroxyapatite, which was determined by incubation with both substances. Figure 5 shows 
respective ion-pair HPLC chromatograms (using fluorescence detection) of the final product 
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before and after incubation with HA or gold. From the chromatograms, it can be concluded 
that the added polymer is removed completely from the incubation solution, since it is being 
adsorbed to HA or gold surfaces. For both incubated solutions no remaining peak is 
detectable, which can be compared with the run of the polymer alone without incubation. The 
high effectiveness of the removal of the polymer by both gold and HA confirm the presence 
of functional groups, the free bisphosphonate groups and the presence of thiol group. 
 
 
Figure 5: Ion-pair HPLC chromatograms of polymer modified with free bisphosphonate 
without HA and gold, after incubation with HA or with gold 
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4. Conclusions: 
Bifunctional thioalkylated poly(ethylene glycol) derivatives have been successfully 
synthesized, which allow both the binding to gold and to hydroxyapatite surfaces. These 
polymers possess both a high affinity for gold surfaces due to the functionalization of the 
hydrophilic PEG polymer by a terminal thiol containing alkyl group. The polymer was further 
conjugated to a bisphosphonate moiety, which is known for its specific affinity to 
hydroxyapatite contained in bone tissue. Therefore, the synthesized bisphosphonate-modified 
polymer showed a high binding to the bone mineral hydroxyapatite. The presented data 
demonstrate that the synthesized bisphosphonate-modified polymers represent a well defined 
platform for the development of bone targeting drug delivery system based on gold 
nanoparticles functionalized with the PEG derivatives via the formation of self assembled 
monolayers. However, further experiments are necessary to optimize the functionalization of 
the nanoparticles with the synthesized polymers and to optimize the development of 
particulate-based bone drug delivery system intended for the treatment of bone diseases. 
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1. Introduction 
 For the successful coating of the gold nanoparticles, polymers are needed, which have 
defined functionalities on both sides of the molecule, which are the binding sites for the gold 
nanoparticles and at the same time the intended functionalities at the end of  the PEG 
polymer. 
 The PEGylated thioalkyl polymers intended for the surface modification were 
previously already synthesized in our group [1], but their functionalities were not always well 
defined. The reactions were mainly done in solid support making the purification steps always 
possible by rinsing the used gold for the surface modification of quartz crystals (solid 
support). The applied rinsing scheme was used in order to remove excess of reagents or non 
bound molecules of byproducts, e.g. not bearing the thiolated alkyl chain, which is necessary 
for the binding of gold. In order to coat nanoparticles this cleaning procedure is not 
applicable, so an optimized synthesis had to be developed. In order to compare the possible 
reaction procedure, a retrosynthetic analysis was applied, which can further highlight the 
differences of the two applied synthesis schemes. 
 
1.1. Retrosynthetic analysis of poly(ethylene glycol)-undecyl mercaptane 
 The desired polymeric compounds are heterobifunctional PEG derivatives consisting 
of an alkanethiol part and attached PEG chains, also bearing certain functionalities. Based on 
the published papers on these heterobifunctional PEG derivatives [1] and known facts such as 
the solubility of the used compounds, a retrosynthetic scheme can been created to depict the 
different possible synthetic pathways for the preparation of the poly(ethylene glycol)-undecyl 
mercaptane derivatives (Figure 1). Due to the two main new linkages (A and B), there are two 
possible ways to prepare these PEG derivatives: for the first one (Route I), each part (the 
aliphatic thiol part and the PEG chain) is synthesized separately and then finally linked to 
obtain the target molecule. For the second route (Route II), the aliphatic part is reacted first 
with PEG chain and afterwards the thiol group is attached to the aliphatic part. 
 For the different routes a careful protection of the functional groups is necessary to 
obtain defined products, which are necessary for the intended coating of the gold 
nanoparticles. Especially during the Williamson ether synthesis the reaction with the thiol has 
to be prevented in order to maintain the gold binding functionality. 
 Based on literature data, the second method seemed to be more common and also 
more versatile, as the stepwise modification also allows exchanging the chemical 
functionalities. The proposed retrosynthetic schemes were applied to different poly(ethylene 
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glycol)2000-undecyl mercaptane derivatives, which are expected to chemically form stable and 
also protein resistant coatings for gold nanoparticles and also bear the ability being further 
functionalized with targeting moieties. The structures of the desired compounds are illustrated 
in Figures 1 and 2 (compound I and II) together with a short description of the necessary 
synthetic steps using the two different synthetic routes. 
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1) Addition of the thioacetate to 11-bromo-1-undecene (Linkage A) 
 Removal of acetic acid 
 Protection of the thiol group in order to avoid side reaction 
2) Williamson ether synthesis with monomethoxy poly(ethylene glycol) 
(Linkage B) 
 Removal of thiol protection group 
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1) Williamson Ether synthesis with monomethoxy poly(ethylene glycol) and 11-
bromo-1-undecene (Linkage B) 
2) Addition of the thioacetate to the unsaturated double bond (Linkage A) 
 Removal of acetic acid 
 
Figure 1: Retrosynthesis of methoxy poly(ethylene glycol)-undecyl mercaptane 
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1) Addition of the thioacetate to 11-bromo-1-undecene (Linkage A) 
 Removal of acetic acid 
 Protection of the thiol group in order to avoid side reaction 
2) Williamson ether synthesis with protected amino poly(ethylene glycol) (Linkage B) 
 Removal of thiol and amino protection group 
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II
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O
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ht
 
1) Williamson Ether synthesis with protected amino poly(ethylene glycol) and 11-bromo-1-
undecene (Linkage B) 
2) Addition of the thioacetate to the unsaturated double bond (Linkage A) 
 Removal of acetic acid and amino protection group 
 
Figure 2: Retrosynthesis of amino poly(ethylene glycol)-undecyl mercaptane 
  
 For both synthetic routes several critical reaction steps had to be considered, which 
will be explained briefly in the following paragraphs. 
Step 1: Deprotection of thiol and amine group functionalities  
 Because of the thiol group’s sensitivity against oxidation to the corresponding 
disulfide, its deprotection is usually performed as the final step during synthesis. Many 
different parameters should be considered for the selection of the appropriate deprotection 
strategy, which generally can be carried out in alkaline as well as in acidic medium. Strong 
alkaline conditions must be avoided because the ethylene glycol chains are unstable in strong 
alkaline media and consequently can be cleaved yielding shorter polymer chains [2]. Due to 
this possible side reaction, the chosen method of deprotection was either mild acidic or mild 
basic conditions. Both of the two methods can be applied to S-acetyl or S-benzyl derivatives. 
However, the acidic conditions are more preferred, since basic conditions may even more 
promote the formation of disulfides. Additionally, in case of the amino poly(ethylene glycol)-
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undecyl mercaptane the mild acidic conditions would deprotect  the thiol and the amine 
groups in one reaction step. 
Step 2: Introduction of thiol group. 
 Aliphatic thiol groups can be introduced using a protected form of sulfur either by 
radically initiated addition of thioacetic acid or benzyl mercaptane to terminal n-alkenes [3] or 
alternatively by nucleophilic substitution of sulfur nucleophiles with corresponding primary 
alkyl halides [4]. Although the synthetic routes starting from of alkenes or alkyl halides are 
nearly similar, the preparation of thiols from alkenes usually gives better yields and higher 
purities. On the other hand, terminal-alkene substrates are difficult to be obtained chemically 
or from the supplier and are more expensive than corresponding alkyl halides [5]. Addition of 
thioacetic acid [6], thiobenzoic acid [7] and 3-mercaptopropionic acid [8] to terminal alkenes 
in the presence of benzoyl peroxide or AIBN follows anti-Markonikov rule and therefore the 
desired protected terminal thiols are obtained in high yields (above 80-90%). The mild 
conditions for the introduction and subsequent deprotection are the main advantages of this 
method [5]. 
Step 3: Williamson ether synthesis             
 For both PEG derivatives, the newly formed alkyl ether (Bond B) can be obtained by 
addition of methoxy terminated poly(ethylene glycol) or protected amino poly(ethylene 
glycol) to either a dihaloalkane (X-(CH2)n-X) or to a terminal haloalkene. In case of using the 
dihaloalkane, the reaction of both halogen atoms may occur and subsequently both ends of the 
aliphatic chain might be PEGylated, giving rise to a mixture of mono-PEGylated and di-
PEGylated alkane which can be further used only after extensive purification. In case of the 
haloalkene, there is only the possibility for one reaction to take place, which is through 
nucleophilic substitution of the terminal halogen atom by the PEG anion. The double bond on 
the other side of the haloalkene is inert towards a nucleophilic substitution and consequently 
doesn’t need protection. Furthermore the double bond is a very convenient precursor for the 
thiol group as already explained before. For the ether formation a strong base is required in 
order to activate the hydroxyl terminus of the PEG chain by converting it into the conjugated 
base (PEG anion or PEG alkoxide). This conjugated base can then react with the haloalkene 
through nucleophilic substitution of the halogen atom. Different bases such as sodium hydride 
and sodium hydroxide have been applied in order to obtain the active conjugated base. Excess 
of haloalkene (3-4 folds) should be applied, to obtain as much as possible conversion of the 
PEG chains, which would be the most difficult compounds to separate from each other [9-11]. 
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Step 4: Protection of the amino group of poly(ethylene glycol)-monoamine 
 Di-(t-butyl) dicarbonate (di-BOC) is usually used as amine protecting group because 
during cleavage of the protecting groups it also produces stable tertiary carbocation and can 
be removed under mild acidic conditions. The BOC protection of the amines usually takes 
place in alkaline medium in order to selectively protect amines and leave hydroxyl groups 
free, which are needed for the following ether synthesis (Figure 3) [12]. 
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Figure 3: Retrosynthesis scheme of BOC-Protected amino poly(ethylene glycol) 
 
 1.2. Retrosynthesis of bisphosphonate-modified amino poly(ethylene glycol)-undecyl 
mercaptane 
 From the retrosynthetic point of view, conjugation of the bisphosphonate compound to 
amino poly(ethylene glycol)-undecyl mercaptane can be done by two synthetic pathways, 
either using the organic soluble ester form or the water soluble free form of the 
bisphosphonate. Since the free form of the bisphosphonate is highly hydrophilic and insoluble 
in organic medium, EDC/NHS chemistry needs to be applied for the conjugation. The optimal 
conditions for the reaction with the water soluble EDC is a slightly acidic buffer solution in 
order to obtain stable NHS-esters of bisphosphonate [13-16]. However, under these conditions 
the amine will be protonated and loose much of its chemical reactivity. Alternatively, the 
reaction can be carried out in non aqueous medium applying the DCC/NHS principle. In this 
case the unhydrolyzed bisphosphonate will react with DCC and NHS to form the active esters, 
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which subsequently react very rapidly with the primary amine group of amino poly(ethylene 
glycol)-undecyl mercaptane, yielding the unhydrolyzed bisphosphonate-conjugated polymer 
[17,18]. Hydrolysis of the ester form of the bisphosphonate-conjugated PEG can be done 
using acidic hydrolysis with concentrated HCl or 30% HBr in acetic acid. However, these 
strong conditions, usually result at the same time in the cleavage of the amide bond 
connecting the PEG chain and bisphosphonate molecule or eventually also the breakdown of 
the PEG chain [19-21]. Alternatively, this hydrolysis can be done using reagents from peptide 
synthesis, which can perform the quantitative dealkylation of the bisphosphonate ester under 
mild conditions, e.g. an excess of bromotrimethylsilane followed by methanolsis of the 
resulting trimethylsily ester [22-25]. The retrosynthetic analysis toward the synthesis of the 
desired compounds is depicted in Figure 4. 
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1) Conjugation of the protected ester of phosphonic acid with the poly(ethylene 
glycol) using DCC and NHS chemistry in organic medium 
2) Cleavage of the phosphonic acid ester groups 
 
N
H
O
O
O
NH
N
H
PO(OH)2(HO)2OP
HS(CH2)11
PO(OH)2
PO(OH)2 
13
 
R
o
u
te
 
II
 
Conjugation of the phosphonic acid compound with the poly(ethylene glycol) 
using EDC chemistry in aqueous medium 
 
Figure 4: Retrosynthesis of bisphosphonate modified poly(ethylene glycol)-undecylmercaptane 
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2. Materials  
 11-bromo-1-undecene, dibenzoyl peroxide, thioacetic acid (TAA), acetyl chloride, 
sodium sulphate, 2-chlorotrityl chloride, sodium hydride (NaH), sodium hydroxide (NaOH), 
sodium borate decahydrate, methoxy poly(ethylene glycol) 2000 (mPEG), ethylene oxide gas 
(EO), potassium bis(trimethylsilyl) amide, α,α´ azoisobutyronitril (AIBN), di(tert-
butyl)dicarbonate (di-BOC), tetramethylsilane (TMS), potassium hydroxide (KOH), 4-
phenylspiro[furan-2(3),1’-phthalan]-3,3`-dione (fluorescamine), N-hydroxyl succinimide 
(NHS), N,N\-dicyclohexyl cardodiimide (DCC), bromotrimethylsilane. DEAE-sephadex A25, 
dialysis tubing molecular weight cutoff (MWCO) 1000 Da. Toluene, methanol, hexane, 
chloroform, 1,4-dioxane, acetone, methanol, acetonitrile, diethyl ether, tetrahydrofuran 
(THF), methylene chloride, sodium sulphate, hydrochloric acid, sulfuric acid, acetic acid, 
sodium acetate, ammonium carbonate, zinc powder, ammonium heptamolybdate tetrahydrate, 
diethyl ether, ascorbic acid and hydroxyapatite (HA) were purchased from Merck (Darmstadt, 
Germany). Deuterated chloroform was from Deutero GmbH (Kastellaun, Germany). 3,5-
di(tetraethyl ethylamino-2,2-bisphosphonate)benzoic acid and 3,5-di(ethylamino-2,2-
bisphosphono) benzoic acid were synthesized according to the reported method [26]. 
Ibandronate was supplied from Boehringer (Mannheim, Germany). 
 
3. Methods 
3.1. Synthesis of methoxy poly(ethylene glycol)-undecyl mercaptane  
3.1.1. Route I (previously reported method) 
 In this method the two main parts of the polymer, the thioalkylated part and the PEG 
chain, were separately synthesized and then liked together. 
a. Synthesis of 11-bromo-undecylmercaptane 
 The alkanethiol residue consisting of 11 carbon atoms and a terminal thiol group was 
synthesized from 11-bromo-1-undecene, 5 ml of thioacetic acid and 75 mg of dibenzoyl 
peroxide were dissolved in 100 ml of dry toluene and heated at 80 oC for three hours in order 
to start the radical formation for the addition of the thioacetate to produce bromoundecyl 
thioacetate ester. Methanolic HCl prepared by slow addition of 20 ml of acetyl chloride to 200 
ml of cooled degassed methanol was then used to cleave the acetate from the intermediate 
after evaporation of toluene. The obtained product is commonly extracted using hexane, 
which is then washed with water and finally dried using sodium sulphate, before evaporation 
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of the solvent, yielding the liquid product, which can easily be characterized using NMR 
[27,28]. 
b. Protection of the thiol group of 11-bromo-1-undecanethiol 
 The subsequently necessary protection of the free thiol is performed by reacting 11-
bomo-undecyl mercaptane with 2-chlorotrityl chloride, which is an effective protecting group 
for mercaptane. 4 g of the 11-bromoundecyl mercaptane and 4.7 g of 2-chorotrityl chloride 
were dissolved in chloroform and stirred overnight at room temperature. The chloroform was 
finally evaporated and the protected thiol was characterized by NMR [29,30].   
c. Williamson ether synthesis of methoxy poly(ethylene glycol)-undecyl mercaptane  
 For the final conjugation with the polymer, 4 g (2 mmol) of methoxy poly(ethylene 
glycol) were dissolved in 100 ml of dry dioxane and 240 mg (10 mmol) of sodium hydride 
were added and stirred for one hour for a complete deprotonation of the terminal alcohol. 
Then, 5.7 g (10 mmol) of the protected 11-bromo-undecyl mercaptane were added and thee 
reaction mixture was stirred for 24 hours at room temperature. The solution was filtered after 
addition of 5 ml methanol (to quench excess sodium hydride) and then the solvent was 
evaporated under vacuum. The obtained product was purified by repeated precipitation in 
200 ml cold diethyl ether and finally dried. For the deprotection, 3 g of the PEG with the 
protected thiol group were dissolved in 20 ml of methanol containing 200 mg iodine and the 
solution was stirred at room temperature for one day. After evaporation of the methanol, the 
residue was dissolved in water and excess of iodine was removed using an ion exchange resin 
[31]. After evaporation of water, the produced polymer was purified by repeated precipitation 
in cooled diethyl ether and finally characterized by HPLC and NMR. 
 
3.1.2. Route II for the synthesis of methoxy poly(ethylene glycol)-undecyl mercaptane 
a. Synthesis of methoxy poly(ethylene glycol)-1-undecene  
• Using 50% aqueous sodium hydroxide 
 The synthesis was carried out according to a procedure described by Prime et al. [32] 
(Scheme 1), 4 g (2 mmol) of methoxy poly(ethylene glycol) (1) were melted then 0.5 ml of a 
50% aqueous solution of sodium hydroxide were added and the obtained mixture was heated 
to 110 °C in an oil bath for 30 minutes. Subsequently, 2.0 ml of 11-bromo-1-undecene (2) 
were added and the reaction mixture was kept at that temperature under stirring overnight. At 
the end of reaction, the mixture was dissolved in toluene (50 ml) and filtered to remove 
formed inorganic salts (NaOH and NaBr). After evaporation of toluene, the obtained polymer 
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residue was dissolved in acetone and precipitated in cooled ether, collected, dried and 
characterized by HPLC and NMR [33].       
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Scheme 1: Synthesis of methoxy poly(ethylene glycol)-1-undecene 
 
• Using sodium hydride powder 
 Alternatively, 4 g (2 mmol) of methoxy poly(ethylene glycol) (1) were melted, then 
different amounts of sodium hydride were added and the mixture was allowed to react at 110 
°C in an oil bath for 30 minutes. After the evolving of hydrogen stopped, 2.0 ml of the 11-
bromoundecne were added and the reaction was continued for 24 hours at this temperature. 
After quenching excess sodium hydride with methanol, the added excess of methanol was 
evaporated, the residue was dissolved again in toluene and filtered to remove inorganic salts. 
After evaporation of toluene, the residue was dissolved in the least amount of acetone and 
precipitated again in ice cooled diethyl ether. The polymer product was collected by filtration, 
dried under vacuum and finally analyzed by NMR and HPLC [34].  
b. Addition of thioacetic acid to methoxy poly(ethylene glycol)-1-undecene  
 For the addition of the thiol functionality, 4.2 g of methoxy poly(ethylene glycol)-1-
undecene (3) were dissolved in dry methanol, thioacetic acid and α,α´ azoisobutyronitrile 
(AIBN) were added and the mixture was refluxed under argon atmosphere to give methoxy 
poly(ethylene glycol)-undecane thioester (4) according to Scheme 2. The concentrations of 
thioacetic acid and AIBN as well as the reaction time have been varied to give the highest 
possible conversion of the thiol group [35]. 
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Scheme 2: Synthesis of methoxy poly(ethylene glycol)-undecane thioester 
 
c. Hydrolysis of methoxy poly(ethylene glycol)-undecane thioester 
 Subsequently, the obtained thioester was hydrolyzed to the free thiol as described 
before. HCl in MeOH was added to the thioester of the polymer and the reaction mixture was 
refluxed overnight (Scheme 3). After evaporation of the solvent, the thioalkylated polymer 
was purified by repeated precipitation in cooled diethyl ether. 
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Scheme 3: Acidic hydrolysis of methoxy poly(ethylene glycol)-undecane thioester to methoxy 
poly(ethylene glycol)-undecyl mercaptane 
 
3.2. Synthesis of amino poly(ethylene glycol)-undecyl mercaptane 
3.2.1. Synthesis of poly(ethylene glycol) monoamine (PEG-NH2). 
 Poly(ethylene glycol) monoamine (6) was synthesized according to the Scheme 4. 
About 25 g of ethylene oxide gas (EO) were condensed in 150 ml of dried THF (dried by 
molecular sieve) cooled to -79 oC using dry ice in methanol, then 25 ml of 0.5% potassium 
bis(trimethylsilyl) amide solution in toluene were added. After stirring the solution for 
36 hours at room temperature, the solution was concentrated under vacuum until a viscous 
polymer was obtained. To obtain the pure polymer product, the viscous liquid was dissolved 
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in methylene chloride, centrifuged to remove any undissolved impurities and finally 
precipitated in ice cooled diethyl ether for several times. The precipitated product was 
collected by filtration and vacuum dried for two days [36]. 
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Scheme 4: Synthesis of poly(ethylene glycol) monoamine 
 
3.2.2. Protection of the terminal primary amine group 
 Before application to the Williamson ether synthesis, the amino group has to be 
protected as described before to avoid the alkylation of the amine. Therefore, 5 g (2.5 mmol) 
of the synthesized PEG-NH2 and 600 mg of potassium hydroxide were dissolved in 15 ml of 
water and the solution was cooled down to 0 °C in an ice bath. 0.6 or 2.750 g of the di(tert-
butyl)dicarbonate (2.75 or 12.5 mmol, 1.1 and 5 molar equivalents respectively) were 
dissolved separately in 15 ml of dioxane and added dropwise to the aqueous cooled solutions 
of PEG-NH2. The obtained reaction mixtures were stirred at 0 °C for four hours, and finally 
allowed to warm to room temperature while stirring overnight (Scheme 5). After the 
evaporation of the solvent, the residues were dissolved again in acetone, filtered to remove 
insoluble salt (KOH) and the solid protected polymers (PEG-NH-BOC) were obtained by 
precipitation in ice cold diethyl ether. The obtained protected PEG-NH2 (7) was dried under 
vacuum and analyzed [12,37,38]. 
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Scheme 5: Synthesis of BOC-protected amino poly(ethylene glycol) 
      
3.2.3. Determination of free amine groups using the fluorescamine assay 
 In order to quantify the success of the protection, the free amine groups of the 
polymers were quantified using fluorescamine. A standard curve for HO-PEG-NH2 was 
obtained according to the following procedure, 600 µl of a fluorescamine solution (10 mg in 
100 ml acetone) were added to 1400 µl of borate buffer (50 mM, pH 8.5) containing different 
concentrations of the synthesized PEG-NH2 (5, 10, 15, 20, 25 and 50 µM). The solutions were 
then allowed to react at room temperature for 5 minutes, after which the fluorescence intensity 
was measured at 390 nm excitation and 475nm emission wavelengths. Subsequently, the 
amount of free amine in the protected polymer was determined by adding the same amount of 
fluorescamine to borate buffer containing 25 µM of the protected amino PEG, which was 
measured as described before. 
3.2.4. Synthesis of BOC-protected amino poly(ethylene glycol)-1-undecene 
 BOC-protected poly(ethylene glycol) monoamine (compound 7) was reacted with an 
excess of 11-bormo-1-undecene (2) using sodium hydride as described before for the 
synthesis of methoxy poly(ethylene glycol)-1-undecene similar to Scheme 1. 
3.2.5. Addition of thioacetic acid to the terminal double bond of the BOC-protected 
amino poly(ethylene glycol)-1-undecene. 
 The reaction between thioacetic acid and BOC-protected amino poly(ethylene glycol)-
1-undecene (8) was conducted similar to that described before for mPEG-Undecene. BOC-
protected amino poly(ethylene glycol)-1-undecane thioacetate ester (9) was obtained as in 
Scheme 6. The subsequent hydrolysis of the thioester was performed as described for the 
methoxy derivative. However, during this step also the BOC protecting group is cleaved 
yielding the final polymer product (10), which commonly dimerizes forming the 
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corresponding disulfide. For an extended purification and removal of byproducts, the amino 
poly(ethylene glycol)-undecyl mercaptane was dissolved in 50 ml dichloromethane and 
washed several times with 25 ml water containing 400 mg sodium bicarbonate in separating 
funnel. Afterwards, the organic layer was dried by sodium sulfate and the polymer was 
obtained again by precipitation in cold diethyl ether and investigated by 1H-NMR, HPLC and 
MALDI-ToF. 
SH
O
O N
H
O
O
O
n
 
O
O
N
H
O
O S O
n
 
NH2 O
O S
n
 
2
8 AIBN M eO H3 days
9
HCl/M eO H
reflux, 18 h
10
+
 
Scheme 6: Synthesis of BOC-protected amino poly(ethylene glycol)-1-undecane thioacetate 
ester and amino poly(ethylene glycol)-undecyl mercaptane 
  
3.3. Synthesis of bisphosphonate-modified amino poly(ethylene glycol)-
undecyl mercaptane 
 The bisphosphonate-modified polymer was synthesized using the above described 
synthesis schemes in aqueous and organic media, however, only the organic route yielded a 
successful product. For this reaction, 3,5-di(tetraethyl ethylamino-2,2-bisphosphonate)benzoic 
was dissolved in dry dioxane and different amounts of N-hydroxyl succinimide (NHS) and 
N,N‘-dicyclohexyl carbodiimide (DCC) were added and reacted for 2 hours at room 
temperature. Subsequently, amino poly(ethylene glycol)-undecyl mercaptane was added and 
allowed to bind for different times to yield the polymer modified with the unhydrolyzed 
bisphosphonate (12) (Scheme 7). At the end of the reaction, the mixture was centrifuged to 
remove the formed byproduct (dicyclohexylurea), and the solvent dioxane was finally 
evaporated. The obtained viscous residue was then dissolved in a minimum amount of 
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acetone, precipitated in ice cooled diethyl ether, collected, dried and analyzed. The free 
bisphosphonate containing compound was obtained by hydrolysis of compound 12 using 
bromotrimethylsilane followed by methanolsis to give the free bisphosphonate-modified 
polymer (13) [26]. 
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Scheme 7: Synthesis of bisphosphonate-modified poly(ethylene glycol)-undecyl mercaptane 
 
 The free bisphosphonate-modified polymer was further purified using an anion 
exchange column DEAE-sephadex A25. Therefore, 2 g of the sepharose were swollen in 
0.2 M acetate buffer of pH=4 for two days. Then the obtained polymer was dissolved in 
acetate buffer and added to the sepharose while stirring the mixture at room temperature. 
Unbound impurities were then removed by filtration and subsequently the polymer was eluted 
by exchanging the buffer to basic 0.2 M ammonium carbonate buffer (pH 8.5). This washing 
step was repeated 2-3 times to completely elute the polymer. The buffer salt ammonium 
carbonate was subsequently removed by freeze drying and dialysis of the initially freeze dried 
polymer for 48 hours against deionized water using dialysis tubes of 1 kDa cutoff.      
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3.4 Analysis of the Synthesized Polymers 
3.4.1. 1H-NMR analysis 
 1H-NMR (nuclear magnetic resonance spectroscopy) spectra were recorded on a 
Bruker Avance 600 spectrometer (Bruker Biospin, Rheinstetten, Germany). For the 
measurement, the polymer samples were dissolved in deuterated chloroform and TMS was 
used as internal standard. 
3.4.2. HPLC analysis 
 High pressure liquid chromatography (HPLC) analysis was done using a setup 
consisting of a DGU-14A degasser, LC-10-AT pump, SIL-10 AD autosampler, RF-10A XL 
fluorescence detector, SPD-10A VP UV-Vis detector and a SCL-10A VP system controller all 
from Shimadzu, Duisburg, Germany). 
 HPLC of the synthesized polymers was performed under the following conditions. A 
linear gradient of 20% to 100% solvent B (90% acetonitrile in water) in solvent A (10% 
acetonitrile in water) over 30 minutes was applied as mobile phase at a flow rate of 1 ml/min. 
50 µl samples (5 mg/ml) were separated at 40 °C using a combination of a PL-RPS guard 
column and an analytical column (PL-RPS 300 Å, 5 µm). The samples were detected by a low 
temperature evaporative light scattering (ELSD) detector (Method I) [39]. 
 Ion-pair chromatography of the free bisphosphonate containing samples was 
performed on a standard C18 column (25 cm × 4,6 mm I.D., 5 µm, Supleco, Deisenhofen, 
Germany). Here, the mobile phase used was a mixture of 18 mM n-amylamine aqueous 
solution (adjusted to pH 7.0 with acetic acid) and acetonitrile (95:5, v/v). The flow rate was 
1 ml/min and the experiments done at room temperature (Method II) [40,41]. 
3.4.3. Mass Spectrometry of the Polymers (MALDI-ToF MS) 
 Matrix assisted laser desorption/ionization mass spectrometry (MALDI-ToF) was 
performed on a HP G2030A spectrometer in positive mode. The polymers were analyzed in 
the range of 0-6000 m/z, data were averaged from about 150 laser shot per spectrum using 
indoleacrylic acid dissolved in THF (0.15 mg/ml) as matrix. The samples were prepared on 
the target by depositing 1 µl of a mixture of matrix solution and polymer solution (1 mg/ml) 
(3:1).  
3.4.4. Determination of bisphosphonate content of the modified-polymer  
 Quantitative determination of the bisphosphonate incorporated in the polymer was 
performed after oxidation of the bisphosphonate to orthophosphate and the subsequent 
reaction with molybdenum-ascorbate reagent to yield a phosphomolybdate complex, which 
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can be detected at 820 nm. Pure ibandronate was used as standard for the construction of the 
calibration curve [42-44].    
3.4.5. Determination of PEG concentration in the synthesized polymer  
 Additionally, a spectrophotometric method for the quantitative determination of PEG 
concentrations was used based on the absorbance measurement of fluorescein dye after 
partitioning into an aqueous two-phase system containing PEG in the upper phase and 
ammonium sulfate in the lower phase. The decrease of fluorescein absorbance in the lower 
phase here is directly proportional to the PEG concentration. To 300 µl of ammonium sulfate 
(31% w/v in 0.5 M acetate buffer pH 5 containing 77 µM fluorescein), 40 µl of the respective 
PEG samples are added. The samples are allowed to settle in dark for 30 minutes at room 
temperature before measuring the absorbance at 475 nm using a 96-well plate reader. PEG 
solutions of known concentration are used for the construction of standard curve [45].      
 
4. Results and Discussion 
4.1. Synthesis of methoxy poly(ethylene glycol)-undecyl mercaptane 
4.1.1. Route I  
 Using the already described method for the PEG synthesis as described by Knerr et al. 
[1], methoxy poly(ethylene glycol)-undecyl mercaptane and amino poly(ethylene glycol)-
undecyl mercaptane were synthesized by first thiolating the alkene and later forming the ether 
link. 
a. Synthesis of 11-bromo-undecylmercaptane 
 11-bromo-1-undecene was reacted with thioacetic acid in the presence of dibenzoyl 
peroxide using a radical mediated addition to the double bond, which followed the anti-
Marconikov rule and gave acetate protected thiol derivative (11-bromoundecyl thioacetate 
ester). The 1H-NMR spectrum of this intermediate is characterized by the following signals; 
δH: 3.4 (t, 2H, BrCH2-), 2.85 (t, 2H, -CH2S-), 2.3 (s. 3H, CH3COS-), 1.2-1.9 (m, 18H, the 
remaining protons of the aliphatic part), which allowed to quantify the amount of conversion 
to the thioacetate of almost 90%. 
 To obtain the free 11-bromoundecyl mercaptane, the intermediate was refluxed with 
degassed methanolic HCl overnight. 1H-NMR spectrum of the mercaptane is presented in 
Figure 5 and it is characterized by the representative signals for the alkyl protons neighboring 
the brome and the mercaptyl group; δH: 3.4 (t, 2 H), 2.55 (m, 2 H), and 1.9-1,2 (m, 18 H). 
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Figure 5: 1H-NMR spectrum of 11-bromoundecyl mercaptane  
 
b. Protection of the thiol group of 11-bromo-1-undecanethiol 
 Because of the high reactivity and to avoid byproducts, the thiol group needs to be 
protected before the further reaction with PEG chain. Otherwise, the thiol group would 
participate in the reaction and a modification of the alkanethiol part would occur from both 
ends with PEG chains, which also would prevent the attachment of the polymer to gold 
surfaces. The protection was performed by reacting the 11-bromoundecyl mercaptane with 2-
chlorotrityl in chloroform. This reaction produced 11-bromoundecyl-(2-chloro trityl) sulfide 
[29], which is characterized by the following 1H-NMP signals; δH: 6.7-8.1 (m, 14 H), 3.41 (t, 
2 H), 1.98 (t, 2 H), and 1.9-1,2 (m, 18 H). 
 c. Williamson ether synthesis of methoxy poly(ethylene glycol)-undecyl mercaptane 
 For the subsequent Williamson ether synthesis, the hydroxyl group of methoxy 
poly(ethylene glycol) was reacted with the protected 11-bromoundecyl mercaptane in the 
presence of sodium hydride to form the new ether bond between the aliphatic part and the 
PEG chain. Sodium hydride firstly reacts with the hydroxyl group of the PEG forming the 
respective alkoxide. This alkoxide acts then as powerful nucleophilic reagent with the alkyl 
halide and results in the ether formation [46]. 
 The 1H-NMR of the thioalkylated methoxy poly(ethylene glycol) after cleavage of the 
thiol protection group with iodine is presented below in Figure 6, the obtained spectrum is 
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characterized by the following signals; δH: 3.8-3.8 (m, 180 H), 3.3 (s, 3 H), 2.00 (t, 1 H) and 
1.85-1.2 (m, 6 H). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: 1H-NMR spectrum of methoxy poly(ethylene glycol)-undecyl mercaptane 
synthesized by route I 
 
 The expected integrals for the complete conversion of the PEG to alkylated PEG, 
however, should be 182, 3, 0, and 16 protons, respectively. While there was no obvious 
correlation between the expected and measured integrals, the signal of the methylene group 
adjacent to the SH group (δtheo. = 2.55 ppm) was completely missing as shown in Figure 6. 
 In order to characterize the obtained product, HPLC analysis of the polymer was 
performed on the reversed phase polymer column (Method I) as presented in Figure 7. Here 
the observed retention time of the main peak for the synthesized polymer did not differ much 
from the educt methoxy poly(ethylene glycol), which indicates that only little conversion of 
the PEG was obtained, which is visible at the later occurring peak at 20 min in the 
chromatogram B. In order to improve the conversion, the reaction conditions were changed 
several times, but no significant improvement was achieved, which was attributed to the fact 
that no big excess of mPEG could be used. When excess mPEG are used to PEGylate all the 
used thioalkylated part, a mixture of thioalkylated PEG and mPEG will be obtained, which is 
very difficult to be separated from each other giving rise to a purification problem.  As the 
polymers for the modification of colloids can’t be purified using the adsorption step, which 
was done in the earlier publication, an improved method had to be developed to solve the 
problem. 
(p pm )
0 .81 .21 .62 .02 .42.83 .23 .64 .04 .4
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Figure 7: HPLC chromatograms of mPEG (A) and mPEG-AlkSH synthesized by route I 
(B) 
 
4.1.2. Route II for synthesis of methoxy poly(ethylene glycol)-undecyl mercaptane 
 The improved synthesis route was based on the following steps: 
(1) Reaction of 11-bromo-1-undecene with methoxy poly(ethylene glycol) using highly 
concentrated base to produces polymer-alkene product 
(2) Addition of thioacetic acid to the terminal double bond of the polymer-alkene 
intermediate using α,α´-azoisobutyronitril (AIBN) to produce the thioacetate 
(3) Hydrolysis of the thioester by methanolic HCl to obtain the desired thioalkylated polymer. 
 
a-Synthesis of methoxy poly(ethylene glycol)-1-undecene 
I - Using Sodium Hydroxide as base 
 Methoxy poly(ethylene glycol) was reacted first with 11-bromo-1-undecene using 
aqueous 50% sodium hydroxide solution as base. Therefore the sodium hydroxide solution 
was added to the melted PEG and allowed to react for 30 minutes at 110 °C. The formed 
mPEG alkoxide reacted with the alkyl bromide by nucleophilic displacement of the bromine 
leaving group forming the methoxy poly(ethylene glycol)-1-undecene as described in Scheme 
1 [47]. The double bond of 11-bromo-1-undecene, as convenient precursor of the later 
introduced thiol, does not need any protection, because it is inert towards nucleophilic 
substitution [5]. The 1H-NMR spectrum of the obtained intermediate (3) (Scheme 1) is 
characterized by the following signals; δH: 5.9-5.7 (m, 1 H) CH of the double bond, 5.05-4.9 
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(t, 2 H) CH2 of the double bond, 3.85-3.53 (m, 180 H) protons of the PEG part, 3.49-340 (m, 
2 H) CH2O of the alkene part, 3.38 (s, 3 H) methoxy group of mPEG, 2.10-2.0 (m, 2 H) CH2 
adjacent to the double bond, 1.65-1.25 (m, 14 H) residual protons of the alkene part. The 
obtained integrals agreed with the expected values, indicating that every mPEG molecule is 
attached to one molecule of alkene part (i.e 100% conversion). 
 The HPLC chromatogram of the obtained product is compared to that of mPEG in 
Figure 8. The chromatogram of mPEG is characterized by a single peak eluting at 15 minutes 
(chromatogram A). Modification of mPEG with 11-bromoundecne using both investigated 
bases produced compounds eluting significantly later at about 20 minutes, which can be 
attributed to the attachment of the lipophilic alkyl chain (chromatogram B and C). 
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Figure 8: HPLC chromatograms of mPEG (A), mPEG-undecene prepared by sodium 
hydroxide (B) and mPEG-undecene prepared by sodium hydride (C) 
 
II - Using sodium hydride powder as base 
 The synthesis of the mPEG-undecene (3) was additionally investigated using sodium 
hydride powder instead of the aqueous sodium hydroxide. The exchange was performed in 
order to ensure the stability of poly(ethylene glycol), which can eventually be hydrolyzed in 
strong alkaline media to shorter PEG chains [2], and furthermore the reaction scheme known 
from literature had to be adapted in order to conjugate the alkene to the BOC protected amino 
PEG, which would be sensitive to water due to its contained urethane group. Consequently, 
the reaction was carried in absence of added water. 
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 The 1H-NMR spectrum of the obtained product is presented in Figure 9 and exhibited 
no differences to the spectrum obtained with sodium hydroxide catalysis, also the obtained 
integrals are in good agreement with the expected theoretical values. A similar agreement was 
obtained also for the HPLC analysis, which was already described above.  
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Figure 9: 1H-NMR spectrum of methoxy poly(ethylene glycol)-1-undecene 
 
b. Addition of thioacetic acid to the terminal double bond to form the thioester  
 Thioacetic acid was used as the most common and versatile reagent for the free radical 
addition of thiol precursor to terminal alkenes. It is inexpensive and can be easily deprotected 
to the free thiol. The conversion of the terminal double bond of mPEG-undecene into mPEG-
undecane thioester was carried out by radical addition of thioacetic acid under reflux in 
methanol in the presence of azoisobutyronitrile (AIBN) as radical initiator. 
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Figure 10: 1H-NMR spectrum of methoxy poly(ethylene glycol)-1-undecene (A) and methoxy 
poly(ethylene glycol)-1-undecane thioacetate ester (B) 
  
 The addition of thioacetic acid was followed via 1H-NMR by monitoring the 
disappearance of the signals of the double bond at 5.8 ppm (m, 1H, CH=CH2) and 5.0 ppm (t, 
2H, CH2=CH) as well as the signal of the adjacent methylene group at 2.0 ppm (m, 2H, 
CH2CH=) (Figure 10, spectrum A). The ongoing reaction was, furthermore, characterized by 
the appearance of new signals at approximately 2.85 ppm for the methylene triplet in 
neighborhood of the thioester and at 2.3 ppm a singlet corresponding to the acetate end group 
(Figure 10, spectrum B) [48]. The conversion was investigated at different concentrations of 
thioacetic acid and AIBN as well as after different reaction times as shown in Table 1. 100% 
addition of thioacetic acid to the double bond was obtained by a 1.5 molar equivalent of 
AIBN, 12 molar equivalent of thioacetic acid and a reaction time of 72 hours under reflux in 
20 ml dry methanol. Similar results were obtained by Oliveira et al. [49], who found that the 
addition of thioacetic acid to the double bond was increased by increasing the concentration 
of the radical initiator AIBN. 
 
 
 
 
 
 
Chapter 3                                                                        Optimization of the Polymer Synthesis 
 
 
96 
Table 1: Effects of different concentrations of thioacetic acid and AIBN as well as the 
reaction time on amount of thioacetate ester produced in methanol 
AIBN 
(molar equivalent) 
TAA 
(molar equivalent) 
Conversion % 
0.11 2 25 
0.51 4 35 
1.02 8 80 
1.52 12 100 
  1
 reaction time = 48 hours 
  2
 reaction time = 72 hours 
 
c. Hydrolysis of methoxy poly(ethylene glycol)-1-undecane thioester 
 Because the thiol group is rather sensitive and easily oxidized to the disulfide, its 
deprotection is usually the final step of the synthesis. Hydrolysis of the thioester can be done 
in acidic or basic conditions. In case of alkaline condition, a significant level of disulfide is 
obtained. In order to avoid too much disulfide formation, hydrolysis was performed under 
acidic conditions and with inert gas to reduce the amount of oxygen [5]. The stability of the 
ether linkages allowed the hydrolysis of mPEG-undecane thioester to be carried out with 
methanolic hydrochloric acid (HCl/MeOH) to produce the deprotected mPEG-undecyl 
mercaptane polymer. The 1H-NMR spectrum of methoxy poly(ethylene glycol)-undecyl 
mercaptane (Figure 11) is characterized by the following signals; δH: 3.8-3.5 (m, 180 H), 3.45 
(t, 2H), 3.35 (s, 3H), 2.7-2.45 (tt, 2H) and 1.8-1.2 (m, 18H) corresponding to the PEG chain, 
methylene group of the aliphatic part adjacent to newly formed ether bond, methoxy group of 
the PEG chain, methylene group adjacent to thiol group and the remaining protons of the 
aliphatic part, respectively. 
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Figure 11: 1H-NMR spectrum of methoxy poly(ethylene glycol)-undecyl mercaptane 
 
 Besides 1H-NMR, HPLC analysis of the methoxy poly(ethylene glycol)-undecyl 
mercaptane was performed to compare it with the educt methoxy poly(ethylene glycol) 
(Figure 12). The chromatogram of the polymer modified with the thioalkyl chain 
(chromatogram B) is characterized by two peaks at 19 and 22 minutes, which correspond to 
the reduced form of the polymer (mPEG-AlkSH monomer, 19min) and the respective 
oxidized form ((mPEG-AlkS)2 dimer, 22min). The chosen column was here separating the 
two synthesized compounds and the PEG according the lipophilicity (C18-material) and 
additionally according their size (size exclusion). The attachment of aliphatic part to the 
mPEG chain results in an increased hydrophobicity and the still occurring dimerization by 
oxygen increases the molecular weight of the product, yielding the typical double peak for 
these compounds, which were already observed by Knerr et al. [50] and which can be 
removed using reducing agents just before the chromatography.     
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Figure 12: HPLC chromatograms of methoxy poly(ethylene glycol) (A) and methoxy 
poly(ethylene glycol)-undecyl mercaptane (B) 
 
4.2. Synthesis of amino poly(ethylene glycol)-undecyl mercaptane  
4.2.1. Synthesis of poly(ethylene glycol) monoamine 
 Bifunctional polymer, poly(ethylene glycol) monoamine with a molecular weight of 
about 2000 Da, was synthesized by ring opening polymerization of ethylene oxide using 
potassium bis(trimethylsilyl) amide. Due to the absence of the internal standard of the 
methoxy group in mPEG, the number average molecular weight was determined after 
modification with trifluoroacetic acid anhydride (TFAA). The 1H-NMR spectra of the 
synthesized polymers are depicted in Figure 13. The 1H-NMR confirmed the structure of HO-
PEG-NH2, which is characterized by two signals, one signal at δH: 2.95-2.80 ppm 
corresponding to the two protons adjacent to the amino group (NH2CH2-), and a second large 
peak at δH: 3.9-3.4 ppm corresponding to protons of the PEG chain. The number average 
molecular weight was calculated using the NMR integrals according to a method described by 
Tessmar et al. [51] for the molecular weight determination of HO-PEG-NH2 and NH2-PEG-
PLA. The number average molecular weight was calculated after acylation of the amine and 
hydroxyl groups with TFAA. The protons of the ethylene unit neighboring the hydroxyl group 
were shifted from δH: 3.6 ppm to δH: 4.4 ppm, and as well the protons adjacent to amino 
group (2.95-2.8 ppm) shifted up field to the same position of the main PEG protons at 3.9-3.4 
ppm due to formation of the amide link. The integrals of the polymer signals before and after 
reacting with trifluoroacetic acid anhydride are listed in Table 2. Based on these values, the 
average molecular weight of the polymer was calculated to be about 1990 Da. 
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Figure 13: 1H-NMR spectra of amino poly(ethylene glycol) (PEG-NH2), amino poly(ethylene 
glycol) + trifluoroacetic acid (PEG-NH2+TFAA) and amino poly(ethylene glycol) protected 
with BOC (PEG-NH-BOC)  
 
Table 2: Chemical shifts and integrals of the above NMR spectra 
Signals integration Chemical 
shift (ppm) HO-PEG-NH2 HO-PEG-NH2 + TFAA HO-PEG-NH-BOC 
1.3-1.4 0.00 0.00 8.61 
2.8-2.95 2.00 0.00 0.00 
3.4-3.9 179.99 181.0 179.5 
4.1-4.2 0.00 0.00 2.05 
4.4-4.5 0.00 2.00 0.00 
 
 
 In order to confirm the molecular weight calculation, MALDI-ToF was performed, 
which also showed the size distribution of the obtained polymer (Figure 14). The mass 
spectrum of the HO-PEG-NH2 showed the molecular weight distribution with the typical 
repeat units of 44 Da and a Gaussian distribution. The peak maximum was observed at the 
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molecular weight of 2038 Da. The number of monomers (n) for this polymer can be 
calculated to be about 46 repeat units (2038/44 ≈ 46), which agrees well with the data 
obtained by 1H-NMR, since 46 ethylene units would carry 46*4 = 184 protons [52,53]. 
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Figure 14: MALDI-ToF mass spectrum of synthesized amino poly(ethylene glycol) 
 
 After characterization of the obtained polymer, the terminal amino group had to be 
protected to avoid alkylation of both ends. The primary amine group was protected by 
reacting amino PEG with di(tert-butyl)dicarbonate (di-BOC). The reaction was carried out 
under alkaline conditions and low temperature in a dioxane/water mixture to allow selective 
protection of the amino group since the ester formed on the hydroxyl group would be 
immediately cleaved [12,54]. The 1H-NMR spectrum of the protected polymer (HO-PEG-
NH-BOC), using 1.1 molar equivalent of BOC, is displayed in Figure 13 with the integrals in 
Table 2. The characteristic signals of the spectrum appear at δH: 3.9-3.4 ppm for the PEG 
chain and 1.4-1.3 ppm for the BOC group. Similarly as for the TFAA modification the PEG 
protons adjacent to the amine are shifted up field to 4.2-4.1 ppm due to formation of the 
urethane with BOC. 
 A quantification of the successful protection was carried out by fluorescamine assay of 
the primary amine. Fluorescamine reacts rapidly and in high sensitivity with primary amines 
to form a fluorophor with an excitation wavelength of 390 nm and an emission wavelength of 
475 nm. The obtained fluorescence intensity is proportional to the primary amine 
concentration, stable over several hours, and excess reagent is hydrolyzed within minutes [55-
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58]. Since the fluorescence of the conjugate is dependent on the amine, a standard curve was 
recorded for the HO-PEG-NH2 with fluorescamine in borate buffer. 
 Based on the standard curve, the amounts of free amine in HO-PEG-NH2 after 
protection using different concentrations of BOC (1.1 and 5 molar equivalents) were found to 
be less than 1% (Figure 15) indicating the successful protection of the primary amine of PEG 
by using this method with both BOC concentrations. 
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Figure 15: Fluorescence intensity after reaction of different concentrations of HO-PEG-NH2 
and BOC protected HO-PEG-NH2 using 1.1 and 5 molar equivalents with fluorescamine 
 
4.2.2. Synthesis of BOC-protected amino poly(ethylene glycol)-1-undecene 
 BOC protected amino PEG was subsequently reacted with 11-bromo-1-undecene 
using sodium hydride as already described to avoid the presence of water, the reaction was 
carried out as described for the synthesis of methoxy poly(ethylene glycol)-1-undecene. The 
1H-NMR spectrum of the obtained BOC-NH-PEG-undecene is presented in Figure 16. The 
spectrum again shows the characteristic signals of both the aliphatic part and the protected 
amino PEG chain, located at δH: 5.9-5.8 (m, 1 H), 5.05-4.9 (t, 2 H), 4.2 (m, 2 H), 3.9-3.3 (m, 
180 H), 2.0 (m, 2H) and 1.8-1.2 ppm (m, 23 H). The integrals of these signals agreed well 
with the theoretical values and indicated that the reaction took place only on the hydroxyl end 
of the polymer. 
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Figure 16: H-NMR spectrum of BOC protected amino poly(ethylene glycol)-1-undecene 
 
 The HPLC chromatogram of BOC-NH-PEG-1-undecene compared to HO-PEG-NH2 
is presented in Figure 17 (chromatogram A and B). The peak of amino poly(ethylene glycol) 
is detected at a retention time of 14 minutes (chromatogram A), while BOC protected amino 
poly(ethylene glycol)-1-undecene eluted later at about 20 minutes (chromatogram B) due to 
the attachment of two hydrophobic moieties, BOC group and the alkene chain. 
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Figure 17: HPLC of amino poly(ethylene glycol) (A), BOC protected amino poly(ethylene 
glycol)-1-undecene (B), and amino poly(ethylene glycol)-undecyl mercaptane (C) 
 
4.2.3. Addition of thioacetic acid to the terminal double bond 
 The addition of thioacetic acid to the terminal double bond yielded the thioacetate 
ester of the BOC protected amino PEG-undecane. Figure 18 shows the 1H-NMR spectrum of 
the produced thioacetate ester with no signs of the educts double bond and the newly 
introduced appeared acetate’s signals (δH: 4.2-4.1 ppm (t, 2H, protons adjacent to the urethane 
bond), 3.9-3.4 ppm (m, 182 H), 2.8 ppm (t, 2 H), 2.3 ppm (s, 3 H) and 1.8-1.2 ppm (m, 27 
H)). 
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Figure 18: H-NMR spectrum of BOC protected amino poly(ethylene glycol)-1-undecene 
thioacetate ester 
 
4.2.4. Hydrolysis of BOC-protected amino poly(ethylene glycol)-undecane thioester 
 The last step, the hydrolysis of thioacetate ester and deprotection of the amino group, 
was done in methanolic HCl, which hydrolyzes both the ester and the BOC protecting group, 
yielding amino poly(ethylene glycol)-undecyl mercaptane [5,38,59]. The added washing step 
was performed to deprotonate the amine for further modification. The 1H-NMR spectrum 
showed the signals of the alkanethiol part and PEG chain with the characteristic signals (δH: 
3.9-3.4 ppm (m, 182 H, protons of PEG chain), 2.9-2.8 ppm (t, 2 H, protons adjacent to amino 
group), 2.55 ppm (t, 2 H, protons adjacent to thiol group) and 1.8-1.2 ppm (m, 16 H)). HPLC 
analysis of the finished polymer is presented in Figure 17 (chromatogram C). The 
chromatogram is characterized again by two peaks as for the mPEG derivative; the first peak 
related to the reduced form (free thiol) eluted at about 18 minutes and the second peak related 
to the oxidized form (disulfide form) eluted at 21 minutes. 
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4.3. Synthesis of bisphosphonate-modified amino poly(ethylene glycol)-
undecyl mercaptane 
 The conjugation of the poly(ethylene glycol) amine was investigated in aqueous and 
organic medium. However, in water the conjugation was not successful due to side reactions 
with the phosphonic acid and the low reactivity of the amine. In organic solvent the carboxyl 
group of unhydrolyzed bisphosphonate (compound 11) was first activated by DCC and NHS 
to form the active ester, which then reacted with the amine group of the polymer forming a 
stable amide bond (Scheme 7) [60]. Figure 19 shows the HPLC chromatograms of the 
polymer before (chromatogram A) and after (chromatogram C) conjugation to bisphosphonate 
compared to bisphosphonate alone (chromatogram B). The chromatogram of the unmodified 
polymer shows the characteristic peak of the oxidized form of the polymer at 20 minutes, 
while the relative hydrophilic and smaller bisphosphonate is characterized by a peak at 
approximately 8 minutes. After attachment to the polymer a new peak is resulting, which is 
eluted at about 15 minutes. 
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Figure 19: HPLC chromatograms of amino poly(ethylene glycol)-undecyl mercaptane (A), 
3,5-di(tetraethyl ethylamino-2,2-bisphosphonate)benzoic (B) and the product (C) 
  
 Due to the slow reaction of the bisphosphonate ester with the polymer, the effect of the 
reaction time on the conversion was investigated. Increasing the reaction time from 24 hours 
to 48 hours resulted in further decrease of the amount of the unreacted polymer, while 
increased reaction time did not reduce this amount much more, most likely due to the 
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deactivation of the activated bisphosphonate. For further investigations a reaction time of 48 
hours was, therefore, considered to be optimal. 
 Similar experiments were carried out to investigate the effect of the molar ratio of 
bisphosphonate to polymer on the percent conversion. The highest conversion was obtained 
for the 2 molar equivalents of bisphosphonate to amino poly(ethylene glycol)-undecyl 
mercaptane. The final dealkylation of the tetraethyl ester of bisphosphonate-modified polymer 
was done using bromotrimethylsilane under mild conditions and produced the free 
bisphosphonate modified-polymer [61,62]. 
4.3.1. Determination of bisphosphonate concentration in the modified-polymer  
 In order to quantify the amount of bisphosphonate conjugated to the polymer, a 
sensitive spectrophotometric method for its determination was established according to 
Daley-Yates [42], which depends on oxidation of bisphosphonate to orthophosphate with 
ammonium persulfate and the subsequent formation of a colored complex with molybdenum-
ascorbate reagent (λabs=820 nm). The chosen method had a wide linearity range up to 500 
µg/ml phosphate with 10 ng/ml a determination limit [43,44]. A standard curve of a 
commercial bisphosphonate (ibandronate) was used for calibration. Quantification of the 
amount of incorporated phosphate in the polymer was performed according the similar 
procedure as for the standard and showed that about 95 ± 3.6 % of the theoretical amount of 
phosphorus were incorporated in the polymer, which indicates the successful modification 
with the bisphosphonate group. 
4.3.2. Determination of PEG concentration in the synthesized polymers  
 The chosen method to quantify PEG was based on the measurement of the decrease of 
fluorescein absorbance in an aqueous two phase system with PEG acting as a phase transfer 
catalyst. This indirect method of quantification is know from literature and allows to detect 
PEG concentrations as low as 0.1 µM [45]. Serial dilutions of methoxy poly(ethylene glycol) 
(mPEG) and the synthesized amino poly(ethylene glycol) (PEG-NH2) were added to the 
fluorescein solution and the alteration of absorbance was measured. A direct relation between 
the PEG concentration and the absorbance difference of fluorescein was observed (increasing 
PEG concentrations led to increase in the absorbance differences) as indicated in Figure 20.  
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Figure 20: Determination of methoxy poly(ethylene glycol) 2000 (mPEG), R = 0.998, and 
amino poly(ethylene glycol) 2000 (PEG-NH2), R = 0.988, by fluorescein 
  
 In case of the synthesized thioalkylated polymers, methoxy poly(ethylene glycol)-
undecyl mercaptane (mPEG-AlkSH) and amino poly(ethylene glycol)-undecyl mercaptane 
(NH2-PEG-AlkSH), the determination could not be performed as indicated in Figure 21, 
which was attributed to the interference of the thioalkylated parts of the polymers with the 
phase transfer of fluorescein. Consequently an accurate determination of the PEG content 
could not be performed and the polymer had to be further investigated according to its 
functionality as already described in chapter 2. 
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Figure 21: Quantitative determination of methoxy (A) and amino (B) poly(ethylene glycol)-
undecyl mercaptane with no observed fluorescence changes 
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5. Conclusions 
 The synthesis of polymers used for the later modification of gold nanoparticles was 
thoroughly optimized in order to have defined substances for the coating of the surfaces. The 
already described synthesis was lacking the necessary purity in order to be sure of the surface 
composition of the later obtained nanoparticles. The synthesis schemes were optimized to 
achieve high conversions, which were done by using an excess of the easier to remove 
reagents, and also the following purification was performed making use either of the unique 
solubility of PEG or the high negative charges of the bisphosphonate group. By applying 
these optimization steps, high conversions were achieved and the polymers were obtained 
with very high purities. Since they are mainly used for the surface modification of small 
nanoparticles, the amounts synthesized were sufficient, but for a commercial application of 
the polymer an improvement of the yields without sacrificing the amounts of conversion 
would be further necessary. 
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1. Introduction 
 Colloidal gold consists of sub-micrometer-sized particles of gold usually dispersed in 
water. The synthesis of gold nanoparticles (GNPs) has received considerable attention and a 
lot of different synthetic procedures have been described to obtain gold nanoparticles in 
different sizes, shapes, and dispersion media (either aqueous or non aqueous). Controlling the 
size, shape and structure of gold nanoparticles is technologically important because of the 
strong relation between these parameters and the resulting properties, such as the interaction 
with light, which is valuable for many applications of gold nanoparticles [1-5]. 
 Aqueous gold nanoparticles dispersions are the most common especially for 
biomedical and biological applications. The simplest method of preparation is based on the 
reduction of aqueous hydrogen tetrachloroaurate solution by trisodium citrate. In this method, 
citrate anions have a dual function; in the beginning they act as the reducing agent to reduce 
Au+3 to Au0. Later they also act as a stabilizing agent for the nanoparticle dispersion by 
forming a charged layer of citrate anions on the surface of the formed particles [6]. The 
mechanism of citrate reduction of gold chloride salts to form gold nanoparticles occurs 
through a multi-step process [7]. The initial step is the oxidation of citrate ions to produce 
dicarboxy acetone: 
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The second step is the reduction of auric (gold III) salt to aurous (gold I) salt: 
2e-AuCl3   + AuCl    + 2Cl
-
 
The third step is the disproportionation of the different aurous species to gold atoms where 
three gold I chloride combine together to produce elemental gold and one molecule of auric 
chloride. The gold atoms serve as nucleation sites for the growth of gold nanoparticles [8]. 
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 The further growth of the nanoparticles is dependent on the ratios of the reactants, 
temperature and also the stirring rate, and can therefore be used to control the sizes of the 
obtained particles [9]. The finally obtained particles then posses a surface consisting of excess 
of citrate, which renders the particles negatively charged and consequently well disperses in 
the reaction medium. 
 Subsequently, the surface of the citrate-stabilized gold nanoparticles demands a further 
protection in order to increase the aggregation stability. For this task, self assembled 
monolayers (SAMs) on gold provide a versatile tool to protect and stabilize gold nanoparticles 
by separating the metal core from the surrounding environment, in order to prevent occurring 
particle growth and reversible agglomeration [10]. Poly(ethylene glycol) (PEG) derivatives 
here have been widely used to coat and stabilize gold nanoparticles, because they are 
hydrophilic, water soluble, biocompatible and also resistant to unspecific protein adsorption 
due to the steric stabilization of the PEG chains [11-14]. 
 Many different research papers describe the useful application of similarly 
functionalized gold nanoparticles. Yoshimoto et al. [15], for example, reported the preparation 
of PEGylated GNPs, which were intended to be used as high-performance photothermal 
agents in photothermal therapy (PTT). Gold nanoparticles can also be applied as X-ray 
contrast agent with absorption properties that overcome some limitations of traditional agents 
due to their particulate character [16]. They appear to be non-toxic and enable higher and 
longer imaging times than currently possible using standard iodine-based agents [17]. A very 
recent study showed the successful use of antibody-conjugated PEGylated gold nanoparticles 
to label human cancer tissue that has been surgically resected from patients. The study takes 
the advantages of strong optical scattering of gold nanoparticles to image the actual 
distribution of the tumor and its stomal tissue with a simple darkfield microscope. Since the 
used gold nanoparticle-antibody conjugates are effectively stabilized by heterofunctional PEG 
molecules, they are highly stable under the biological conditions and unbound particles can be 
rinsed away quantitatively when the incubated tissue doesn’t contain the targeted antigen [18]. 
 The objectives of this chapter are to describe the preparation of stable gold 
nanoparticles with sizes suitable for the intravenous administration and the optimization of 
their synthesis. Furthermore, the effect of subsequent surface modifications by PEGylation 
using methoxy and amino terminated poly(ethylene glycol)-undecyl mercaptane on particle 
properties, such as size, zeta potential and dispersion stability, were analyzed in the presence 
of electrolytes and proteins, which normally lead to significant aggregation of only citrate 
stabilized particles. 
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2. Experimental 
2.1. Materials and Methods 
 Hydrogen tetrachloroaurate tri-hydrate (HAuCl4.3H2O), methoxy poly(ethylene 
glycol) 2000, ultrafilteration tubes (50,000Da MWCO), and bovine serum albumin were 
purchased from Sigma-Aldrich Chemical Company (Steinheim, Germany). Trisodium citrate, 
sodium chloride, nitric acid, hydrochloric acid were purchased from Merck (Darmstadt, 
Germany). Methoxy poly(ethylene glycol)-undecyl mercaptane (mPEG-AlkSH), amino 
poly(ethylene glycol)-undecyl mercaptane (NH2PEG-AlkSH) were synthesized as described 
in chapter 2. All glassware was thoroughly washed with freshly prepared aqua regia (HCl: 
HNO3
 
= 3:1), extensively rinsed with Millipore water several times and oven-dried at 150 oC 
for 2-3 h before use. All solutions were filtered through 0.22 µm membrane filter (Corning 
Incorporated, Corning NY 14832, Germany) before use. 
 
2.2. Preparation of gold nanoparticles 
 Gold nanoparticles (GNPs) were synthesized in one step aqueous preparation, in 
which hydrogen tetrachloroaurate was brought to boiling and reduced by rapid addition of 
sodium citrate. 100 ml water containing different concentrations of HAuCl4.3H2O was heated 
until boiling under reflux, and then 1 ml aqueous solution of tri-sodium citrate trihydrate 
solution was added rapidly. Boiling and stirring were continued for 20 minutes. After that, the 
heating mantle was removed and the solution was stirred until it was cooled down to room 
temperature. Stock solutions of the gold salt (1%) and trisodium citrate (170 mg/ml) were 
prepared using Millipore water and were filtered through 0.22 µm membrane filter. Different 
volumes of the above mentioned solutions were applied in order to investigate the effect of 
citrate/gold ratio on the size of the obtained nanoparticles. The produced nanoparticles were 
characterized by UV-Vis spectroscopy, size and zeta potential measurements using photon 
correlation spectroscopy [19]. 
 
2.3. Characterization of the prepared gold nanoparticles  
2.3.1. UV-visible spectroscopy of the prepared nanoparticles 
 Ultraviolet-visible light absorption spectra of the citrate-stabilized and the PEG-coated 
GNPs were taken at room temperature using a spectrophotometer (Uvikon-941, Kontron 
Instrument, Germany).      
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2.3.2. Size and zeta potential measurements by photon correlation spectroscopy (PCS)  
 The size distributions and the zeta potentials of the synthesized gold nanoparticles 
before and after polymer coating were analyzed by photon correlation spectroscopy (PCS) 
using a Zetasizer 3000 HAS (Malvern, Instruments GmbH, Germany). For a typical 
measurement 300 µl of GNPs were added to 3 ml of Millipore water immediately before 
measuring their size and zeta potential. The refractive index and the viscosity of water were 
used for the calculation of the results. 
2.3.3. Determination of nanoparticle concentrations by ICP-OES 
 The actual concentration and consequently also the number of gold nanoparticles per 
volume after synthesis were determined by using inductively coupled plasma-optical emission 
spectroscopy (ICP-OES). Defined volumes of the nanoparticle dispersion were dissolved in 
aqua regia, more precisely diluted with Millipore water and the obtained samples were 
directly analyzed by ICP-OES (Horiba Jobin Yvon, 70P, S+S, Munich, Germany). The gold 
content of the dissolved particles was determined from a calibration curve constructed from 
different concentration, from 10 to 100 ppm, of hydrogen tetrachloroaurate tri-hydrate [20]. 
2.3.4. Stabilization and surface-functionalization of gold nanoparticles 
 Citrate stabilized GNPs were used without modification and after coating with either 
methoxy poly(ethylene glycol)-undecyl mercaptane (mPEG-AlkSH) or amino poly(ethylene 
glycol)-undecyl mercaptane (NH2PEG-AlkSH). Different amounts of the two polymers, 
1-5 µg per ml of the nanoparticles dispersion, were added to the nanoparticles to study the 
effect of coating on their size and also to determine the necessary concentration for a 
complete surface coating. The mixture was incubated while permanently stirring at room 
temperature for one day to allow sufficient exchange of citrate anions on the particle surface. 
The excess of unbound polymers was removed by several times ultracentrifugation using 
ultrafiltration tubes having molecular weight cut-off (MWCO) of 50.000 Da. The effect of 
surface coating of the particles was observed for their UV-Vis absorption, particle size and 
zeta potential. 
a. Testing the dispersion stability of the surface-functionalized nanoparticles  
 In order to test the dispersion stability at high electrolyte concentration, the gold 
nanoparticles were incubated with 300 µl of 5 M NaCl for 2 ml of particle dispersion. The 
measured changes in UV-Vis absorbance, size and zeta potential of nanoparticles were used 
as indicators for their stability [21-23].  
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b. Interaction of surface-functionalized nanoparticles with proteins (BSA and bovine 
serum) 
 The interaction of citrate stabilized, methoxy and amino PEG coated gold 
nanoparticles with BSA (200 µg per ml of colloidal solution) and serum (10% v/v) was 
studied to investigate the effect of the different surface properties of the nanoparticles on 
protein adsorption. The particle samples were incubated with proteins over night at room 
temperature while permanently shaking the flasks. The interaction of the gold nanoparticles 
and proteins was monitored by UV-Vis spectroscopy, size determination and zeta potential 
measurement [23]. 
 
3. Results and Discussion 
3.1. Preparation and characterization of gold nanoparticles 
3.1.1. Effect of citrate concentrations on the size of the produced nanoparticles 
 The size of the nanoparticles prepared by the reduction of gold salt normally depends 
on a number of parameters, such as the type of reducing agent and the initial concentration of 
the metal precursor. The type of reducing agent determines the rate of nucleation and 
subsequently the particle growth: a slow reduction produces large particles, while fast 
reduction usually produces smaller particles [24]. The chosen synthesis of gold nanoparticles 
by citrate reduction represents a good model system for the production of GNPs in context of 
this thesis, because of its simplicity and reproducibility. After addition of trisodium citrate to 
the boiling solution of the gold salt, a bluish color appeared, indicating the formation of gold 
nuclei. A few minutes later, the solution turned brilliant deep red due to the formation of the 
nanoparticles. The deep red color of gold nanoparticles in water is due to the strong light 
absorption in the visible region due to the oscillation of surface electrons after exposure to 
light, a phenomenon characteristic for metallic nanoparticles called surface plasmon 
resonance (SPR). This general phenomenon of metallic particles depends mainly on their size, 
shape, composition and dielectric environment [25,26]. The obtained size and size distribution 
of the gold nanoparticles are very important parameters, which determine their physical and 
chemical properties. In order to prepare gold nanoparticles suitable for intravenous 
administration, different concentrations of trisodium citrate were used. By increasing the 
citrate to gold ratio from 3 to 34 the sizes of the particles were reduced from 145 ± 17 nm to 
38 ± 1.5 nm. Table 1 shows the effect of the amounts of the used citrate on the size and UV-
Vis absorption spectra of gold nanoparticles. Using a weight ratio of citrate to gold of 3, the 
average size of the obtained nanoparticles was 145 nm, as determined by photon correlation 
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spectroscopy, and the corresponding surface plasmon resonance (SPR) band in the UV-Vis 
spectrum was 533 nm. In case of a citrate to gold ratio of 17 the obtained particle sizes were 
91 nm and λmax of SPR was 530 nm. Increasing the ratio of citrate to gold to 34, the size of 
the obtained GNPs was 38 nm with a λmax of the SPR of 524 nm. Consequently, lower 
concentrations of sodium citrate resulted in a smaller number of nuclei and so more gold 
atoms aggregate per particles, which results in the increase of the average particles diameter 
[6]. The obtained results are in good agreement with many results reported in literature [27-
30]. 
 Furthermore, different batches of gold nanoparticles were prepared using the highest 
concentration of sodium citrate (citrate/gold = 34), from these experiments gold nanoparticles 
with similar sizes and acceptable polydispersity indices (Table 2) were obtained each time 
indicating high reproducibility of the citrate reduction for the preparation of gold 
nanoparticles. Figure 1 shows the measured size distributions of different batches of as-
prepared gold nanoparticles. The obtained nanoparticles show a quite narrow monomodal size 
distribution with only one peak observed in the size distribution curve (Figure 1). The average 
diameter of different batches of as-prepared gold nanoparticles is about 36.7 ± 1.7 nm  
[31,32]. 
 
Table 1: Effect of the amounts of sodium citrate on the size and the Surface Plasmon 
Resonance (SPR) of the synthesized gold nanoparticles 
 
HAuCl4.3H2O 
(mg) 
Trisodium citrate 
dihydrate (mg) 
Citrate/Gold 
ratio 
Size 
(nm) 
SPR maximum 
(nm)1 
20 60 3 145 ±17 533 
10 170 17 91 ±14 530 
5 170 34 38 ± 1.5 524 
1
 Size is determined by PCS 
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Table 2: Size and polydispersity index of different batches of gold nanoparticles 
 
Batch Mean size (nm) S.D Polydispersity index 
B1 38.8 2.132 0.336 
B2 34.9 0.589 0.486 
B3 35.8 1.617 0.252 
B4 37.2 0.954 0.495 
Mean ± SD 36.7 ± 1.7 - 0.392 ± 0.118 
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Figure 1: Size distribution of different batches of synthesized gold nanoparticles 
 
3.1.2. Determination of the nanoparticles concentrations 
 The gold content of the nanoparticles from different batches was analyzed by ICP-
OES. The results indicated that almost all the added gold was converted to gold nanoparticles, 
which shows that the reduction of HAuCl4.3H2O by sodium citrate is about 100% completed 
under the above mentioned conditions. For further calculations of the actual number of gold 
nanoparticles per ml, the determined concentration and the size of the obtained nanoparticles 
were used. 
3.2. Stabilization and surface-functionalization of gold nanoparticles 
 Citrate-stabilized gold nanoparticles are typical hydrophobic colloids carrying a large 
excess of negative surface charges and consequently they are only stable in very low ionic 
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strength solutions, where the adsorbed charges are still able to prevent the close contact 
between individual particles. Due to this properties, gold nanoparticles are thermodynamically 
very unstable and consequently require special stabilization [33]. It is therefore especially 
important to modify their surfaces in order to increase the colloidal stability also in 
physiological fluids. To this end, thiol chemistry has been widely applied due to the high 
affinity of sulfur to gold surfaces with chemical species ranging from small molecules to 
larger biomacromolecules and also polymers [13].    
            
                       
             
Figure 2: Surface stabilization and functionalization of gold nanoparticles with mPEG-
AlkSH (A) and with NH2PEG-AlkSH (B) 
 
 The surface of the produced gold nanoparticles was subsequently stabilized and further 
functionalized by methoxy poly(ethylene glycol)-undecyl mercaptane (mPEG-AlkSH) and 
amino poly(ethylene glycol)-undecyl mercaptane (NH2PEG-AlkSH) as depicted in Figure 2. 
Different concentrations of the respective polymers ranging from 1-5 µg per 1 ml of the 
colloidal solution from one batch have been used. Figure 3 shows the observed effects of the 
concentration of mPEG-AlkSH and NH2PEG-AlkSH on the size of the coated nanoparticles 
compared to the effect of non thioalkylated mPEG. Addition of 1 µg of mPEG-AlkSH to 1 ml 
of nanoparticle solution (containing 7*1010 particles) resulted in an increase of the average 
particles size from 38.8 to 43.6 nm as measured with photon correlation spectroscopy. Further 
increasing the concentration to the double concentration (2µg/ml) increased the size slightly 
to 44.2 nm. Further increase did not affect the size of GNPs anymore, which indicates that a 
sufficient amount of polymer was provided to completely coat the available nanoparticle 
surfaces. In case of H2NPEG-AlkSH, applying 1 µg/ml increased the measured size to 45.54 
nm. While further increasing the concentration more than 1 µg/ml did not result in any further 
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increase of the size. Addition of different concentrations of pure mPEG to GNPs solution did 
not result in any increase of the particle size, since mPEG can’t bind to gold surfaces due to 
the lack of thiol functionalities. The increase of particle size after addition of mPEG-AlkSH 
and NH2PEG-AlkSH on the other hand can be attributed to a single layer coating of the 
particle surfaces with the added polymers, which both contain thiolated alkyl chains with a 
strong affinity to gold surfaces suitable to form self assembled monolayers on gold via the 
sulfur-gold bond [34]. 
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Figure 3: Effect of different concentrations of mPEG, mPEG-AlkSH and NH2PEG-AlkSH on 
the size of gold nanoparticles 
 
 Figure 4 shows the measured size distribution of gold nanoparticles before and after 
coating with polymers as determined by photon correlation spectroscopy. The size of the 
mPEG-AlkSH coated gold nanoparticles is generally larger than those of uncoated 
nanoparticles, with an obvious shift of the particle size distribution peak to larger sizes, but 
nevertheless the nanoparticles still have the same narrow size distribution and low 
polydispersity index and no signs of the formation of larger sized aggregates. 
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Figure 4: Size distribution of citrate-stabilized gold nanoparticles (a) and mPEG-AlkSH-
coated gold nanoparticles (b) 
 
 The surface charge plays an important role for the stability of nanoparticles. Therefore, 
the zeta potential of gold nanoparticles was measured before and after coating with polymers 
(Figure 5). The zeta potential of citrate stabilized nanoparticles was determined to be -47.3 ± 
5.5 mV, while the zeta potential of mPEG-AlkSH coated nanoparticles increased to be about -
20 mV. This observation is attributed to the shielding effect (screening of some of the 
negative charges on the particle surfaces) of the neutral PEG chains attached to nanoparticle 
surface and also to the occurring replacement of most of the adsorbed citrate anions on the 
particle surfaces. The measured zeta potential of NH2PEG-AlkSH-coated gold nanoparticles 
is almost neutral most likely due to the presence of amine groups, which can be protonated 
and become positively charged, leading to the formation of only slightly negative or neutral 
nanoparticles [23,35,36]. 
Chapter 4                                                                          Preparation and Stabilization of GNPs  
 
 
126 
-60
-50
-40
-30
-20
-10
0
0 1 2 3 4 5
Polymer conc. (µg/ml)
Ze
ta
 
po
te
n
tia
l (m
V)
mPEG-AlkSH
amino-PEG-AlkSH
 
Figure 5: Effect of different concentrations of mPEG-AlkSH and NH2PEG-AlkSH on the 
zeta potential of gold nanoparticles 
 
3.3. Purification of gold nanoparticles from excess polymer 
 Removal of the excess of unbound polymers from the coated nanoparticle dispersion is 
one essential step before further application of nanoparticles due to possible interactions of 
the free PEG with the conducted measurements. In order to investigate the purification, an 
excess of mPEG-AlkSH (5 µg/ml) was added to the nanoparticle dispersion to ensure 
complete coating of the particles. The remaining free fraction (unbound to the surface) was 
removed by ultrafiltration at 750 g for 20 minutes using ultrafiltration tubes (molecular weight 
cut-off (MWCO), 50 kDa), which retain only the nanoparticles and allow the free polymer to 
pass with the filtrate. After four cycles of ultrafiltration, no further free polymers were 
detected via iodine-assay in the filtrate, indicating a complete removal of the unbound 
polymers. The zeta potential (surface charge), size and size distribution of the gold 
nanoparticles were measured before and after ultrafiltration to investigate the impact of the 
purification process on the resulting properties of nanoparticles. Figure 6 shows the sizes of 
GNPs coated with mPEG-AlkSH before and after ultrafiltration compared to the size of 
merely citrate-stabilized GNPs. Ultrafiltration had no detectable effect on the size of GNPs as 
shown in Figure 6. In contrast, the zeta potential of the coated particles was increased from -
31.5 ± 6.1 to -18.2 ± 7.0 mV after four cycles of ultrafiltration (Figure 7), which could be 
attributed to the removal of still present citrate anions adsorbed on the particles surface during 
the purification process. 
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Figure 6: Effect of ultrafiltration on the size gold nanoparticles coated with  mPEG-AlkSH  
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Figure 7: Effect of ultrafiltration on the zeta potential of gold nanoparticles coated with  
mPEG-AlkSH 
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3.4. Dispersion stability of surface-functionalized gold nanoparticle 
 Dispersion stability of unfunctionalized nanoparticles is mediated via the electrostatic 
repulsion of their charged surfaces, lacks of the sufficient surface charge or the absence of 
other stabilizing agents will always lead to particle aggregation and subsequent precipitation 
once a certain size of the aggregates is reached. The reduction of gold salts by sodium citrate 
produces nanoparticles with an excess of citrate anions adsorbed to the particle surfaces 
creating sufficient surfaces charge that stabilize the particle dispersion [37]. The aggregation 
of the nanoparticles is characterized by particle increase observed with photon correlation 
spectroscopy and a shift of the maximum absorbance peak to longer wave lengths. This red 
shift of aggregated gold nanoparticles thereby arises from the formation of absorption bands 
of the extinction spectrum at long wave length. These additional absorption bands are caused 
by electric dipole-dipole interactions and coupling between plasmons of neighbouring 
particles inside the aggregates, under the prerequisite that the interparticle distances inside the 
aggregates are smaller than the respective particle diameters [38]. Upon addition of sodium 
chloride to the merely citrate-stabilized GNPs, the color of gold colloids gradually changed 
from red to blue followed by appearance of a new very broad absorption band in the UV-Vis 
spectrum above 700 nm (Figure 8c) indicating the occurrence of aggregation [39,40]. The 
very rapid aggregation of citrate-stabilized nanoparticles by sodium chloride is due to the 
shielding of the negative charge and the subsequent reduction of the electrostatic repulsion 
between the individual particles, which allows the particles to clump together [25,41]. 
However, when NaCl was added to the PEG-coated GNPs, the plasmon bands were not 
affected (Figure 8a and 8b), because the surface PEGylated GNPs are not mainly stabilized by 
electrostatic repulsion, but they are stabilized by the steric repulsion of the uncharged 
hydrophilic polymers attached to their surfaces [42,43].  
 In order to characterize the aggregation, particle size measurements are often used, to 
facilitate the understanding of the aggregation processes. In addition, the apparent size mainly 
affects the biological application of nanoparticles by destroying their biocompatibility [44]. 
Figure 9 for example shows the effect of NaCl (5M) addition on the size, determined by 
photon correlation spectroscopy, of PEG-coated and uncoated (citrate-stabilized) gold 
nanoparticles. Sodium chloride induced a large size increase of the citrate-stabilized GNPs 
most likely due to agglomeration of the non-sufficiently shielded nanoparticles [45]. On the 
other hand, the size of mPEG-AlkSH and NH2PEG-AlkSH coated GNPs did not show any 
size increase after sodium chloride addition due their stabilization by the polymer coating. 
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These results are additionally confirmed by the UV-Vis spectroscopy (Figure 8), similar 
results were also reported by Nagasaki et al. [13,46]. 
 
Figure 8: Effect of sodium chloride on the UV-Vis spectra of mPEG-AlkSH-coated GNPs (a), 
NH2PEG-AlkSH-coated GNPs (b) and citrate-stabilized GNPs (c) 
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Figure 9: Effect of sodium chloride, BSA and 10% v/v bovine  serum on the size of mPEG-
AlkSH-coated GNPs, NH2PEG-AlkSH-coated GNPs and citrate-stabilized GNPs) 
  
 The effect of sodium chloride on the zeta potential of the gold nanoparticles is 
depicted in Figure 10. A pronounced increase of the zeta potential is observed for the citrate-
stabilized gold nanoparticles after addition of sodium chloride, which demonstrated the 
shielding and the occurring neutralization of some of the surface charges. The slightly 
positive zeta potential observed after addition of sodium chloride to PEG-coated GNPs may 
be attributed to the adsorption of some sodium cations to the PEG chains and for the amino 
PEG derivative also a certain amount of charged amine groups may be present.   
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Figure 10: Effect of sodium chloride, BSA and 10% v/v serum on the zeta potential of 
mPEG-AlkSH-coated GNPs, NH2PEG-AlkSH-coated GNPs and citrate-stabilized GNPs) 
 
3.5. Interaction of the surface functionalized gold nanoparticles with proteins (BSA and 
bovine serum) 
 For a further evaluation of the suitability of the particles for intravenous 
administration, the stability of the particles was investigated in presence of different proteins, 
which are present in body fluids. The interaction of the prepared gold nanoparticles either 
coated or only citrate-stabilized with bovine serum albumin (BSA), the most abundant protein 
in the plasma, and bovine serum was studied. Citrate-stabilized GNPs used for this 
investigation rapidly aggregated after addition of bovine serum albumin (BSA) and serum, 
which is indicated by the disappearance of the characteristic surface plasmon resonance peak 
in the UV spectrum, in case of BSA, (Figure 11) or by appearance of a new wide absorption 
band at wave lengths above 650 nm as in case of serum (Figure 12).  The large size increase 
of the citrate-stabilized GNPs induced by the addition of BSA and serum, as shown by photon 
correlation spectroscopy measurements (Figure 9) furthermore confirms the instability. The 
observations could be attributed to the interaction of cysteine groups of the added proteins 
with the GNPs, or the shielding of the negative surface charges by extensive protein 
adsorption on the particle surface, which then also may induce the further formation of 
aggregates in the dispersion. In contrast to the bare particles, the spectra of polymer-protected 
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GNPs are either not affected (in case of mPEG-AlkSH coated GNPs) or show only a slight 
increase in the size (in case of NH2-PEG-AlkSH-coated GNPs) by addition of BSA and 
serum. The slight size increase of NH2PEG-AlkSH-coated GNPs can be attributed to the 
occurring interaction of the exposed protonated amino groups with negatively charged 
carboxylate groups on the added proteins, which may lead to a partial protein coating of the 
particles [47]. The protein resistance (i.e. the stability) of PEG-coated GNPs is a consequence 
of the present interfacial water layer, which prevents a direct contact between the lipophilic 
particle surface and the added proteins [48]. 
 
 
Figure 11: Effect of BSA on the UV-Vis  spectra of mPEG-AlkSH-coated GNPs (a), 
NH2PEG-AlkSH-coated GNPs (b) and citrate-stabilized GNPs (c) 
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Figure 12: Effect of bovine serum  on the UV-Vis spectra of mPEG-AlkSH-coated GNPs (a), 
NH2PEG-AlkSH-coated GNPs (b) and citrate-stabilized GNPs (c) 
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4. Conclusion 
 Uniform gold nanoparticles were prepared in aqueous solutions by sodium citrate 
reduction of HAuCl4.3H2O. The obtained sizes and size distribution as well as the measured 
surface plasmon resonance of the prepared nanoparticles was strongly influenced by the 
gold/citrate ratio and could be optimized to produce reproducibly sufficiently small particles. 
The surface functionalization and further stabilization of the gold nanoparticles was achieved 
using the heterobifunctional thioalkylated poly(ethylene glycol) derivatives, which were 
already described in this thesis and which are well known to form well ordered and packed 
self assembled monolayers on gold surface. The size of the accordingly modified particles 
slightly increased, while there was also a pronounced increase of the zeta potential observed 
after the PEGylation of the particles. The finally obtained PEG-coated gold nanoparticles 
showed a significantly enhanced stability in the presence of electrolyte and proteins. 
In conclusion the here presented nanoparticles provide a valuable tool for further 
modifications on the incorporated terminal amine group, which allows further binding or 
attachment of biomolecules or other moieties to the particles. The obtained particles then can 
be used for in vitro or in vivo studies due to their excellent stability in biological fluids. 
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Abstract 
 Gold nanoparticles (GNPs) possess a great potential as model systems for particulate drug 
delivery due to their ease of production, low toxicity and also the high stability of the noble metal 
in biological fluids. Due to their unique surface chemistry they can be used as building platform 
for stable self assembled monolayers of thioalkylated polyethylene glycols with different surface 
functionalities. In order to functionalize particles, bisphosphonate and methoxy modified 
poly(ethylene glycol)-undecyl mercaptane (BP-PEG-AlkSH and mPEG-AlkSH) were mixed in 
different ratios and used to coat gold nanoparticles. The investigations showed that the polymer 
coated nanoparticles slightly increased in size as determined by PCS, but no significant changes 
were observed with TEM due to the low contrast of the polymer layer. The surface charge and 
UV-Vis absorption spectra of the particles were also only slightly changed, indicating well 
separated particles and a successful replacement of the citrate coating by the polymers. The 
polymer-coated nanoparticles were stable in different media (5M NaCl, 200 µg/ml BSA and 10% 
v/v serum), indicating a strong binding of polymers. Bisphosphonate coated particles were 
furthermore incubated with porous hydroxyapatite ceramics (Endobon®, Biomet) and it was 
observed that their adsorption to the apatite was dependent on the content of bisphosphonate in 
the particle surfaces and the adsorption was not affected by calcium ions or proteins added to the 
media. 
In conclusion, the bisphosphonate modified GNPs showed a very good stability, reduced 
protein adsorption, and a high affinity to hydroxyapatite, which makes them extremely useful for 
the investigation of the in-vivo bone targeting of gold particles. 
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1. Introduction 
  In recent years, a lot of effort was devoted towards the preparation of targeted drug delivery 
system based on nanoparticles. Many delivery vehicles have been designed based on 
nanomaterials, such as dendrimers [1,2], nanorods [3], polymeric nanoparticles [4], liposomes 
[5], nanotubes [6] and metallic nanoparticles [7,8]. 
  Among metallic nanoparticles, gold nanoparticles (GNPs) represent a perfect nanoscale 
agent, since it has been used for a wide range of biomedical and pharmaceutical applications [9]. 
These comprise drug delivery [10-12], tumor therapy [13-16], DNA detection [17-20], sensing of 
protein and carbohydrates [21,22], tissue engineering [23,24], as well as imaging and diagnosis 
[25,26]. Wang et al. [27] demonstrated that the combination of anticancer drugs with gold 
nanoparticles could be used as a novel, convenient agent to sensitively target and label drug-
resistant cancer cells. The above mentioned applications of gold nanoparticles take the 
advantages of the unique properties of GNPs, which include simplicity of preparation, low costs 
of starting materials, low toxicity, high stability and ease of detection due to the high extinction 
coefficient in UV-Vis spectrum [28,29].  
  Surface functionalization of nanoparticles is the key step to target them to specific areas of 
the body or to allow them to selectively interact with a certain cell or tissue. Nanoparticles have 
been successfully functionalized with different molecules and have been targeted also to different 
cells [30,31]. For these approaches, GNPs offer a unique surface chemistry that could be used as 
platform, on which self assembled monolayers of organic molecules can be formed. Various 
polymers have been reported to form self assembled monolayer (SAMs) on gold nanoparticle 
surfaces via either chemisorption or physisorption. Thiolated polyethylene glycols are strongly 
attached to gold surfaces, due to the high affinity of sulphur to gold, and subsequently protect 
them from aggregation by steric stabilization of the bulk polymer [32]. The protective shell not 
only serves for the stabilization of nanoparticles, but can also be used for further functionalization 
with specific components such as drugs or targeting moieties [33].     
   Until now, the targeting of nanoparticles to bone has not been achieved to a satisfactory 
extent and the advantages of such systems would be enormous, since a specific delivery of 
therapeutic agents can be used to treat diseases ranging from osteoporosis to bone cancer. 
Therefore, the main goal of this research is the preparation and characterization of gold 
nanoparticles as model nanoparticles for the investigation of in vitro bone targeting of a 
nanoparticulate system. In order to prepare a targeted particulate system, citrate-stabilized gold 
Chapter 5                                                          Binding of Functionalized GNPs to Hydroxyapatite 
 
142 
nanoparticles are functionalized with the previously synthesized thioalkylated poly(ethylene 
glycol)s. The ability of polymer coating to stabilize the GNPs under different conditions (such as 
the presence of high concentration of electrolytes or proteins) is studied. To obtain an idea about 
the bone targeting ability of the bisphosphonate-functionalized GNPs, the hydroxyapatite binding 
affinity of the prepared GNPs is one of the main objectives of the in vitro experiments. These 
binding experiments will be used to determine the influences of different conditions on the bone 
mineral binding affinity of functionalized GNPs.  
 
2. Materials  
  Hydrogen tetrachloroaurate tri-hydrate (HAuCl4.3H2O), ultrafiltration tubes (MWCO 
50,000 Da), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich Chemical 
Company (Steinheim, Germany). Tri-sodium citrate di-hydrate, hydrochloric acid, nitric acid, 
sodium chloride and calcium chloride were purchased from Merck (Darmstadt, Germany). 
Methoxy poly(ethylene glycol)-undecyl mercaptane (mPEG-AlkSH), bisphosphonate-modified 
amino poly(ethylene glycol)-undecyl mercaptane (BP-PEG-AlkSH), endobone granules 
(Endobone®, Merck, Darmstadt). All glassware was thoroughly washed with freshly prepared 
aqua regia (HCl: HNO3 = 3:1), extensively rinsed with Millipore water several times and oven-
dried at 150 °C for 2-3 h before use. All used solutions filtered through 0.22 µm filter before use. 
 
3. Methods 
3.1. Preparation of colloidal gold nanoparticles 
Gold nanoparticles (GNPs) were synthesized by citrate reduction of tetrachloroaurate tri-
hydrate according to the reports in the literatures with slight modifications [34,35]; citrate 
stabilized nanoparticles of approximately 40 nm in diameter were obtained using the following 
conditions, 0.5 ml of 1% HAuCl4.3H2O was added to 100 ml of Millipore water in a 250 ml 
round flask. The solution was heated to reflux under vigorous stirring. 1 ml of water containing 
170 mg of tri-sodium citrate was then added rapidly to the boiling solution. The addition of the 
citrate salt resulted in gradual change of the solution color from pale yellow to pink and finally to 
deep red. Boiling and stirring was continued for another 20 minutes. After that, the heating jacket 
was removed and the particle dispersion was gradually cooled under stirring to room temperature. 
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The obtained colloidal dispersion was then centrifuged at low speed (2500 rpm) for 15 minutes to 
remove coarse particles.  
 
3.2. Modification of nanoparticle surface with different polymers 
Methoxy poly(ethylene glycol)-undecyl mercaptane and the bisphosphonate modified 
PEG polymer were used to coat the originally citrate stabilized GNPs. Excess amounts of each 
polymer (5µg/ml) were added to the nanoparticle dispersion to ensure a complete coating of the 
particle surfaces with polymer. For the preparation of GNPs coated with mixed polymers, a 
parallel adsorption method of both polymer types was applied. The desired polymers (methoxy 
poly(ethylene glycol)-undecyl mercaptane and the bisphosphonate modified polymer) were added 
to the nanoparticle dispersion (total concentration of both polymers; 5µg per one ml of the 
colloidal solution). For example, 50 µl of the first polymer (1µg/µl) and 50 µl of the second 
polymer (1µg/µl) were mixed together and added to 20 ml of nanoparticle solution to obtain 
GNPs coated with 50% of each polymer. The resulting mixture was shaked over night in a 
horizontal shaker set to 200 rpm at room temperature to allow a complete exchange of the citrate 
anions with the thiolated polymers on the particle surface. Excess of unbound polymer was 
subsequently removed by four times of ultrafiltration at 750 g [36].         
 
3.3. Characterization of the prepared nanoparticle 
3.3.1. UV-Vis spectroscopy 
UV-Vis absorption spectra of the aqueous dispersions of citrate stabilized and coated 
nanoparticles were recorded using spectrophotometer (Uvikon-941, Kontron Instrument, 
Germany). 
3.3.2. Particle size analysis and zeta potential measurements 
The medium size, size distribution and the zeta potential of the prepared gold 
nanoparticles were analyzed by photon correlation spectroscopy using a Zetasizer 3000 HAS 
(Malvern, Instruments GmbH, Germany). 300 µl of the initial GNP dispersions were added to 3 
ml of Millipore water immediately before measuring their size and zeta potential at room 
temperature. The refractive index and the viscosity of water were used for calculation of the 
results. The photon correlation spectroscopy measurements were used to calculate the average 
particle size and their polydispersity index (PI), as dimensionless measure for the broadness of 
the size distribution [37].  
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3.3.3. TEM imaging of the nanoparticles 
10 µl of the nanoparticle samples were dropped on copper grids (Plano Formvar/Carbon 
films on 400 mesh grids, 3.05 mm diameter) and dried at room temperature overnight before 
taking transmission electron microscopy (TEM) images (Zeiss EM 10 C/CR, Germany). 
3.3.4. Determination of nanoparticles concentration by ICP 
1 ml of the nanoparticle dispersions was treated with the equal volume of aqua regia to 
dissolve the nanoparticles in order to determine the concentration of elemental gold using 
inductively coupled plasma optical emission spectroscopy (ICP-OES) (Horiba Jobin Yvon, 70P, 
S+S, Munich, Germany). The gold concentration was calculated using a standard curve 
constructed from different concentration of hydrogen tetrachloroaurate tri-hydrate [38].    
3.3.5. Dispersion stability of GNPs 
High ionic strength salt solution (5 M NaCl), bovine serum albumin (BSA, 200µg/ml) and 
bovine serum (10% v/v) were added to the particles to test the dispersion stability of coated 
GNPs in comparison with citrate-stabilized nanoparticles. The stability of the colloidal 
dispersions was monitored by size determination, zeta potential measurement and by changes in 
the UV-Vis spectra of nanoparticle dispersions [39,40]. 
3.3.6. Adsorption of bisphosphonate functionalized gold nanoparticles to endobone 
 Different concentrations of gold nanoparticles functionalized with different amounts of 
bisphosphonate contained in the coating were used to study the adsorption behavior of GNP-BP 
to hydroxyapatite granules (Endobone®) compared to nanoparticles coated with only methoxy 
poly(ethylene glycol)-undecyl mercaptane. 3 ml of the colloidal dispersions were added to 0.5 g 
of Endobone granules (size; 2.85-5.6 mm) and incubated for different time intervals at room 
temperature on a horizontal shaker set to 200 rpm. The percentage of nanoparticles adsorbed to 
the hydroxyapatite was calculated from the following equation (Equation 1): 
 
            
%100% ⋅
−
=
before
afterbefore
Abs
AbsAbs
Adsorbed
       (Equation 1) 
ABS before: absorbance of nanoparticles at λmax before incubation 
ABS
 after: absorbance of nanoparticles at λmax after incubation 
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 The amount of gold nanoparticles (µmol) adsorbed per m2 on endobone granules (Q) was 
determined applying equation 2 [41]. 
 
                                   SW
VCCQ eqi
⋅
⋅−
=
)(
 
 
(Equation 2) 
 
 
 
 Q: amount adsorbed per of gold nanoparticles per m2 on endobone granules. 
Ci: initial concentration of nanoparticles (µmol/L). 
Ceq: equilibrium concentration of nanoparticles (µmol/L). 
V: volume of the solution (3 ml). 
W: weight of endobone granules 
S: specific surface area of endobone granules (0.1 m2/g) [42].     
 
 Furthermore, the binding was studied in the presence of calcium chloride (2,5 mM), BSA 
(200 µg/ml) and serum (10 % v/v). 
 
4. Results and Discussion 
4.1. Preparation and characterization of gold nanoparticles 
 
 
HAuCl4
Na-Citrate
R-PEG-AlkSH
R = OCH3 or Bisphosphonate
 
Figure 1: Diagram representing the synthesis of gold nanoparticle 
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 Monodisperse GNPs were prepared by the reduction of HAuCl4⋅3H2O solution using tri-
sodium citrate as reducing agent as presented in Figure 1. The prepared GNPs were obtained with 
ruby red color. The formation of the nanoparticles was followed using the UV-Vis spectrum, 
which shows the characteristic surface plasmon resonance (SPR) at about 524 nm (Figure 2). 
From the narrow peak of the citrate stabilized GNPs at 524 nm it can be concluded that these 
particles are well dispersed and the size of the obtained particles (bare GNPs) is about 40 nm 
[43]. After coating of the particles with synthesized polymers, the SPR at 524 exhibited a red 
shift of approximately 8 nm relative to the uncoated GNPs [44]. The observed red shift may be 
attributed to a change of the refractive index of the environment surrounding the nanoparticles as 
result of attached polymer layer around the particles, which is also an indication of the successful 
coating of nanoparticles with the polymers [45,46].  
 The gold content of the GNPs after synthesis was measured by ICP-OES. The determined 
concentrations of gold showed that nearly all the added gold in the flasks (2.5 mg) was converted 
to nanoparticles. The number of nanoparticles per ml was calculated based on the ICP 
measurement and the TEM images and it was found to be about 7*1010 particles/ml [47,48]. 
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Figure 2: UV-Vis absorption spectra of citrate stabilized and coated gold nanoparticles; mPEG-
AlkSH, BP-PEG-AlkSH and citrate coated GNPs (from top to bottom) 
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 Several methods are applied to characterize particles, especially in terms of size, but none of 
them is generally fully satisfactory. Therefore, a combination of at least two methods, one of 
which should be a microscopic is highly recommended [49]. The sizes of different preparations 
of GNPs were determined by photon correlation spectroscopy are listed in Table 1. The sizes of 
different citrate stabilized gold nanoparticle preparations (1-4 preparations) range from 38.6 ± 
0.153 to 46.1 ± 1.12 nm with acceptable polydispersity indices (less than 0.6) [12,37]. 
Modification of the nanoparticles with thiol containing polymers increased the hydrodynamic 
sizes as expected due to formation of a PEG monolayer around the nanoparticles. The measured 
size increases of the GNPs range from 7 to 12 nm. Consequently, the thickness of the polymer 
layer on the gold nanoparticle was between 3.5 to 6 nm, which agrees well with the results 
reported in the literatures [40,50]. 
 
Table 1: Sizes, polydispersity indices (PI) and zeta potentials of different batches of citrate 
stabilized and polymers coated GNPs determined by photon correlation spectroscopy 
Gold nanoparticle preparations Hydrodynamic 
size by PCS (nm) 
Poly. Index 
(PI) 
Zeta potential 
(mV) 
Citrate coated GNPs 1 46.1 ± 1.12 0.479 ± 0.0.68 -48.7 ± 5.1 
Citrate coated GNPs 2 44.2 ± 0.436 0.543 ± 0.055 -46.0 ± 4.5 
Citrate coated GNPs 3 38.6 ± 0.153 0.416 ± 0.08 -47.7 ± 3.2 
Citrate coated GNPs 4 41.8 ± 1.03 0.395 ± 0.018 -51.9 ± 8.9 
1 coated with mPEG-AlkSH 57.3 ± 3.11 0.426 ± 0.061 -19.4 ± 6.1 
2 coated with NH2PEG-AlkSH 55.5 ± 1.39 0.578 ± 0.005 -2.1 ± 5.3 
3 coated with BP-PEG-AlkSH 45.2 ± 1.1 0.465 ± 0.014 -44.6 ± 7.1 
 
 To further characterize the morphology and to verify the size of the prepared 
nanoparticles, imaging by transition electron microscopy (TEM) was applied. The obtained 
citrate stabilized GNPs are spherical, all smaller than about 100 nm and well-separated from each 
other when dried on the coated copper grid (Figure 3A). Upon examination of the nanoparticles 
with higher magnifications it was found that most of the synthesized nanoparticles are spherical 
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with only few of them exhibiting a slight polygonal shape (Figure 3B). The TEM images 
revealed no difference in the morphology and the appearance between bare and polymer coated 
nanoparticles, most likely due to the weak contrast of the polymer shell, which consequently is 
not visible in the micrographs (Figures 3B, 3C and 3D). The measured size differences range 
from 7 to 14 nm (between the coated and uncoated GNPs), which is a reasonable size of the 
polymeric coat of the nanoparticles. Furthermore, these observations also indicate that the 
integrity of GNPs is not affected by modifying the particles with the used polymers [46]. 
 
           A            B 
          C            D 
Figure 3: TEM images of the prepared GNPs; citrate stabilized GNPs (A and B), mPEG-
AlkSH coated (C) and BP-PEG-AlkSH coated (D) 
 
 The surface charges of different gold nanoparticle preparations are listed in Table 1. The 
zeta potential measurements show that the surface charge of bare (citrate stabilized) GNPs is 
negative with approximately -48.5 ± 5.5 mV, which is attributed to the adsorption of the negative 
citrate anions to the particle surface during their synthesis. For dispersed particles the measured 
surface charge plays an important role for their stability. It is known from the literature that 
aggregation is very unlikely for charged particles with optimum zeta potentials (ξ > 30 mV) due 
to electrostatic repulsion forces between similarly charged particles [51]. Consequently the 
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charged particles are kept dispersed, because the double layer repulsion caused by the charges is 
counteracting the attractive van der Waal forces between two identical gold spheres [52]. 
 Coating of citrate stabilized GNPs with mPEG-AlkSH resulted in an increase of the zeta 
potential from about -48.7 ± 5.1 to about -19.4 ± 6.1 due to the substitution of some the citrate 
anions adsorbed on the particle surface by the thiol groups of the polymer [53]. However, the 
PEG-coated gold nanoparticles were still well dispersed and stabilized, but instead of the 
electrostatic repulsion due to the steric repulsion of the polymer chains attached to the particle 
surfaces [54]. For the bisphosphonate-modified GNPs on the other side a high negatively charged 
particle surface was observed with zeta potentials similar to that of citrate stabilized GNPs (Table 
1), which is explained by the presence of additional anionic bisphosphonate groups on the 
particle surface [55,56]. 
 
4.2. Dispersion stability of GNPs 
 For the biological applications of GNPs, the stability of different GNP preparations was 
investigated in the presence of high ionic strength media and in the presence of proteins (BSA 
and bovine serum). The addition of 5 M NaCl to bare GNPs resulted in a rapid aggregation of the 
nanoparticle monitored by drastic change of their color from ruby red to violet and finally to a 
colorless solution due to the resulting precipitation of the nanoparticles. The characteristic surface 
plasmon resonance disappeared and a new broad peak at much higher wave lengths (above 600 
nm) was observed due to the formation of larger gold aggregates (Figure 4). The instability of 
citrate coated GNPs in the presence of high concentrations of NaCl could also be monitored by a 
large increase of the hydrodynamic size as measured by photon correlation spectroscopy (Figure 
5). The GNP aggregation induced by addition of NaCl is due to the reduction of the electrostatic 
repulsion between surface-charged nanoparticles caused by the added sodium and chloride ions 
and consequently the decreasing distance between the particles favoring the interaction via van 
der Waals forces [57,58]. Polymer-coated GNPs on the other hand are not affected by NaCl, as 
shown in Figure 4 and 5, because they are not stabilized by the surface charge but by the steric 
repulsion effect of the polymer chains [39]. 
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Figure 4: Effect of NaCl on the UV-Vis absorption spectra of mPEG-AlkSH (a), BP-
PEG-AlkSH (b) and citrate (c) coated gold nanoparticles 
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Figure 5: Size of GNPs before and after coating with polymers and the effect of 
addition of NaCl, BSA and 10% bovine serum on the on the size of coated and citrate 
stabilized  GNPs  
  
 Similarly to the sodium chloride addition, citrate-coated GNPs rapidly aggregated after 
addition of bovine serum albumin (BSA) and also serum, which can be demonstrated by the 
disappearance of the characteristic surface plasmon resonance (Figure 6 and 7) and by their large 
size increase as shown by photon correlation spectroscopy measurements (Figure 5). These 
observations could be attributed to specific interactions of cysteine residues of the added proteins 
and GNPs or most likely to the adsorption of proteins on the nanoparticles, which both yields a 
shielding of the negative charges of the GNPs and the subsequent aggregation. In contrast, 
polymer-protected GNPs are either not affected at all (in case of mPEG-AlkSH coated GNPs) or 
show only a slight size increase (in case of BP-PEG-AlkSH coated GNPs) by addition of BSA 
and serum. The protein resistance (i.e. the stability) of PEG-coated GNPs is a consequence of the 
high stability of the interfacial water layer, which prevents direct contact between the particle 
surface and the proteins [59]. The slight increase in particle size after addition of BSA and serum 
to nanoparticles coated with BP-PEG-AlkSH (Figure 5) can be attributed to the presence of 
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negative charges of the bisphosphonate groups, which can interact with positively charged groups 
of the proteins. 
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Figure 6: Effect of BSA on the UV-Vis absorption spectra of mPEG-AlkSH coated GNPs, BP-
PEG-AlkSH coated GNPs and citrate coated gold nanoparticles (from top to down) 
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Figure 7: Effect of bovine serum (10 % v/v) on the UV-Vis absorption spectra of mPEG-AlkSH, 
BP-PEG-AlkSH and citrate coated gold nanoparticles (from top to bottom)  
 
4.3. Adsorption of gold nanoparticles to hydroxyapatite 
 The adsorption of bisphosphonate modified GNPs (GNPs-BP) to hydroxyapatite was 
studied to evaluate the affinity of surface-modified gold nanoparticles to bone mineral. For this 
study endobone was used as a porous hydroxyapatite ceramic produced by sintering of bovine 
bone and it consequently can be used as model of bone, because it is the major constituent of the 
natural bone besides the protein [42]. The hydroxyapatite binding of GNPs modified with 
different amounts of bisphosphonate in the polymer layer was compared with the binding of 
GNPs coated with 100% of mPEG-AlkSH (0% bisphosphonate). The results showed that 
increasing the amount of binding ligand for the hydroxyapatite surface (bisphosphonate) led to 
increasing amounts of GNPs adsorbed to hydroxyapatite as depicted in Figure 8. 
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Figure 8: Hydroxyapatite binding of GNPs modified with different amounts of bisphosphonate 
(e.g, 75% means that GNPs are coated with 75% BP-PEG-AlkSH and 25% mPEG-AlkSH)  
  
 GNPs modified with 0% Bp (100% mPEG-AlkSH) showed no affinity to hydroxyapatite, 
while about 25% of the initially added GNPs modified with 25% BP (75% mPEG-AlkSH) 
adsorbed to hydroxyapatite within 24 hours. This adsorbed amount increased to about 40% after 
48 hours with no further increase in the adsorbed amount by shaking for longer time (up to 4 
days). The bound amounts of particles modified with 50% bisphosphonate were about 45% after 
one day and reached 64% after two days. The adsorbed amounts of GNPs modified with 75% and 
100% bisphosphonate were 58% and 37% after one day, and 76% and 81% after two days and 
reached 86% and 100% after four days respectively. The steady increase in the adsorbed amounts 
with increasing concentration of bisphosphonate in the particle surface can be explained by the 
higher hydroxyapatite affinity of GNPs containing more bisphosphonate in their surface. The 
relatively long time (about two days) to establish the equilibrium between the adsorbed and free 
particles can be attributed to the necessary diffusion of the particles within the large volume of 
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the dispersion medium and the necessary penetration into the macro and micro pores of endobone 
granules on the bottom of the flasks to reach the adsorption sites. Similar results are obtained by 
many other authors who studied the binding of nanoparticles to hydroxyapatite [55,60].  
 Since it is well known that bisphosphonate strongly binds to divalent ions, such as 
calcium [61], the binding assay of bisphosphonate-modified GNPs was repeated in presence of 
calcium chloride to explore effect of calcium ions on the affinity of the nanoparticles. The used 
calcium concentration was 2.5 mM, which is the physiological concentration present in blood 
serum. The binding affinity of 100% bisphosphonate-modified GNPs to hydroxyapatite in the 
presence and absence of calcium chloride is depicted in Figure 9. It could be observed that there 
is no difference in the binding of nanoparticles either in presence or absence of calcium. This 
indicates that the binding affinity of particles to hydroxyapatite is not affected by the presence of 
calcium ions in the colloidal solution.  
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Figure 9: Effect of calcium chloride on the hydroxyapatite binding of bisphosphonate-
modified GNPs 
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 Furthermore, the in-vitro binding of bisphosphonate-modified GNPs was carried out in 
presence of BSA (200 µg/ml) and serum (10% v/v) to determine, if the interaction of 
bisphosphonate with these proteins compromises the binding to hydroxyapatite. The results of 
these experiments are presented in Figure 10, which shows that the binding affinity of 
nanoparticles to hydroxyapatite is not affected by the presence of BSA or serum. The obtained 
data indicate that the bisphosphonate-modified GNPs are stable and the observed interaction of 
particles and proteins, especially BSA (Figure 5), does not influence their bone mineral affinity. 
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Figure 10: Effect of BSA (200 µg/ml) and bovine serum (10% v/v) on the binding of 
bisphosphonate-modified GNPs to hydroxyapatite 
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5. Conclusions 
 In conclusion, it could be shown that the synthesized polymers, methoxy poly(ethylene 
glycol)-undecyl mercaptane and the bisphosphonate derivative, are suitable to functionalize gold 
nanoparticles prepared by citrate reduction. The obtained particles were characterized with 
respect to size, surface charges and dispersion stability. The polymer modified GNPs showed an 
enhanced stability against aggregation in different solutions such as high ionic strength NaCl 
solutions, as well as solutions containing BSA and serum. 
 Furthermore, the modification of the particles with bisphosphonate modified polymers 
allowed the preparation of particles with high affinity and strong binding to hydroxyapatite. The 
binding affinity to bone mineral could be adjusted by increasing the amount of bisphosphonate 
(targeting ligand) on the particle surfaces. Furthermore, it was demonstrated that the binding is 
not affected by present calcium ions as well as in presence of proteins. 
 Based on the conducted in vitro studies, bisphosphonate-functionalized GNPs seem to be 
a promising model for the investigation of the in vivo bone targeting of nanoparticles. An 
adjustment of the binding affinity can be achieved by changing the amounts of immobilized 
bisphosphonate modified polymers. An exchange for other suitable ligands allows using the 
nanoparticle system also for other targets and the possible exploration for other applications than 
bone. 
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1. Introduction 
 Over the past years, a lot of research was devoted to the development of targeted 
nanoparticles for a localized drug delivery, because of the multitude of advantages and further 
treatment options this kind of therapy would offer. After in vivo administration of colloidal 
carriers, the biodistribution and interaction of particulate carriers with different cells and 
tissues largely depends on the particle size and surface properties such as surface charges and 
surface hydrophilicity [1,2]. Due to this fact we aimed at the production of a versatile model 
system that allowed for the use of various targeting ligands. It is based on a gold 
nanoparticulate core and a stabilizing shell consisting of a stabilizing PEG layer with attached 
ligands suitable for targeting. 
 Nanoparticles, like all other colloidal carriers, are taken up by the Kupffer cells of the 
liver or the macrophages of the spleen and blood stream after intravenous administration. 
Therefore, the liver represents a major obstacle or sink for the efficient targeting of colloidal 
carriers to specific sites other than reticuloendothelial system (RES).  For a successful 
targeting approach, the most promising strategy is to avoid the uptake of nanoparticles by the 
RES by steric stabilization of nanoparticles using a hydrophilic polymer layer such as 
poly(ethylene glycol) (PEG). The presence of PEG on the particle surface decreases opsonin 
adsorption and thus also of nanoparticle phagocytosis by the liver, which leads consequently 
to longer circulation half life of such particles in the blood [3-5]. 
 Metallic nanoparticles are not only used as model systems but also for therapeutic 
applications. They are very attractive due to their size, physical, chemical and surface 
properties, which include high chemical stability and easy detection. Flexible nanoparticle 
surface coatings and functionalization can be utilized to increase the blood residence time, 
reduce nonspecific biodistribution and investigate the targeting to specific tissues or specific 
cells by using surface immobilized targeting ligands [6]. Melancon and et al. [7], for example, 
studied the in vitro and in vivo targeting of hollow gold nanoshells for photothermal ablation 
therapy, which makes use of the high absorptivity of the nanoparticles in order to irradiate 
targeted tumor tissues. In vivo results showed that antibody-conjugated 111In-labelled particles 
have the potential to be delivered to specific sites after intravenous administration in mice, 
which makes them useful as enhancer for the subsequent photothermal treatment.  
 For this study we chose bone as target tissue, since bone selective delivery of drug-
loaded nanoparticles can potentially lead to high local drug concentrations of bone therapeutic 
agents suitable to fight osteoporosis or bone cancer. This kind of treatment would additionally 
minimize the distribution of the cytostatic drugs in the whole body and thereby decrease the 
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systemic toxicity. Several investigations were already conducted to develop bone targeted 
drug delivery system using bisphosphonates, small chemical entities with very high affinity to 
the main inorganic component of bone, the bone mineral hydroxyapatite [8-10]. Based on this 
knowledge Hengst et al. [11] studied the in vitro bone targeting ability of bisphosphonate-
conjugated liposomes as nanoparticulate drug delivery system. The obtained results indicated 
that the bisphosphonate-conjugated liposomes are useful to target the bone mineral 
hydroxyapatite in vitro. Further investigations in the literature, however, only describe the use 
of bisphosphonate labeled proteins used for bone targeting, which apparently are much 
smaller in size than the here investigated nanoparticles [12].  
 To investigate the bone targeting ability of recently designed gold nanoparticles with 
high affinity to hydroxyapatite in vitro, bisphosphonate-modified PEGylated gold 
nanoparticles were intended to be applied intravenously to mice. The study examines the 
effect of surface functionalization and PEGylation on the pharmacokinetic profile and the 
resulting distribution of the gold nanoparticles in vivo. Furthermore, the study elucidates the 
impact of the bisphosphonate density on the particles surface on the in vivo bone targeting of 
the functionalized gold nanoparticles.            
 
 
2. Experimental 
2.1. Materials 
 Amino poly(ethylene glycol)-undecyl mercaptane, methoxy poly(ethylene glycol)-
undecyl mercaptane and bisphosphonate-modified amino poly(ethylene glycol)-undecyl 
mercaptane were synthesized as described in chapter 2. Hydrogen tetrachloroaurate trihydrate 
(HAuCl4.3H2O), tri-sodium citrate dihydrate, diethylenetriaminepentaacetic (DTPA) 
dianhydride, triethylamine (TEA), dialysis tubing (MWCO 1000 Da), dialysis tubing (MWCO 
3500 Da), ultrafiltration tubes (50,000 Da MWCO), bovine serum albumin (BSA) and 
tetramethylsilane (TMS) were purchased from Sigma-Aldrich Chemical Company 
(Steinheim, Germany). Bovine serum, chloroform, calcium chloride, physiological buffer 
solution, endobone granules, and acetate buffer pH 5.5, were obtained from Merck 
(Darmstadt, Germany). Deuterated chloroform was from Deutero GmbH (Kastellaun, 
Germany). Radioactive indium (111In) was obtained from OctreoScan® Kit (Mallinckrodt, 
Inc.).  
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2.2. Methods 
2.2.1. Synthesis and characterization of DTPA-PEG-AlkSH 
 Amino poly(ethylene glycol)-undecyl mercaptane DTPA (DTPA-PEG-AlkSH) 
derivative was prepared from amino poyl(ethylene glycol)-undecyl mercaptane (NH2-PEG-
AlkSH) and diethylenetriaminepentaacetic (DTPA)  as following. To the stirred suspension of 
DTPA dianhydride (1.43 g, 4 mmol) in 40 ml chloroform, TEA (0.81 g, 8 mmol) and amino 
poly(ethylene glycol)-undecyl mercaptane (NH2-PEG-AlkSH) (2.2 g, 1 mmol) were added 
and further stirred at room temperature for 3 h. After the reaction, chloroform and TEA were 
removed by heating to 65 °C under vacuum. The obtained DTPA-PEG-AlkSH was purified 
by dialysis against deionized water using dialysis tube (MWCO, 1000), immediately freeze 
dried and later characterized by 1H-NMR. The synthesis of DTPA-PEG-AlkSH is described in 
Scheme 1 [13-15]. 
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Scheme 1: Synthesis of the amino poly(ethylene glycol)-undecyl mercaptane DTPA derivative 
 
2.2.2. Preparation of gold nanoparticles functionalized with bisphosphonate 
 Citrate stabilized gold nanoparticles with an average particle size suitable for 
intravenous administration were synthesized by the reduction of hydrogen tetrachloroaurate 
tri-hydrate (HAuCl4.3H2O) using tri-sodium citrate as described in chapter 4. For the 
subsequent modification of the gold nanoparticle surface, a parallel adsorption method was 
applied using different combinations of the functionalized polymers. Methoxy poly(ethylene 
glycol)-undecyl mercaptane, bisphosphonate modified poly(ethylene glycol)-undecyl 
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mercaptane and DTPA modified poly(ethylene glycol)-undecyl mercaptane were added to the 
nanoparticle dispersion with a total concentration of 5µg/ml. The amount of DTPA-PEG-
AlkSH was kept constantly at 10% of the polymer mixture, while the concentrations of 
mPEG-AlkSH and BP-PEG-AlkSH were changed to obtain different functionalities of the 
particles. Three types of gold nanoparticles solutions were prepared from citrate stabilized 
gold nanoparticles stock solution with a concentration of 7*1010 particles/ml and with size of 
37 nm. Solution I (control) which is modified by 10% DTPA-PEG-AlkSH and 90% mPEG-
AlkSH, solution II, which is modified with 10% DTPA-PEG-AlkSH , 50% mPEG-AlkSH and 
40% BP-PEG-AlkSH, and solution III, which is modified by modified by 10% DTPA-PEG-
AlkSH, 10% mPEG-AlkSH and 80% BP-PEG-AlkSH. Excess polymers were removed by 
ultrafiltration at 750 g using ultrafiltration tubes.     
 
 
 
 
 
 
 
 
 
Figure 1: Preparation strategy of surface functionalized gold nanoparticles. 
 
2.3. Characterization of gold nanoparticles 
2.3.1. UV-Visible spectroscopy 
  UV-Vis absorption spectra of aqueous dispersions of the citrate stabilized and 
polymer coated nanoparticles were recorded using double beam spectrophotometer (Uvikon-
941, Kontron Instrument, Germany). 
2.3.2. Size distribution and surface charge measurements 
 Particle size distributions of the gold nanoparticles were determined using the 
Zetasizer 3000HSA (Malvern Instruments, GmbH, Germany). Nanoparticle dispersions were 
appropriately diluted with 0.22 µm-filtered Millipore water and size measurements were 
carried out at a 90° angle with respect to the incident beam. The measurements of the particle 
surface charges were performed in the standard capillary electrophoresis cell of Zetasizer 
HAuCl4 Na-Citrate
R-PEG-AlkSH
R = OCH3, DTPA or Bisphosphonate
R
R
R
R
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3000 HSA (Malvern Instruments, GmbH, Germany), measuring the electrophoritic mobility at 
25 °C. Refractive index and viscosity of water were used for the calculation of the results. 
2.3.3. TEM imaging of the particles 
 10 µl of the nanoparticle samples were dropped on graphite coated copper grids and 
dried at room temperature overnight before taking the images by transmission electron 
microscopy (TEM) (Zeiss EM 10 C/CR, Germany).  
2.3.4. Dispersion stability of nanoparticles 
 High ionic strength solutions (5M NaCl), bovine serum albumin (BSA, 200µg/ml) and 
bovine serum (10% v/v) were applied to the test the dispersion stability of coated GNPs in 
comparison with bare nanoparticles using photon correlation spectroscopy and UV-Vis 
adsorption spectroscopy. 
2.3.5. Determination of nanoparticles concentration by ICP 
 1 ml nanoparticle dispersion was treated with an equal volume of aqua regia to 
dissolve the nanoparticles before determining the concentrations of the elemental gold using 
inductively coupled plasma optical emission spectroscopy (ICP-OES) (Horiba Jobin Yvon, 
70P, S+S, Munich, Germany). The concentration was calculated using standard curve 
constructed by using different concentrations of auric chloride. 
 
2.4. In vitro binding of gold nanoparticles to hydroxyapatite 
 The bone mineral affinity of solution I and II compared to that of the control was 
investigated before carrying out the in vivo studies. 3 ml of the nanoparticle dispersions were 
added to 0.5 g of the bone mineral hydroxyapatite (Endobone) and shaked on an orbital 
shaker at 200 rpm at room temperature. The percentages of adsorbed nanoparticles with time 
were calculated according to equation 1: 
 
%100% ⋅
−
=
before
afterbefore
Abs
AbsAbs
Adsorbed
 
 
(Equation 1) 
ABS before: is the absorbance of nanoparticles at λmax before shaking with HA 
ABS
 after: is the absorbance of nanoparticles at λmax after shaking with HA 
 
 Binding studies in the presence of calcium chloride, BSA and serum were also 
performed in order to investigate the effect of the presence of electrolytes and proteins on the 
affinity of the nanoparticles to hydroxyapatite.       
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2.5. Radiolabelling of gold nanoparticles. 
 For the accurate in vivo quantitative analysis, gold nanoparticles were labeled with the 
111In, which has a half life of 67.3 h. This long half life enables the in vivo detection of the 
nanoparticles up to 48 h after conjugation and injection of the particles in the animals [7]. 1 
ml of gold nanoparticle dispersion (7*1010 particles per ml) was added to 3.75 ml of acetate 
buffer (pH = 5.5) containing 0.8-0.9 MBq of 111In. The mixture was then stirred at room 
temperature for 15 minutes. Excess of unbound radioactive indium was removed by dialysis 
for 2 h against physiological buffer using dialysis membrane with a cutoff of 3500 Da. 
 
2.6. Animal biodistribution  
 The biodistribution experiments were carried out using SWISS male mice weighing 
between 28 and 34 g (provided by the animal house of the University of Angers) in 
accordance with the French regulations for animal experiments (law 0189.4 of January 24, 
1990). About 100 µl of the dispersions of 111In-labeled gold nanoparticles, with the later 
determined actual amounts of each solution, were injected intravenously in the tail vein of a 
mouse under gaseous isoflurane anesthesia. The injected volumes in each mouse would 
correspond to about 5.6*108 particles and 2.5*105 cpm of radioactivity. The animals had free 
access to food and water ad libitum prior to and during the course of the experiments. Four 
injected mice were sacrificed at specific time points of 15 minutes, 1, 6, 24 and 48 h after the 
administration of particles. Different organs of each mouse including liver, heart, spleen, 
lungs, muscles, bone (femur), stomach, small intestine, colon (large intestine), kidneys, 
urinary bladder, brain, carcass and an accurately weighed sample of blood were taken and 
placed in scintillation tubes for counting the radioactivity. Additionally, two times three mice 
were placed in special cages for the collection of urine and faeces samples for the high 
bisphosphonate carrying particles. The weight of each organ was determined and the 
corresponding radioactivity in that organ was recorded using a gamma counter (Packard 
Auto-Gamma 5000 series, Packard Instruments). Tissue concentrations of the nanoparticles 
were calculated and expressed as percent of the still present injected dose per gram of the 
respective tissue (% ID/g). The radioactivity still remaining in the tail was also recorded and 
taken into consideration for the calculation of the total present radioactivity dose in the 
animals. Blood samples were taken and the concentrations of nanoparticles in correctly 
weighed blood samples were recorded with time to investigate the pharmacokinetic profile of 
the injected particles.  
             
Chapter 6                                                                  Targeting of Functionalized GNPs to Bone 
 
172 
2.7. Pharmacokinetic analysis in the blood.  
 To compare between the different injected nanoparticle solutions, the pharmacokinetic 
parameters for all types of injected gold nanoparticles such as the area under the curve 
(AUC), elimination half life (t1/2), elimination rate constant (Kel) and mean residence time 
(MRT) were calculated according to the literature [16,17].   
 
3. Results and discussion 
3.1. Synthesis and characterization of DTPA-PEG-AlkSH. 
 Diethylene triaminepentaacetic (DTPA) acid reacted with amino group of amino 
poly(ethylene glycol)-undecyl mercaptane (NH2PEG-AlkSH), which resulted in the formation 
of the DTPA-PEG-AlkSH derivatives. The 1H-NMR spectrum in deuterated chloroform 
(Figure 1) is characterized by the signals at δH: 3.9-3.4 ppm (m, 192 H), 3.2 (s, 8 H), 2.8-2.5 
ppm (m, 2 H) and 1.8-1.2 ppm (m, 18 H). The integral of signal at δH 3.2 ppm is 7.2 protons, 
which should be 8 protons. Based on this results, the conversion to product DTPA-PEG-
AlkSH was calculated to be about 90%, which agrees well with the results described in the 
literature [15].    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: 1H-NMR spectrum of poly(ethylene glycol)-undecyl mercaptane DTPA derivatives 
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3.2. Preparation and characterization of the bisphosphonate coated gold nanoparticles 
3.2.1. Particles sizes and surface charges measurements 
 Nanoparticles with average particle size in the low nanometer range were synthesized 
by reducing tetrachloroaurate trihydrate with sodium citrate, a method already described in 
chapter 4. The formation of the gold nanoparticles is accompanied by a change of the solution 
color from pale yellow to ruby red. The size of the prepared nanoparticles determined by 
photon correlation spectroscopy was 37.0 ± 1.5 nm with a polydispersity index (P.I) of 0.495 
± 0.093. The zeta potential of the citrate-stabilized gold nanoparticles out of the synthesis was 
measured to be about -55.5 ± 13.4 mV (Table 1). This relatively high negative surface charge 
of nanoparticles is the main cause for the stability of the citrate coated colloidal solution. 
Coating of the nanoparticles with the mixed polymers resulted in an increase of the size by 
12-14 nm due to the hydrophilic polymer coating. The morphology and the surface structure 
of different samples were investigated by TEM and the obtained results confirmed the size 
results determined by photon correlation spectroscopy. The coating of nanoparticles with the 
hydrophilic polymers did not affect the polydispersity index. Solution I, which is modified by 
10% DTPA-PEG-AlkSH and 90% mPEG-AlkSH showed an increase in the zeta potential 
from -55.5 mV to -26.3 mV due to replacement of the citrate anions adsorbed on the particles 
surfaces. While solution II, which is modified by 10% DTPA-PEG-AlkSH, 40% BP-PEG-
AlkSH and 50% mPEG-AlkSH showed lower increase in the zeta potential (from -55.5 mV to 
-31.0 mV)  due to the incorporation of 40% of the negatively charged bisphosphonate groups 
within the coating. Solution III, which is modified by 10% DTPA-PEG-AlkSH, 80% BP-
PEG-AlkSH and 10% mPEG-AlkSH showed the lowest increase in zeta potential (from -55.5 
mV to -38.3 mV) due to the incorporation of the highest amount (80%) of bisphosphonate in 
the coat as shown in Table 1.    
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Table 1: Size, polydispersity index (P.I) and zeta potential of the citrate-stabilized and 
polymers- coated gold nanoparticles 
 Size (nm) Polydispersity 
index (P.I) 
Zeta potential 
(mV) 
Citrate stabilized GNPs 37.0 ± 1.51 0.495 ± 0.093 -55.5 ± 13.4 
solution I GNPs (coated with 10% 
DTPA-PEG-AlkSH and 90% mPEG-
AlkSH) 
 
48.9 ± 0.53 
 
0.465 ± 0.085 
 
-26.3 ± 7.8 
solution II GNPs (coated with 10% 
DTPA-PEG-AlkSH, 40% BP-PEG-
AlkSH and 50% mPEG-AlkSH) 
 
49.5 ± 0.92 
 
0.549 ± 0.012 
 
-31.0 ± 6.8 
solution III GNPs (coated with 10% 
DTPA-PEG-AlkSH, 80% BP-PEG-
AlkSH and 10% mPEG-AlkSH) 
 
50.4 ± 1.73 
 
0.561 ± 0.005 
 
-38.3 ± 9.1 
 
3.2.2. UV-Vis absorption spectra  
 Figure 3 shows the UV-Vis spectra of the bare gold nanoparticles compared with the 
modified particles of solution I, II and III. The characteristic surface plasmon resonance 
(SPR) band of citrate stabilized gold nanoparticles was observed at 522 nm confirming the 
presence of the spherical nanoparticles. Because the SPR is sensitive to the surface 
modification of the gold nanoparticles, a slight red shift in the λmax was observed (from 522 
nm to 526 nm). The red shift of λmax indicates the disturbance of the electrical double layer 
present around the nanoparticles by addition of the polymer and confirms their successful 
attachment (solution I, II and III) [18]. 
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Figure 3: UV-Vis absorption spectra of bare gold nanoparticles, solution I, II and III 
 
3.2.3. Dispersion stability of nanoparticles 
 As preliminary investigation for the stability of the particles before the in vivo 
experiments, the stability of solution I, II and III in comparison to citrate-stabilized gold 
nanoparticles was tested in the presence of sodium chloride, BSA and bovine serum. Citrate-
stabilized gold nanoparticles were significantly more sensitive and are rapidly aggregated to 
larger particles in the presence of electrolytes (NaCl), BSA and serum. While polymer-coated 
nanoparticles (solution I, II and III) are resistant and are not affected by the addition of salt or 
proteins, due to the presence of a protective layer of polymers around the particle surfaces. 
These results agreed well with results reported in chapter 4.       
 
3.3. In vitro binding of gold nanoparticles to hydroxapatite 
 The hydroxyapatite adsorption assay was performed in order to confirm the affinity of 
surface modified nanoparticles to bone. The bone mineral affinities of the different solutions 
are presented in Figure 4. About 40% binding of solution II, which contains 40% 
bisphosphonate, was obtained after 2 days of shaking with endobone granules at room 
temperature compared to only very small amounts (about less than 5% ) adsorbed from 
solution I, which contains no bisphosphonate. The bound amounts of solution III, which 
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contains 80% bisphosphonate, were 50% and 80% after 2 and 4 days, respectively. 
Consequently, the affinity to endobone was increased by increasing the bisphosphonate 
content on the particles surfaces due to the presence of more binding sites, these results 
confirms the results reported in the literature [19].  
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Figure 4: In vitro hydroxyapatite binding affinities of the investigated gold nanoparticle 
solutions 
 
 The effects of BSA, serum and also calcium ions on the binding of gold nanoparticles 
to hydroxyapatite were also investigated, since the in vivo bone binding is expected to take 
place in the presence of serum proteins and other cations, such as calcium, which are capable 
to compete with the bone mineral binding. The obtained results showed that the binding of 
bisphosphonate-modified gold nanoparticles is not affected by the presence of calcium 
chloride, BSA and serum as already presented in chapter 5.  
 
3.5. Biodistribution of bisphosphonate-modified gold nanoparticles. 
 The results of nanoparticles biodistribution at different time points are expressed as 
percentage of the still present injected dose per gram of the respective tissue (% ID/g) to 
facilitate the analysis of nanoparticles distribution inside the body. Different tissues were 
excised at specified time points from the sacrificed animals and the contained radioactivity 
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was measured. Figure 5 shows the biodistribution of the control gold nanoparticles (solution I, 
without bisphosphonate) in the various tissues at 0.25, 1, 6 and 24 hours after injection. The 
highest concentration of nanoparticles in the blood was observed at 1 h after injection and the 
complete distribution in the blood, which were about 20% of ID/g. This concentration 
decreased to about 10% after 6 h and to about 3% after 24 h. Remarkably, only about 5% ID/g 
of the injected nanoparticles accumulated in the liver and spleen after 24 h, which 
consequently means that the injected particles have the ability to avoid the uptake in liver and 
spleen, which is the usual route for non-shielded nanoparticulate formulations. These results 
agree well with results observed for other surface PEGylated nanoparticles [5,20-24].  
 Accumulation of the even not targeted nanoparticles in the bone reached 10% after 24 
h. This can however also be attributed to the small weight of the femur. The biodistribution 
patterns to heart, stomach, small intestine, colon, lung, muscle and brain in addition to liver 
and spleen did not show substantial accumulation in these organs. 
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Figure 5: Biodistribution of solution I of gold nanoparticles coated with 0 % bisphosphonate 
 
 In contrast, a progressing increase of the radioactivity was observed in the kidneys 
especially at later time points. The accumulation of the radioactivity in kidneys is 
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accompanied by a rapid decrease of radioactivity in blood, which indicates the elimination of 
the 111In-labelled nanoparticles from the systemic circulation and deposition also in the 
kidneys (Figure 6). This might be explained by an entrapment of the nanoparticles inside the 
kidneys, because of their relative large size (47 nm) and the hydrophilic coating (due to 
grafting of PEG to the particles surfaces). The accumulation of radioactivity in the kidneys 
increases with time, which can be explained by the accumulation of intact nanoparticles and 
not only the labeled polymers removed from the particles surfaces, because they would be 
small enough to be excreted via the urine. These results also reflect the high in vivo stability 
of the thioalkylated PEG-coated gold nanoparticles and support the results from literature [25-
27]. The relatively low concentration of nanoparticles in carcass expressed as %ID/g (which 
refers to the entire body of the animal without the organs and tissues indicated in Figure 5) is 
mainly attributed to the relative large weight of carcass compared to other tissues and organs. 
However, if just the injected dose is considered about 50% accumulate in the carcass, which 
also demonstrates the ability of the particles to extravasate in many tissues. 
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Figure 6: Biodistribution of solution I of gold nanoparticles (control) on the blood and kidney 
 
 No large differences were observed for the biodistribution of gold nanoparticles 
functionalized with 40% bisphosphonate, solution II GNPs, (Figure 7). Solution II gold 
nanoparticles showed only a slight increase in the bone accumulation relative to the control, 
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which eventually could be attributed to the presence of the targeting moiety (bisphosphonate). 
The insignificant difference of the bone accumulation between the bisphosphonate 
functionalized and the control GNPs may be due to many different reasons, such as the 
trapping of many gold nanoparticles in the kidneys, the difficult extravasation of the highly 
hydrophilic coated gold nanoparticles in the bone, the relative large size of the injected 
nanoparticles [8,28] or merely the relatively small portion of bone that was used for the 
investigation in comparison to the remaining bone tissue in the animal (carcass).  
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Figure 7: Biodistribution of solution II gold nanoparticles coated with 40% bisphosphonate 
 
 The biodistribution of gold nanoparticles functionalized with 80% bisphosphonate 
(Figure 8) again is quite similar to the biodistribution of solution II GNPs (containing 40% of 
BP, Figure 7) and the control GNPs solution (Figure 5). For an easier comparison, the aimed 
bone accumulation of the injected colloidal solutions (solutions I, II and III) is shown in 
Figure 9. Gold nanoparticles functionalized with the highest BP concentration nevertheless 
show the highest relative bone accumulation in femur when compared to the other solutions. 
The bone concentrations of solution III after 6 and 24 h, expressed as %ID/g bone, are 17.15 
± 1.79 and 16.41 ± 3.75 respectively compared to 10.14 ± 2.29 and 11.12 ± 1.49 for solution 
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II, and 8.16 ± 1.26 and 10.43 ± 9.64 for solution I. These data show that the targeted gold 
nanoparticles (containing BP) have a tendency to target and accumulate in bone compared to 
the non-targeted gold nanoparticles. However, the bone concentration of solution III, which 
contains 80% BP on the surface, reached a maximum at 6 h after injection, 17.15 ± 1.79 
%ID/g and then decreased again to 16.41 ± 3.75 %ID/g after 24 h and to 12.51 ± 2.6 %ID/g at 
48 h, which is not in accordance with the above mentioned properties of bisphosphonates and 
certainly demands for further investigations. 
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Figure 8: Biodistribution of solution III coated with 80% bisphosphonate. 
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Figure 9: Accumulation of different gold nanoparticles (solutions I, II and III) in  bone 
 
3.6. Pharmacokinetic analysis of the tested gold nanoparticles in blood 
 A non compartmental model was used in order to estimate the pharmacokinetic 
parameters of the nanoparticle formulations after intravenous injection. Blood concentration-
time profiles for the injected nanoparticles are presented in Figure 10 with the calculated 
parameters summarized in Table 2. For a successful application of the particles as targeted 
drug delivery system a low elimination rate constant and a long half life in blood is necessary. 
The determined half life in blood for the three samples are in the following order; solution III 
> solution II > solution I, between 8.96 to 7.25 hours, which are certainly not statistically 
significant. The relatively long half lives of the investigated gold nanoparticles are due to the 
surface PEGylation of the nanoparticles, which significantly increases the half lives of 
nanoparticles as well known form literature [4,5,29,30]. Furthermore, the long circulation half 
life of nanoparticles helps the particles in vivo to reach their intended target, because the 
particles need to circulate in blood for a sufficiently long time to have the chance to interact 
with their specific target cells or tissues [31,32]. In contrast to the here observed behavior, the 
half life of the non-PEGylated nanoparticles is commonly very short and they rapidly excreted 
form the blood. Simon et al. [33] studied the circulation half time and body distribution of 
amine modified polystyrene nanoparticles. They observed that the half lives of the studied 
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particles are very short and after 30 minutes 60-70% of the 100 nm particles are already 
accumulated in the liver, which prohibits further reaching of the target organ. 
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Figure 10: Blood profiles of the gold nanoparticles in blood after intravenous administration 
 
           
Table 2: Pharmacokinetic parameter of the injected gold nanoparticles 
 Kel ( h-1) t1/2 ( h) AUC (ng/g*h) MRT (h) 
Solution 1 (control) 0.0955 7.25 1973.19 8.25 
Solution 2 (40% BP) 0.0869 7.97 2040.3 9.45 
Solution 3 (80% BP) 0.0773 8.96 3356.56 11.2 
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5. Conclusions 
 The presented study revealed that the prepared gold nanoparticles can be successfully 
stabilized and modified to perform their intended tasks for in vivo experiments. The 
nanoparticles were synthesized with an appropriately small size and their surfaces were 
modified with mixtures of polymers, which on the one hand made them inert to high ionic 
strength or protein solutions, but on the other hand also introduced a high specific affinity to 
the main bone mineral hydroxyapatite. The conducted in vivo investigations strongly 
indicated that the functionalized gold nanoparticles showed a minimum uptake by the 
reticuloendothelial system (liver and spleen) and therefore circulated for very long time in 
blood. On the other hand the particle also showed a strong tendency to extravasate or 
distribute to other organs after injection into mice, but the largest accumulation was observed 
in the kidneys. Also in bone a steady accumulation of the bisphosphonate functionalized 
nanoparticles was observed in comparison to the control nanoparticles, but further studies 
have to be conducted here in order to investigate especially the long term fate of the particles 
in bone. 
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1. Summary  
 In general, the application of custom designed nanoparticles offers many new 
opportunities to improve existing diagnostic approaches. Some of these systems, furthermore, 
allow the therapy of hard to treat diseases by novel approaches for a localized delivery with 
the minimization of undesirable side effects. Consequently, targeted nanoparticles have been 
applied as label for in vivo imaging, as probes for cellular imaging and also as carriers for 
therapeutic drug delivery [1]. For the purpose of efficient drug delivery, nanoparticles should 
be sufficiently stable in vitro and in vivo, highly biocompatible and, most importantly, non-
toxic to humans. For the successful application of nanoparticles a suitable surface 
modification is of utmost importance to acquire particles with the desired properties.  
 Based on existing knowledge [2], the first aim of this thesis was to synthesize and 
improve polymers, which can on their one end strongly bind to gold nanoparticle surfaces and 
at the same time can be modified on the other end with targeting moieties for specific 
interactions with tissues or cells. 
 
 
Figure 1: Schematic diagram representing the essential components of the polymer platform 
used for the modification of the gold particles 
 
 The strategy of the polymer development was based on a poly(ethylene glycol) (PEG) 
backbone, a hydrophilic polymer, which is known to enhance the stability of nanoparticles 
[3,4], to minimize unspecific proteins adsorption [5], and finally also to increase circulation 
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half lives of nanoparticles in blood after in vivo administration [6]. For the modification of 
gold thioalkylated PEG derivatives were synthesized (Figure 1), which anchor to gold 
surfaces through a stable S-Au bond. In addition to the anchor group, an aliphatic chain was 
introduced, which is essential to produce a further stabilizing self assembled monolayer on the 
gold surface due to the hydrophobic attractions between the aliphatic chains [7]. Finally, the 
PEG chain was terminally derivatized in order to fulfil multiple functions, like an inert surface 
coating, binding site for radio labels and last but not least the binding site for the targeting 
ligand. 
 Synthesis schemes for thioalkylated PEG derivatives were developed and further 
optimized (Chapter 2 and 3) to obtain polymers with a high degree of conversion to ease the 
later production of the coated particles. Two derivatives were obtained, methoxy 
poly(ethylene glycol)-undecyl mercaptane (Figure 2a) and amino poly(ethylene glycol)-
undecyl mercaptane (Figure 2b). The amine terminated derivative was later further reacted 
with a custom synthesized bisphosphonate as bone targeting ligand producing a functionalized 
polymer with a high affinity to the bone mineral hydroxyapatite and also to gold surfaces, 
which indicated the successful linkage of the thioalkyl chain with PEG and the 
bisphosphonate [8]. 
 The used bisphosphonate was chosen because of its exceptional high affinity to bone 
due to two bisphosphonate groups contained in the molecule, and additionally due to the 
presence of an aromatic ring, which enabled a very sensitive detection of the synthesized 
polymers. The bisphosphonate was synthesized according to published procedures [9], but it 
was used at different stages of the reaction, in order to provide compounds, soluble in aqueous 
and organic medium (Figure 2c, A and B). The finally used polymer was obtained from the 
reaction of the bisphosphonate ester with the amine terminated polymer and activated using 
mild hydrolysis of the esters with bromotrimethylsilane (Figure 2d). 
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Figure 2a: Methoxy poly(ethylene glycol)-undecyl mercaptane 
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Figure 2b: Amino poly(ethylene glycol)-undecyl mercaptane 
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Figure 2c: Bisphosphonates applied for the modification of the polymer: 
A) organic soluble derivative and B) water soluble derivative 
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Figure 2d: Bisphosphonate-modified amino poly(ethylene glycol)-undecyl mercaptane 
 
 Suitably sized gold nanoparticles dispersed in aqueous medium were prepared by 
citrate reduction of auric chloride solutions [1]. Different trials were done to obtain 
nanoparticles, which can be administered intravenously (Chapter 4). The prepared 
nanoparticles were subsequently coated with amino poly(ethylene glycol)-undecyl 
mercaptane and methoxy poly(ethylene glycol)-undecyl mercaptane and the impact of the 
polymer coating on important properties of gold nanoparticles, like size and stability in the 
presence of electrolyte and proteins, was investigated. There was an indirect relation between 
the amount of added reducing agent (sodium citrate) and the size of the obtained gold 
nanoparticles, which allowed the adjustment of the particle size. The performed polymer 
surface modification increased the particle size by a few nanometers and additionally resulted 
in the formation of nanoparticles, which did not aggregate either by high electrolyte 
concentrations or proteins in the aqueous medium. In contrast it was demonstrated that citrate-
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stabilized GNPs were generally greatly influenced by the addition of sodium chloride, BSA or 
serum. 
 The synthesized thioalkylated and targeted polymers (bisphosphonate-modified 
thioalkylated PEG) were, furthermore, applied to prepare bisphosphonate-functionalized gold 
nanoparticles (Chapter 5). For this preparation citrate stabilized nanoparticles (about 40 nm 
in diameter) were incubated with different ratios of targeted and inert polymers to allow an 
exchange of the citrate anions (Figure 3). The coated GNPs showed a slight size increase and 
greatly enhanced stability in different solutions. The zeta potential of the particles increased 
by addition of uncharged polymers, but it was similar for the bisphosphonate-coated and 
citrate-stabilized gold nanoparticles due to the added excess of anionic groups. The 
hydroxyapatite binding affinity of the particles was studied as a function of surface 
bisphosphonate amount and could be varied in a wide range with a steady increase with 
increasing amount of bisphosphonate. Additionally, binding experiments were performed in 
presence of calcium chloride, BSA and bovine serum to elucidate the effect on the 
hydroxyapatite affinity, which was not affected by adding any of the added compounds. 
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Figure 3: Structure of gold nanoparticles used functionalized with a mixture of mPEG-AlkSH 
and BP-PEG-AlkSH 
 
 To investigate the fate of the nanoparticles in vivo, they were firstly labeled with 
radioactive indium in order to allow their tracking in vivo. To elucidate the effect of the 
targeting ligand concentration, nanoparticles containing a low and a high amount (40% or 
80%) of bisphosphonate in comparison to control nanoparticles (0% BP) were intravenously 
administered in mice. The biodistribution to the different organs of the mice and the 
pharmacokinetic profiles of the injected nanoparticles were determined and compared 
between the different formulations of the prepared particles (Chapter 6). The biodistribution 
of nanoparticles demonstrated a promising behavior of the targeted and untargeted particles. 
The nanoparticles exhibited a very long blood circulation time with only minimal uptake by 
spleen and liver. An enhanced accumulation of the particles was observed in the kidneys, 
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which probably are suited to trap a fraction of the injected particles in the glomerulus 
membrane, which certainly necessitates further investigations. On the other hand bone 
accumulation of the bisphosphonate-functionalized nanoparticles was not largely different 
from the control nanoparticles, which could be attributed to the very small portion of bone 
(femur), which was chosen for the distribution study, or to a limited extend of extravasation 
within the bone. However, the long circulation half lives of the particles makes them a 
suitable platform for further investigations also of other targeting approaches, especially since 
the synthesized polymers allow a flexible modification with other suitable ligands, like 
proteins or eventually antibodies. 
 
2. Conclusions 
 Heterobifunctional polymers, which can be used for the modification, 
functionalization and stabilization of gold nanoparticles, were successfully synthesized 
applying a new synthetic strategy. Highly stable gold nanoparticle dispersions were obtained 
after coating citrate-stabilized GNPs with the different synthesized polymers, which stabilized 
the particles by a steric stabilization, which was not affected by the addition of sodium 
chloride or proteins. The functionalization with bisphosphonates, furthermore, produced 
nanoparticles with a high affinity to the bone mineral hydroxyapatite, which was not affected 
by addition of calcium chloride or proteins. Upon intravenous application of the nanoparticles 
in mice, they circulated for a long time in the blood and were well distributed to many organs 
and most importantly did not accumulate in liver and spleen, which are common organs of 
nanoparticle deposition. 
 The here presented nanoparticle system provides a suitable platform for the 
investigation of new drug targeting principles. The investigated particles can be prepared 
using a stable noble metal core for easy detection with electron microscopy, which was coated 
with an inert polymer layer that, furthermore, provided chemical binding sites for many 
different ligands using standard carbodiimide chemistry. Due to their small size the particles 
will extravasate in many different organs, which is essential to make them suitable for the 
investigation of other targeting principles. 
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1. Abbreviations 
1H-NMR proton nuclear magnetic resonance spectroscopy 
%ID % of injected dose 
%ID/g % of injected dose per gram tissue 
λmax Peak of maximum absorption 
ANOVA analysis of variance 
Abs absorbance 
AIBN α,α´ azoisobutyronitrile  
AUC area under the curve  
BBB blood brain barrier 
BOC di-t-butyl dicarbonate  
BP bisphosphonate 
BP-PEG-AlkSH Bisphosphonate modified poly(ethylene glycol)-undecyl mercaptane 
BSA Bovine serum albumin 
CDCl3 deuterated chloroform 
CNS central nervous system 
Da dalton 
DCC N,N\-dicyclohexylcardodiimide  
DIC-BP diclofenac bisphosphonate conjugate 
DTPA diethylenetriaminepentaacetic acid 
DTPA-PEG-AlkSH Diethylenetriaminepentaacetic acid conjugated amino poly(ethylene 
glycol)-undecyl mercaptane 
EDC 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
ELSD evaporative light scattering detector 
EO ethylene oxide gas  
EPR enhanced permeability and retention 
ESI-M electro spray ionization mass spectroscopy 
FDA food and drug administration 
GNPs gold nanoparticles 
HA hydroxyapatite 
HCl hydrochloric acid 
HNO3 nitric acid 
HPLC high pressure liquid chromatography  
ICP-OES inductively coupled plasma-optical emission spectroscopy  
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IDDM insulin-dependent diabetes mellitus 
IL-1 interleukine-1  
IL-6 interleukine-6  
Kel elimination rate constant  
KOH potassium hydroxide  
L-Asp L-aspartic acid 
L-Glu L-glutamic acid 
MALDI-ToF MS matrix assisted laser desorption/ionization mass spectrometry  
MeOH methanol 
Mp peak molecular weight 
mPEG poly(ethylene glycol) monomethyl ether 
mPEG-AlkSH methoxy poly(ethylene glycol)-undecyl mercaptane 
MRI magnetic resonance imaging  
MRT mean residence time  
MRSA multiple resistances staphylococcus aureus 
MS mass spectroscopy 
Mw molecular weight 
MWCO molecular weight cut-off  
NaBr sodium bromide 
NaH sodium hydride 
NaOH sodium hydroxide 
NH2-PEG-AlkSH amino poly(ethylene glycol)-undecyl mercaptane 
NH2-PEG-OH poly(ethylene glycol) monoamine 
NHS N-hydroxysuccinimide  
NMR nuclear magnetic resonance 
NPs nanoparticles 
ODDS osteotropic drug delivery system  
PCS photon correlation spectroscopy 
PEG poly(ethylene glycol)  
PEG-AlkSH poly(ethylene glycol) alkanethiol 
PLGA Poly(lactic-co-glycolic acid) 
PPi inorganic pyrophosphate  
PPO poly(propylene oxide)  
PTH parathyroid hormone  
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PTT photothermal therapy  
QDs quantum dots 
RES reticuloendothelial system 
RGD Peptide sequence ARG-GLY-ASP 
RP reversed phase 
RP-HPLC reversed phase high pressure liquid chromatography 
RT room temperature 
SAMs self assembled monolayers  
SPIONs superparamagntic iron oxide nanoparticles 
SPR surface plasmon resonance  
t1/2 elimination half life  
TAA thioacetic acid  
TEA triethylamine  
TEM transmittance electron microscopy 
TFAA trifluoroacetic acid anhydride  
THF tetrahydrofuran 
TMS tetramethylsilane  
TNF tumor necrosis factor  
TsOH p-toluenesulfonic 
UV-Vis ultraviolet and visible light 
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